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CHAPTER I 
 
BACKGROUND AND LITERATURE REVIEW 
 
Overview of virus receptor utilization 
 Viral pathogenesis is a complex, multi-step process with many factors influencing 
disease development.  In order for a virus to cause disease it must have the capacity to locate 
target organs.  Virus attachment to cellular receptors is the first step in viral replication and 
thus plays a key role in viral tropism and disease.  As such, virus-receptor engagement is a 
critical determinant of disease outcome and a potential target for antiviral therapy.  
 Viruses are capable of recognizing several types of cell-surface features including 
proteins and carbohydrates.  Among the earliest reports of virus receptor identification was 
the suggestion in the late 1950s that influenza virus and coronavirus utilized carbohydrates 
such as sialic acid for receptors (75, 176).   Carbohydrates serve as receptors for many 
families of viruses and, in some cases, these molecule play a key role in viral tropism and 
pathogenesis (11, 16, 198).  Since the advent of molecular cloning, many proteinacetous viral 
receptors have been identified.     
 Three important themes have emerged from the identification and study of virus 
receptors (52).  First, viruses have adapted to utilize receptors that facilitate a variety of 
normal cellular functions.  Virus receptors may be highly specialized proteins with limited 
tissue distribution or more ubiquitous components of cellular membranes.  One commonality 
amongst many virus receptors is that they are cell-junction associated proteins that function 
in maintaining cell-cell contacts, including integrins, coxsackievirus and adenovirus receptor 
(CAR) (23), junctional adhesion molecule-A (JAM-A) (10), Nectin, and intercellular 
adhesion molecule-1 (ICAM-1) (76, 150).   
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 Second, many viruses use more than a single receptor to effect multi-step attachment 
to cells or mediate independent binding and internalization events.  Receptors were long 
thought of as an adsorptive docking point for virus attachment.  It is now established that 
interactions between viruses and receptors are much more complex than the original 
simplistic “lock and key” model in which a single viral protein interacted with a single 
cellular receptor to gain access to the cell.  For example, HIV entry into cells requires 
multiple interactions with receptors (45).  Initial binding of the HIV attachment protein, 
gp120, to CD4 is required but not sufficient for virus infection (40).  Following engagement 
of CD4, gp120 undergoes conformational changes allowing interactions with a coreceptor, 
which depending on the strain, may be either CXCR4 or CCR5 (54, 194).  Upon gp120 
interaction with both CD4 and a coreceptor, the viral fusion protein is exposed, resulting in 
membrane fusion and viral entry (108).  
 Third, in addition to serving as an attachment point for the virus, virus-receptor 
engagement also can activate receptor-linked signaling pathways, including those that initiate 
innate immune responses or induce apoptosis.  Upon binding to the cell surface, viruses 
frequently commandeer the signaling cascades elicited by many receptors such as integrins, 
cytokine receptors, and growth factor receptors (104, 111, 181).      
 Although receptors have been identified for several virus families, little is known 
about the functions of individual receptors in viral tropism and disease.  This key gap in 
knowledge represents a long-standing barrier to efforts to define how viruses select specific 
cellular targets.  Moreover, given the critical importance of the attachment step in viral 
pathogenesis, new insights into the structure and function of viral attachment proteins and 
their cell-surface receptors will be required to understand disease mechanisms and illuminate 
new targets for therapeutic intervention. 
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Reovirus introduction 
 Reoviruses were first isolated in 1950s.  This family of viruses was coined reoviruses 
because they were isolated from the respiratory and enteric tracts and not associated with a 
specific disease (respirator enteric orphan virus) (138).  Reoviruses are nonenveloped viruses 
that contain a segmented, double-stranded RNA (dsRNA) genome (166).  The genome 
consists of ten gene segments that encode eleven proteins, eight of which are structural 
proteins whereas three are not associated with the virion and termed “nonstructural proteins”.  
The virion consists of two concentric protein shells (Figure 1).  The outer capsid contains 
proteins λ2, µ1, σ3, and σ1.  The inner protein shell is termed the core and consists of 
proteins λ1, λ2, λ3, µ2 and σ2 (166).    
 After attachment to the cell surface, the virus is internalized by receptor-mediated 
endocytosis.  Within endosomes, virions undergoes acid-dependent, proteolytic disassembly 
to form infectious subvirion particles (ISVPs).   ISVPs penetrate the endosomal membrane 
and release the transcriptionally active core into the cytoplasm.  Following synthesis of viral 
proteins and replication of viral genomic dsRNA, progeny virions are assembled and released 
fro the cell (Figure 2) (166).   
 Mammalian orthoreoviruses have served as one of the most richly exploited models 
of viral pathogenesis.  There are three major reovirus serotypes each represented by a 
prototype strain: type 1 Lang (T1L), type 2 Jones (T2J), and type 3 Dearing (T3D).  All three 
serotypes are capable of infecting most mammals, including humans, but disease progression 
is restricted to the very young (168).   
 Following oral inoculation of newborn mice, both type 1 reovirus and type 3 reovirus 
undergo primary replication in the intestinal epithelium and Peyer’s patches (190).  However, 
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Figure 1.  The reovirus virion. The reovirus virion contains two concentric protein shells 
termed outer capsid and core.  The core contains 10 dsRNA gene segments that are 
classified by size as large (L), medium (M), or small (S).  The viral attachment protein, 
σ1, is depicted as a ball and stick model protruding from the outer capsid.  
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Figure 2.  The reovirus replication cycle.  Reovirus attaches to the cell surface and 
enters by receptor-mediated endocytosis.  Disassembly occurs in the endosome, resulting 
in the formation of ISVPs.  ISVPs penetrate the membrane and the core is released into the 
cytoplasm to begin transcription.  Following synthesis of viral proteins and replication of 
viral genomic dsRNA, progeny virions are assembled and released from the cell.  
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after primary replication there is a marked dichotomy in both the route of spread and tropism 
between the two serotypes.  Type 1 reovirus spreads hematogenously to ependymal cells 
where it causes sub-acute hydrocephalus (167, 183, 184).  Type 3 reovirus spreads by neural 
routes to the CNS where it infects neurons and causes acute, lethal encephalitis (114, 167, 
183, 184).  This difference in spread and tissue tropism has been mapped using type 1 and 
type 3 reovirus reassortant viruses to the S1 gene, which encodes the viral attachment protein, 
σ1 (167, 183, 184).  The link between σ1 and the route of dissemination in the host and cell 
tropism within the CNS has made its structure and function the focus of considerable interest. 
 
General properties of σ1 
 The first experimental insights into σ1 structure came from composite transmission 
electron micrographs of σ1 molecules purified from virions (64) (Figure 3).  These images 
confirmed earlier predictions of a fiber-like structure of σ1 (13) and clearly revealed two 
distinct morphological domains: a long N-terminal fibrous tail that inserts into the viral 
capsid and a C-terminal globular head that projects away from the virion surface.  The σ1 
protein exhibits substantial flexibility at several discrete regions within the fibrous tail.   
Additional clues about key structural features of σ1 were revealed by increasingly 
sophisticated analyses of its amino acid sequence over many years.  Following an N-terminal 
hydrophobic region that comprises 30 residues and likely serves as the primary anchor of the 
protein into the capsid, the σ1 sequence contains an extended region characterized by heptad 
repeats with non-polar residues at the first and fourth positions of the repeating unit (50).   
Such repeats are characteristic of α-helical coiled coils (182) in which amphipathic 
helices are wrapped around each other to form dimers, trimers, or tetramers.  Accordingly, 
the N-terminal portion of σ1 was predicted to form an oligomeric α-helical coiled coil  
 7
 
 
 
 
Figure 3.  Electron micrograph and model of σ1. The top panel is a composite 
transmission electron micrographs of σ1 molecules purified from virions.  The lower panel 
is a model of σ1 receptor binding domains for serotype 3 reovirus strains.  
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structure  (13).  The actual oligomeric state of σ1 was the subject of some controversy, as 
dimeric (99, 196), trimeric (100, 152), and tetrameric (14, 64) structures were proposed.  
More complex sequence analyses and correlation of sequence data with the observed 
morphology eventually led to a plausible model for the domain architecture of σ1.  This 
model postulated three major structurally distinct regions of σ1, each accounting for about 
one third of its sequence.  The N-terminal third was predicted to form an α-helical coiled coil 
structure, the second third a fiber-like region composed primarily of β-sheet structure, and the 
final third a globular head domain (117),  While this model served to explain several 
properties of σ1, a high-resolution structure was required to accurately describe its features 
and correlate them with functional data. 
Structural analyses of σ1 were complicated by the flexible, fiber-like nature of the 
protein, its poor solubility, and difficulties in producing significant quantities of well-folded 
and functional protein.  Several groups have expressed full-length σ1 protein in bacteria, 
eukaryotic cells, and in vitro using cell lysates (25, 57, 84, 107, 127), and others relied on the 
use of protein purified from whole virions (115, 196).  The small amounts of protein 
recovered using these approaches were sufficient for biochemical experiments but inadequate 
for extensive structural studies of σ1.  However, a breakthrough came with the development 
of an internally truncated σ1 construct that lacked a portion of the predicted N-terminal 
coiled coil while retaining the hydrophobic sequence at the N-terminus and the C-terminal 
two thirds of the protein (35).  This truncated form of σ1 was expressed in insect cells using a 
baculovirus vector, and substantial amounts of folded and stable truncated σ1 protein were 
purified.  Cleavage of this construct with trypsin resulted in a stable and soluble fragment 
(residues 246-455) that formed functional oligomers (35). 
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Structural analysis of the C-terminal σ1 fragment firmly established the oligomeric 
state of the molecule as a trimer (37).  The structure has provided a wealth of information 
about the architecture of σ1 and potential roles of its structural features in viral attachment 
(Figure 4).  The structure also suggests that σ1 is a dynamic molecule poised to undergo 
conformational rearrangements, perhaps in response to viral attachment or disassembly.  The 
crystallized protein forms a homotrimer that features a slender tail domain (residues 246-309) 
and a compact head (residues 310-455).  The tail consists of three triple β-spiral repeats, a 
rare trimerization motif that has so far only been seen in one other protein, the adenovirus 
fiber (113).  The β-spiral is characterized by short, vertically-oriented β-strands that wind 
around each other and bury a substantial number of hydrophobic residues at the center.  The 
head domain is formed from two Greek keys which assemble into a compact ß-barrel (37). 
 
Reovirus receptors 
 Early studies examining the capacity of reovirus strains to agglutinate erythrocytes 
isolated from different species of animals documented a serotype-specific difference in 
hemagglutination that was genetically mapped using reassortant viruses to the σ1-encoding 
S1 gene (124, 185).  Hemagglutination produced by type 3 reovirus is inhibited by 
pretreatment of erythrocytes with various proteases or neuraminidase (2), suggesting that 
sialic acid is the erythrocyte structure bound by type 3 reovirus.  Type 3 reovirus binding to 
some types of cells is also reduced by neuraminidase treatment, indicating that cell-surface 
sialic acid-containing glycoconjugates contribute to productive type 3 reovirus attachment 
(68, 136).  Both T1L and T3D reoviruses can infect L929 cells, a murine fibroblast cell line 
commonly used to propagate reovirus.  However, only sialic acid-binding type 3 strains can 
infect murine erythroleukemia (MEL) cells (36, 135).  Serial passage of non-sialic-acid- 
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β-spiral
repeat 3
β-spiral
repeat 2
β-spiral
repeat 1
Figure 4.  The structure of σ1.  (A) Ribbon drawing of the σ1 trimer. The three σ1 
monomers are shown in red, orange and blue.  Each monomer consists of a head domain 
formed by a compact ß-barrel and a fibrous tail with three ß-spiral repeats.  (B) Enlarged 
view of the σ1 head domain. The two Greek key motifs, shown in red and orange, form a 
compact, cylindrical ß-sheet that contains eight ß-strands (A–H).  With the exception of 
the DE loop, the connections between the ß-strands are very tight.  
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binding type 3 strains in MEL cells results in selection of viral variants that have acquired the 
capacity to bind sialic acid (36).  The variants have substitutions at only three positions 
(Asn198, Arg202, and Pro204).  In each case, the substituted residues are present in all sialic 
acid-binding type 3 strains sequenced to date. 
 
Junctional adhesion molecule-A 
 Many proteins have been proposed to function as reovirus receptors, including the 
beta-adrenergic receptor (42), epidermal growth factor receptor (155), and a p65/p95 
complex (131).  However, to date only junctional adhesion molecule-A (JAM-A) has been 
shown to directly interact with reovirus attachment protein σ1 and confer reovirus infection 
to nonpermissive cells (10).  JAM-A was identified as a reovirus receptor using an expression 
cloning approach in which a non-sialic acid-binding reovirus strain was employed as an 
affinity ligand.  COS-7 cells were transfected with cDNAs from an NT2 teratoma cell library 
and screened for the capacity to support reovirus binding.  Using this approach, four plasmids 
were identified, each of which encoded JAM-A.  Three lines of evidence support the 
contention that JAM-A is a receptor for reovirus.  First, JAM-A-specific monoclonal 
antibodies (mAbs) block reovirus binding and infection.  Second, transfection of 
nonpermissive cells with JAM-A-encoding cDNA confers efficient reovirus growth.  Third, 
and most importantly, the σ1 head domain of strain T3D interacts directly with the JAM-A 
ectodomain, as assessed by surface plasmon resonance (10). 
JAM-A was first identified by screening a panel of mAbs raised against endothelial 
cells in an attempt to characterize proteins localized to endothelial tight junctions (105).  The 
human (h) homolog of JAM-A is a 299 amino acid, type I transmembrane protein that is a 
member of the immunoglobulin (Ig) superfamily (123) (Figure 5).  JAM-A is expressed in 
 12
many tissues, with the highest levels being found in the kidney, liver, and lung (188).  The 
JAM-A cytoplasmic tail has a classical type II PDZ binding motif and is phosphorylated by 
Protein kinase C (PKC) upon platelet activation (59, 122).  Several adaptor proteins have 
been identified as possible binding partners of the JAM-A cytoplasmic tail, including Zonula 
occluden-1 (ZO-1), ALL-1 fusion partner from gene 6 (AF-6), multiple PDZ domain 
containing protein-1 (MUPP-1), and CASK (59, 77, 105).  JAM-A is proposed to form 
homodimers located at tight junctions of polarized cells and may play a role in leukocyte 
migration and tight junction formation through homotypic interactions (18, 106). 
 JAM-A belongs to a group of related proteins termed the junctional adhesion 
molecule family.  Two JAM-A homologs, JAM-B and JAM-C, share approximately 36% 
amino acid identity with JAM-A and have overlapping but also distinct tissue distribution in 
comparison to JAM-A.  While all JAM family members are expressed by endothelial cells, 
JAM-B is predominantly expressed in the heart, and JAM-C is mainly expressed in the brain 
and kidney (4, 44).  Unlike JAM-B, which mediates homotypic interactions, JAM-C forms 
heterodimers with JAM-B (3).  Each of the JAM family members has been proposed to be 
involved in leukocyte transmigration, but only JAM-A serves as a reovirus receptor (29, 
129). 
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Figure 5.  A structural model for JAM-A.   JAM-A contains two immunoglobulin 
domains.  The D1 domain is membrane distal and is responsible for homodimerization of 
the protein, the D2 domain is membrane proximal. The extracellular portion of the protein 
is followed by a putative membrane spanning domain and a cytoplasmic tail which is 38 
aa long.  The cytoplasmic tail contains a classical type II PDZ domain-binding motif.  
 
 
 
 
 
 
 14
Significance of the research 
At the onset of this research, key unanswered questions included:  Is JAM-A a 
serotype-independent reovirus receptor?  What sequences in σ1 and JAM-A are required for 
σ1-JAM-A biophysical interactions?  What are the physiological consequences of reovirus 
infection of polarized cells where JAM-A is expressed in tight junctions?  Answers to these 
questions will contribute to an understanding of the molecular basis of reovirus-cell 
attachment and pathogenesis.  
 The mammalian reoviruses provide an attractive experimental system to study the 
role of virus-receptor interactions in the pathogenesis of viral infections, especially those 
involving the nervous system.  The reovirus attachment protein, σ1, is the primary 
determinant of viral growth in the intestine, spread from the intestine to the central nervous 
system (CNS), and tropism for distinct types of neural tissues.  Because σ1 mediates multiple 
steps in reovirus-host interaction, it is ideally suited for studies of mechanisms by which viral 
attachment determines the outcome of CNS infections.  Studies of molecular determinants of 
reovirus receptor engagement will generate new knowledge about fundamental mechanisms 
used by viral attachment proteins to interact with cellular receptors to mediate viral tropism 
and organ-specific disease.   
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CHAPTER II 
 
JUNCTIONAL ADHESION MOLECULE-A SERVES AS A RECEPTOR FOR 
PROTOTYPE AND FIELD-ISOLATE STRAINS OF MAMMALIAN REOVIRUS 
 
 
Introduction 
 
There are at least three serotypes of reovirus, which can be differentiated by the 
capacity of anti-reovirus antisera to neutralize viral infectivity and inhibit hemagglutination 
(134, 137).  Each of the reovirus serotypes is represented by a prototype strain: type 1 
Lang/53 (T1L/53), type 2 Jones/55 (T2J/55), and type 3 Dearing/55 which differ mainly in 
σ1 sequence (T3D/55) (56, 117).   
Reoviruses appear to infect most mammalian species, but disease is restricted to the 
very young (reviewed in (163)).  Reovirus infections of newborn mice have been used as the 
preferred experimental system for studies of reovirus pathogenesis.  Sequence 
polymorphisms in reovirus attachment protein σ1 play an important role in determining sites 
for reovirus infection in the infected host (11, 92, 183, 184).  
 There are two distinct receptor-binding regions in σ1.  A region in the fibrous tail 
domain of type 3 σ1 binds to α-linked sialic acid (9, 35, 36).  A distinct region in the type 1 
σ1 tail domain also binds to cell-surface carbohydrate (35), and recent evidence suggests that 
sialic acid may be involved in the binding of T1L/53 to intestinal cells (80).  A second 
receptor-binding site is located in the head domain of both type 1 and type 3 σ1 proteins (10, 
116). 
 An expression-cloning approach was used to identify junctional adhesion molecule-A 
(JAM-A) as a receptor for prototype strains T1L/53 and T3D/55 (10).  JAM-A is a 35 kDa, 
type I transmembrane protein that is a member of the immunoglobulin superfamily (102, 
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106).  JAM-A contains two immunoglobulin-like domains, a single transmembrane region, 
and a short cytoplasmic tail.  JAM-A is expressed in a variety of tissues including epithelial 
and endothelial barriers (102, 106, 123), where it is thought to regulate tight-junction 
permeability and mediate leukocyte trafficking (48, 102, 106, 123). 
 The prototype reovirus strains type 1 Lang/53 (T1L/53) and type 3 Dearing/55 
(T3D/55) JAM-A as a receptor (10). The C-terminal half of the T3D/55 σ1 protein interacts 
directly with JAM-A, but the determinants of receptor-binding specificity have not been 
identified (10). The goal of this study was to determine whether JAM-A also mediates the 
attachment of the prototype reovirus strain type 2 Jones/55 (T2J/55) and a panel of field-
isolate strains representing each of the three serotypes.  The results indicate that JAM-A, but 
not the related JAM family members JAM-B or JAM-C, is a receptor for prototype and field-
isolate strains of the three reovirus serotypes.  Analysis of conserved and variable sequences 
in the σ1 head, together with existing structural information for σ1 and JAM-A, suggests an 
especially high tolerance for surface variation while maintaining specificity for receptor 
utilization.  These findings enhance an understanding of the molecular basis of reovirus 
binding to JAM-A and provide clues about mechanisms of reovirus attachment. 
 
Results 
 
JAM-A serves as a receptor for prototype strains of the three reovirus serotypes 
 Our previous work indicates that JAM-A serves as a receptor for prototype reovirus 
strains T1L/53 and T3D/55 (10).  To confirm these observations, and to test whether JAM-A 
is used as a receptor by T2J/55, HeLa cells were treated with PBS, hCAR-specific antiserum 
as a control, or hJAM-A-specific mAb J10.4 prior to viral adsorption.  Infected cells were 
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quantified by indirect immunofluorescence using an anti-reovirus serum (Figure 6).  
Treatment of cells with CAR-specific antiserum had no effect on the capacity of these 
prototype strains to infect HeLa cells.  In sharp contrast, treatment with mAb J10.4 resulted 
in a concentration-dependent inhibition of infection for all three strains.  The minimum 
concentration of mAb J10.4 required to reduce infectivity of these strains by 50% was 
between 0.1 and 1.0 µg per ml (Figure 6).  Infectivity of all three strains was reduced by 
approximately 90% following treatment of cells with 100 µg per ml mAb J10.4.   
 
JAM-B and JAM-C do not serve as receptors for prototype strains of reovirus 
 JAM-A is the only JAM family member tested to date that functions as a receptor 
for T1L/53 (129).  To determine whether JAM family members in addition to JAM-A 
serve as reovirus receptors for other reovirus prototype strains, CHO cells, which are 
poorly permissive for reovirus infection (63), were transfected with cDNAs encoding 
hJAM-A, hJAM-B, or hJAM-C.  Cells also were transfected with hCAR as a negative 
control.  Following confirmation of cell-surface expression of the receptor constructs 
(Figure 7), transfected cells were tested for the capacity to support reovirus infection.  
Infected cells were quantified by indirect immunofluorescence using an anti-reovirus 
serum (Figure 7).  Only CHO cells transfected with hJAM-A were capable of supporting 
efficient infection of each of the three prototype reovirus strains, whereas cells 
transfected with hJAM-B and  hJAM-C did not support infection of any of these strains 
in excess of those transfected with hCAR (Figure 7).  Therefore, JAM family member 
JAM-A, but not JAM-B or JAM-C, functions as a receptor for prototype strains of 
reovirus. 
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Figure 6.  JAM-A blockade reduces infection of prototype reovirus strains. HeLa cells 
at equivalent degrees of confluence as a control, JAM-A-specific mAb J10.4 prior to 
adsorption with T1L/53, T2J/55, or T3D/55 at an MOI of 0.1 FFU per cell.  After incubation 
for 20 h, the cells were fixed and newly synthesized viral proteins were detected by indirect 
immunofluorescence.  (A) Representative fields of view. (B) Reovirus-infected cells were 
quantified by counting fluorescent cells in a minimum of three random fields of view per well 
for three wells at a magnification of x20.  The results are presented as the mean FFU per 
field.  Error bars indicate standard deviations.  
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JAM-A serves as a receptor for field-isolate strains of reovirus 
 Strains of each of the three reovirus serotypes have been isolated from many 
mammalian hosts over a period in excess of 50 years (73, 85).  A type 3 reovirus strain 
isolated from the cerebrospinal fluid of a child with meningitis is capable of using JAM-A as 
a receptor (164).  However, the receptor-binding properties of other field-isolate strains have 
not been reported.  To determine whether JAM-A is used as a receptor by other field-isolate 
strains of reovirus, CHO cells were transfected with hJAM-A, hJAM-B, or hJAM-C and 
tested for the capacity to support reovirus infection.  Ten strains, encompassing four type 1, 
two type 2, and four type 3 viruses (Table 1), were used in these experiments.  In parallel 
with findings made using prototype reovirus strains, each of the field-isolate strains tested 
was capable of utilizing hJAM-A but not hJAM-B or hJAM-C as a receptor (Figure 8). 
 
Analysis of deduced σ1 amino acid sequences of JAM-A-binding reovirus strains 
 To gain insight into σ1 residues that mediate interactions between reovirus and JAM-
A, we analyzed the amino acid sequences of the σ1 proteins of the three prototype and ten 
field-isolate strains chosen for study.  For these experiments, we determined the σ1-encoding 
S1 gene sequences of T1C23/59, T1C50/60, T1Neth/84, T1Neth/85, T2Neth/73, and 
T2Neth/84, and compared these sequences to those reported previously (Table 1).  RT-PCR 
primers complementary to the nontranslated regions of the type 1 and type 2 S1 genes were 
designed to facilitate amplification of entire S1 genes from infected L-cell lysates. 
 To define evolutionary relationships of the S1 gene sequences determined in this 
study with those of the other reovirus strains sequenced to date, we constructed 
phylogenetic trees by using variation in the σ1-encoding S1 gene nucleotide sequences 
and the maximum parsimony method as applied in the program PAUP (Figure 9).  The 
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Figure 7.  CHO cells transfected with hJAM-A support growth of prototype reovirus 
strains. (A) CHO cells were transiently transfected with a plasmid encoding hCAR, hJAM-
A, hJAM-B, or hJAM-C.  Following incubation for 24 h to permit receptor expression, cells 
were incubated with receptor-specific MAbs, and the cell surface expression of receptor 
constructs was assessed by flow cytometry.  (B) Transfected CHO cells were adsorbed with 
T1L/53, T2J/55, or T3D/55 at an MOI of 0.1 FFU per cell.  Reovirus proteins were detected 
by indirect immunofluorescence at 20 h postinfection.  Representative fields of view are 
shown. Magnification, x20.  (C) Reovirus-infected cells were quantified by counting 
fluorescent cells in five random fields of view per well for three wells.  The results are 
presented as the mean FFU per field. Error bars indicate standard deviations.  
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Figure 8. Expression of JAM-A confers infectivity on field-isolate reovirus strains. CHO 
cells were transiently transfected with a plasmid encoding hCAR, hJAM-A, hJAM-B, or 
hJAM-C.  Following incubation for 24 h to permit receptor expression, the cells were 
adsorbed with the indicated field-isolate strains at an MOI of 1 FFU per cell.  Reovirus 
proteins were detected by indirect immunofluorescence at 20 h postinfection and quantified 
by counting of the fluorescent cells in three random fields of view per well for three wells. 
The results are presented as the mean FFU per field.  Error bars indicate standard deviations.  
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most noteworthy feature of the S1 phylogenetic tree is that the strains cluster into distinct 
lineages based on serotype.  A phylogenetic tree generated by using the same data set and 
the neighbor joining algorithm of the phylogenetic analysis program, MacVector 
(MacVector 2001, version 7.1.1), has a topology identical to the tree generated by PAUP 
(data not shown).  Therefore, phylogenetic analysis indicates that the S1 genes of 
reovirus strains cluster tightly into three lineages defined by serotype.  Concordantly, 
changes in the deduced amino acid sequences of σ1 protein within a given serotype are 
confined to a small number of residues.  As each of the strains investigated here is 
capable of using JAM-A as a receptor, the location of these changes provides clues about 
areas that can vary in surface structure without impeding the capacity to engage this 
molecule.  Thus, these changes define areas that are unlikely to interact with JAM-A. 
 
Sequence variability within type 3 σ1 protein 
Structural information is available for the T3D/55 σ1 protein (37).  We therefore 
carried out a structure-based comparison of the deduced amino acid sequences of σ1 proteins 
of type 3 field-isolate strains with that of prototype T3D/55 to define regions of conserved 
and variable sequence within a serotype (Figure 10).  Substantial variability is seen between 
residues 240 and 250, a region that lies just N-terminal to the first β-spiral repeat in the 
crystallized fragment and is disordered in the crystal structure.  The σ1 fragment was 
obtained by trypsin cleavage of a longer construct after residue Arg245 (37).  The fact that 
trypsin cleaves σ1 at only this position suggests that Arg245 lies in an exposed loop that  
likely possesses some flexibility.  Exposed areas in the second and third β-spiral repeats of 
the crystallized fragment also contain a number of substitutions.  Because these areas are 
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Figure 9.  Phylogenetic relationships among S1 gene nucleotide sequences of 13 reovirus
strains. A phylogenetic tree for the σ1-encoding S1 gene sequences of the strains shown in 
Table 1 was constructed by using the maximum parsimony method as applied in the program 
PAUP.  The tree is rooted at its midpoint.  Bootstrap values of >50% (indicated as a 
percentage of 1,000 repetitions) for major branches are shown at the nodes.  Bar, distance 
resulting from 10 nucleotide changes.  
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variable, they are unlikely to significantly contribute to JAM-A binding. 
Most of the remaining substitutions are located at the top of the σ1 trimer, forming a 
highly variable “plateau” that is also unlikely to bind to JAM-A.  Some of the observed 
variations on the plateau are anticipated to alter the structure of the molecule.  For example, 
the replacement of Ser435 with Met in T3D9/61 and T3D18/61 is likely to cause significant 
structural changes as Ser435 is partially buried in the T3D/55 structure (37).  Because they 
are exposed at the protein surface, the polymorphisms seen on the plateau may allow viral 
escape from antibody recognition.  In contrast, the lower portion of the head domain is highly 
invariant, suggesting that the base of the σ1 head is primarily responsible for interactions 
with JAM-A. 
 
Sequence variability within σ1 protein of the three reovirus serotypes 
Alignment of the deduced σ1 amino acid sequences of all of the strains chosen for study 
shows that only 36 of the 210 residues in the crystallized fragment of T3D/55 σ1 (37) are 
conserved (Figure 11).  The variability among the serotypes is substantially greater than the 
variability within each serotype.  Mapping of the conserved residues onto the crystal structure 
of T3D/55 σ1 shows that many of these residues are buried, especially those located at the 
base of the σ1 head trimer interface (Figure 12).  A large fraction of the remaining conserved 
residues cluster in a single, solvent-exposed region at the lower edge of the β-barrel.  Again, 
the regions that are most variable within type 3 σ1 (the β-spiral region and the “top” of the  
extended, contiguous area of conserved residues is located at the base of the head domain, 
and additional, smaller areas of conservation are found along the side of this domain.  
Because these regions are conserved in the JAM-A-binding strains investigated here, they 
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Figure 10.  Sequence conservation and structural variability within the type 3 σ1 
protein. (A) Alignment of deduced amino acid sequences of the σ1 proteins of prototype 
strain T3D/55 and four type 3 field-isolate strains.  The alignment was generated by using 
the program ALSCRIPT, with default conservation parameters applied according to the 
following color scheme: red, identical residues; orange, conserved residues at 80% 
conservation; yellow, conserved residues at 60% conservation; white, nonconserved
residues. The 80% conservation threshold identifies closely related amino acids (e.g., Ile
and Leu), whereas the 60% threshold identifies more distantly related amino acids (e.g., 
Ser and Ala, both of which have small side chains).  The amino acid positions in the 
alignment are numbered above the sequences. The gray line indicates residues present in 
the crystallized fragment of T3D/55 σ1.  (B) Structure of the σ1 trimer, with residues 
colored according to the same color code as that used for panel A.  Four different views are 
shown.  For each of the views, two σ1 monomers are shown in surface representation, and 
the other is depicted as a blue ribbon tracing corresponding to the α-carbon backbone.  The 
first three views each differ by 90° along a vertical axis; the fourth view shows the 
molecule in the third view after rotation by 90° along a horizontal axis.  The positions of 
residues 340 and 419 are marked in the third panel from the left.  
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mark potential contact points for this receptor. 
 The large conserved area at the base of the head domain is formed primarily by a 
stretch of residues (Asn369 to Glu384 in T3D/55 σ1) within a 310 helix and long loop 
between β-strands D and E (37) (Figure 12).  This region also includes Trp421 at the end 
of β-strand F.  The conserved region is fairly hydrophobic, with the side chains of 
Val371, Leu379, and Trp421 accounting for a large portion of the surface area predicted 
to be involved in JAM-A binding.  A second, smaller cluster of conserved residues 
(Leu331, Trp333, Ile360, and His438 in T3D/55 σ1) lies above this putative JAM-A-
binding surface, near the top of the trimer (Figure 12).  While most of the side chains of 
these residues are buried, structural features of this cluster may contribute to receptor 
binding.  The remaining surface area of the σ1 trimer, especially near the top of the head 
and the head-to-head contacts, is almost entirely devoid of conserved residues. 
 
A neutralization-resistant variant of reovirus T3D/55 uses JAM-A as a receptor 
   Variants of T3D/55 selected for resistance to neutralization by mAb 9BG5 ((149)) have 
mutations at Asp340 or Glu419 in the σ1 head (15) (Figure 12).  These variants have 
alterations in central nervous system (CNS) tropism following infection of newborn mice 
(148).  The single mutation in variant K σ1, Glu419 to Lys (15), segregates genetically with 
the altered growth and tropism of this virus in the murine CNS (92).  To determine whether a  
with increasing concentrations of JAM-A-specific mAb J10.4 resulted in a dose-dependent 
inhibition of viral infection, while CAR-specific antiserum had no effect on viral infectivity.  
At the maximal concentration of mAb J10.4 used (100 µg per ml), infectivity was nearly 
abolished, demonstrating that variant K is capable of using JAM-A as a receptor (Figure 13).   
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Figure 11. Sequence conservation within the σ1 proteins of the three reovirus serotypes.
Alignment of deduced amino acid sequences of the σ1 proteins of 3 prototype and 10 field-
isolate reovirus strains.  The alignment was generated by using ALSCRIPT and the scheme 
described in the legend to Figure 10.  Gaps in the aligned sequences are indicated by dots.  
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Figure 12.  Structural variability within the σ1 proteins of the three reovirus serotypes.
Mapping of residues onto the σ1 structure, using the same color code as that depicted in 
Figure 10.  The four views correspond to those in Figure 10.  
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Thus, the mechanism of altered pathogenicity of variant K appears to be independent of 
JAM-A utilization. 
 
Discussion 
Examination of receptor usage by diverse virus families, including arenavirus (30, 
147), adenovirus (23, 67, 140, 192), and measles virus (55, 103, 158), has led to the 
discovery that receptor usage by some viruses varies based on viral clade, serotype, or 
adaptation to passage in cell culture.  We undertook this study to determine whether JAM-A 
is used as a receptor for both prototype and field-isolate strains of reovirus.  The results 
demonstrate that each of the prototype and field-isolate reovirus strains tested, regardless of 
serotype, species, or geographical region of isolation, is capable of utilizing JAM-A as 
receptor. 
 Prior to this work, sequence information for the S1 gene segment of type 1 and type 2 
reovirus strains was limited to prototype strains T1L/53 and T2J/55.  In this study, we 
determined the S1 sequences of four type 1 and two type 2 field-isolate strains.  Phylogenetic 
analysis of the deduced σ1-encoding S1 gene sequences revealed that these reovirus field-
isolate strains associate into discrete lineages defined by serotype.  Given that all reovirus 
strains tested to date are capable of using JAM-A as a receptor, it seems plausible that σ1 
interacts with JAM-A through residues that are conserved among the serotypes, including the 
newly characterized type 1 and type 2 field-isolate strains.  The observation that JAM-A is 
used as a receptor by all reovirus strains tested was unexpected since the σ1 protein is highly 
divergent among the three serotypes.  For example, sequence analysis of the prototype strains 
reveals that the σ1 head domain of T1L/53 and T2J/55 share 50% identical residues, while 
that of T1L/53 and T3D/55 share only 27%. 
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Figure 13.  JAM-A is used as a receptor for a neutralization-resistant variant of 
reovirus T3D/55. HeLa cells were pretreated with PBS, an hCAR-specific antiserum, or the 
hJAM-A-specific mAb J10.4 prior to adsorption with variant K at an MOI of 1 FFU per cell. 
Reovirus proteins were detected by indirect immunofluorescence at 20 h postinfection. (A) 
Representative fields of view.  (B) Reovirus-infected cells were quantified by counting 
fluorescent cells in three random fields of view per well for three wells.  The results are 
presented as the mean FFU per field. Error bars indicate standard deviations.  
 32
Substantial evidence has accumulated to suggest that the σ1 head domain binds to 
cellular receptors.  Truncated forms of σ1 containing only the head domain are capable of 
specific cell interactions (57, 58).  Concordantly, proteolysis of T3D/55 virions leads to 
release of a C-terminal receptor-binding fragment of σ1 (residues 246 to 455) (34) and a 
resultant loss in infectivity (116).  This fragment of σ1 is capable of binding to JAM-A on a 
biosensor surface with nanomolar affinity (10).  Preliminary findings from our laboratory 
indicate that an even smaller fragment of T3D/55 σ1, corresponding to the head domain and 
a single β-spiral repeat, is capable of binding to JAM-A (Guglielmi, K. M., Schelling, P., 
Stehle, T., and Dermody T. S., unpublished observations).  Thus, the σ1 head promotes 
interactions with JAM-A that are distinct from interactions with sialic acid mediated by the 
σ1 tail. 
While most of the residues conserved in the σ1 proteins of the strains tested are 
scattered throughout the molecule, examination of the σ1 surface reveals a single, extended 
patch of conserved residues at the lower edge of the σ1 head.  We think that this region may 
form part of a JAM-A-binding surface.  This conserved region is formed mostly by residues 
in the vicinity of a long loop connecting β-strands D and E of the eight-stranded β-barrel that 
forms the σ1 head.  Although it is easily accessible to ligand, this site is somewhat recessed 
into the protein surface and surrounded by protruding, non-conserved residues on all three 
edges of the trimer.  Only residues from a single monomer contribute to the putative JAM-A-
binding region and its borders, and the regions are not involved in σ1 intersubunit contacts.  
Thus, the location of conserved residues within the trimer suggests that each σ1 monomer 
can independently bind to a JAM-A molecule. 
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Although it may serve as the primary contact point for the receptor, the putative 
JAM-A binding site in σ1 is relatively small, measuring about 15Å in length and 10Å in 
width.  Most other interactions between viral ligands and proteinaceous receptors cover 
somewhat larger areas.  It is therefore likely that additional regions of σ1 contribute to 
interactions with JAM-A.  We note that the putative JAM-A binding site lies at the lower 
edge of a large, concave surface formed by β-strands B, A, D and G of σ1.  Residues on this 
surface, which almost entirely covers one side of the β-barrel, would easily be accessible to a 
receptor and do not participate in inter-subunit contacts.  The top of the σ1 head is formed by 
three prominent protrusions, one from each β-barrel.  These protrusions are entirely devoid of 
conserved residues among the serotypes and also exhibit significant sequence drift within 
type 3 σ1.  It is therefore highly unlikely that the top of the σ1 head participates in receptor 
binding, again implicating regions on the side of each β-barrel as the most likely areas of 
contact with JAM-A. 
Neutralization-resistant variants of reovirus T3D/55 selected using σ1-specific mAb 
9BG5 contain mutations in the σ1 head that segregate genetically with alterations in neural 
tropism (15, 92, 148, 149).  Since reovirus tropism in the murine CNS is determined at least 
in part by σ1-receptor interactions (53, 157), it is possible that the antibody-selected 
mutations in the σ1 head alter receptor binding.  However, we found that variant K, which 
has a Glu to Lys mutation at amino acid 419, uses JAM-A as a receptor.  This observation 
suggests that the mutation in variant K σ1 alters interactions of this strain with cell-surface 
receptors other than JAM-A or influences a post-attachment step in reovirus replication.  It is 
noteworthy that amino acid 419 is adjacent to the σ1 head trimer interface in the vicinity of 
amino acid 340 (37) (Figure 10), which also is targeted for mutation in neutralization-
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resistant variants of T3D/55 (15).  It is possible that mutations at these sites alter σ1 subunit 
interactions required for viral assembly or disassembly. 
Reovirus serotypes exhibit striking differences in tropism and pathogenesis in the 
murine CNS.  Type 1 reovirus spreads to the CNS hematogenously and infects ependymal 
cells (167, 184), resulting in subacute hydrocephalus (183).  In contrast, type 3 reovirus 
spreads to the CNS by neural routes and infects neurons (114, 167, 184), causing lethal 
encephalitis (156, 183).  Analysis of reassortant viruses containing gene segments derived 
from T1L/53 and T3D/55 demonstrated that the pathway of viral spread in the host (167) and 
tropism for neural tissues (53, 184) segregate with the σ1-encoding S1 gene.    
These findings suggest that σ1 determines the CNS cell types that serve as targets for 
reovirus infection, presumably by its capacity to bind to receptors expressed by specific CNS 
cells.  Since all strains of reovirus tested are capable of utilizing JAM-A as a receptor, 
engagement of JAM-A alone does not explain the differences in tropism and virulence 
displayed by the different reovirus serotypes in the murine CNS.  It is possible that JAM-A 
serves as a serotype-independent reovirus receptor at some sites within the host and that other 
receptors, perhaps carbohydrate in nature, confer serotype-dependent tropism.  In support of a 
role for cell-surface carbohydrate in reovirus disease, the capacity to bind sialic acid 
enhances the spread of type 3 reovirus within the host and targets the virus to bile duct 
epithelial cells, leading to obstructive jaundice (9).  It is also possible that serotype-dependent 
differences in pathogenesis are influence by one or more post-binding events. 
 The role of JAM-A utilization in reovirus infection in vivo is not known.  JAM-A is 
expressed on many cell types, including intestinal epithelium, bile duct epithelium, lung 
epithelium, leukocytes, and CNS endothelial cells (106), which serve as sites for reovirus 
infection in mice (175).  It will be interesting to determine whether JAM-A functions as a 
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reovirus receptor at these sites in infected animals.  Mice with targeted disruption of the 
JAM-A gene are viable and fertile (32).  These mice exhibit accelerated migration of 
dendritic cells to lymph nodes, which is associated with enhanced contact 
hypersensitivity (32).  No other developmental or immune abnormalities have been 
noted.  Studies of reovirus infections using JAM-A-deficient animals should clarify the 
function of JAM-A in reovirus pathogenesis and disease. 
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CHAPTER III 
 
CRYSTAL STRUCTURE OF HUMAN JUNCTIONAL ADHESION MOLECULE-A: 
IMPLICATIONS FOR REOVIRUS BINDING 
 
 
Introduction 
 Immunoglobulin (Ig) and Ig-like proteins are extensively studied because of their 
importance in the immune system, intercellular interactions, and interactions with 
microbial pathogens (145).  Proteins within the immunoglobulin superfamily are highly 
modular and consist of Ig-like domains.  Ig-like domains can be classified as being one of 
the following sets; variable-like domains, the V set, the constant-like domains, the C1 and 
C2 sets, and the intermediate set, the I set (78).  JAM-A is a member of the Ig 
superfamily with two extracellular Ig-like domains, a single transmembrane region, and a 
short cytosolic tail.   
 The crystal structure of the extracellular region of murine JAM-A (mJAM-A) 
revealed a dimer stabilized by interactions involving the membrane-distal Ig-like domain 
(95).  The contacts that facilitate JAM-A dimerization are interesting in that they occur 
via the GFCC' face of the membrane distal (D1) Ig-like domain (36, 126).  The only other 
molecules demonstrated to form homodimers using similar interdimer contacts are the 
human coxsackievirus and adenovirus receptor (hCAR) and CD2 (24, 121).  The structure 
of hCAR in complex with the adenovirus fiber knob revealed that fiber engages the D1 
domain of hCAR using residues involved in hCAR homodimer formation and that knob 
mimics the hCAR-hCAR interaction (24, 64).  Biophysical evidence suggests that fiber-
hCAR interactions are thermodynamically favored over hCAR-hCAR interactions, 
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providing support for a model in which residues in the hCAR dimer interface 
preferentially bind fiber over hCAR (28).  The structural similarities between the reovirus 
and adenovirus attachment proteins and between their cognate receptors, paired with the 
absolute conservation of residues in mJAM-A and hJAM-A that mediate homodimer 
formation, suggest that reovirus engages the D1 domain of hJAM-A and that residues 
involved in hJAM-A dimerization are important for reovirus attachment (36). 
The crystal structure of a JAM-A-binding fragment of a σ1 revealed numerous 
structural and functional similarities to the adenovirus attachment protein, fiber, 
suggesting an evolutionary link in the receptor-binding strategies of reoviruses and 
adenoviruses (37).  Most adenovirus serotypes initiate infection by binding to the 
coxsackievirus and adenovirus receptor (CAR) (23).  The crystal structure of the 
adenovirus fiber knob in complex with CAR is known (24).  Although no structural 
information is currently available for a reovirus-receptor complex, analysis of the 
crystallized σ1 fragment revealed a region that is likely involved in the interaction with 
JAM-A (37).  This putative JAM-A-binding site forms a recessed groove at the lower 
edge of the σ1head that contains many of the residues conserved in prototype strains of 
the three reovirus serotypes.  The location of this site suggests that each σ1monomer can 
independently interact with a JAM-A molecule.  
 To enhance an understanding of how reovirus mediates cell tropism and initiates 
organ-specific disease, we used a genetic approach combined with structural analyses to 
define reovirus JAM-A interactions.  Through utilization of chimeric JAM-A-
CARreceptor constructs, we identified the D1 domain of JAM-A to be necessary and 
sufficient for reovirus binding.  In order to understand the structure-function relationships 
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within JAM-A that mediate reovirus binding, we determined the crystal structure of the 
hJAM-A ectodomain.  Analysis of this structure allows us to identify regions of the D1 
domain that are most likely involved in the binding of σ1.  Moreover, comparison of the 
structures of hJAM-A and mJAM-A reveals differences in the dimeric arrangements of 
the molecules despite absolute conservation of residues at the interface, suggesting that 
the JAM-A dimer is dynamic and can undergo rearrangement and perhaps dissociation.  
Finally, we show that the structure of the JAM-A dimer closely resembles that of the 
CAR dimer, mirroring the close resemblance of the reovirus and adenovirus attachment 
proteins and suggesting that the similarities extend beyond conservation of structure 
toward conserved strategies of attachment and entry. 
 
Results 
 
Identification of hJAM-A domains required for reovirus attachment 
 We previously have shown that JAM-A is a serotype-independent reovirus 
receptor (10).  However, specific sequences in JAM-A required for reovirus attachment 
were not known prior to the initiation of this work.  To identify domains in JAM-A 
required for reovirus binding and infection, we generated receptor chimeras using hJAM-
A and Ig superfamily relative hCAR (Figure 14).  hCAR is incapable of supporting 
reovirus binding and infection (10) and was selected as the chimera partner for these 
studies because of its structural similarities to JAM-A (129).  A PCR-based approach was 
used to reciprocally exchange sequences encoding either the D1 or D2 Ig-like domains of  
wild-type receptor cDNAs.  We also generated single-domain deletion mutants of hJAM- 
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Figure 14.  Chimeric and deletion mutant receptor constructs for studies of reovirus 
binding and growth. Ig superfamily proteins hCAR (red) and hJAM-A (blue) were used to 
generate chimeric receptor constructs in which Ig-like domains were reciprocally exchanged. 
Single Ig-like domains of hJAM-A also were deleted.  Nomenclature indicates origin or 
deletion of domains D1, D2, and cytoplasmic tail (left to right) relative to wild-type hCAR or 
hJAM-A.  
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A to complement data obtained using the chimeric receptor molecules.  CHO cells, which 
lack expression of both JAM-A and CAR (23, 106), were transiently transfected with 
plasmids encoding wild-type hJAM-A and hCAR, chimeric receptor molecules CJJ and 
JCJ, and hJAM-A deletion mutants J∆J and ∆JJ.  Cell-surface expression of each 
construct and the capacity of reovirus to bind transfected cells were assessed by flow 
cytometry (Figure 15).  All constructs were detected at the cell surface.  Chimera-
transfected cells stained with both hJAM-A- and hCAR-specific antisera, indicating that 
the molecules are indeed chimeric (Figure 15).  Prototype reovirus strain T1L bound cells 
expressing wild-type hJAM-A, chimera JCJ, and deletion mutant J∆J but failed to bind 
cells expressing hCAR, chimera CJJ, or deletion mutant ∆JJ (Figure 15).  T3 reovirus 
strain T3SA- also bound cells expressing constructs that contained the D1 domain of 
hJAM-A (data not shown).  These data demonstrate that both T1 and T3 reoviruses 
engage the membrane-distal D1 domain of hJAM-A. 
 
Reovirus infection and growth in CHO cells expressing chimeric and deletion mutant 
receptors 
 
 To determine the role of specific JAM-A domains in reovirus infection, CHO cells 
were transiently transfected with plasmids encoding the hCAR-hJAM-A chimeras or 
hJAM-A domain-deletion mutants.  Transfected cells were adsorbed with T1L, and the 
capacity of reovirus to infect these cells was assessed by indirect immunofluorescence.   
 Consistent with the binding experiments, reovirus protein expression was detected 
after infection of cells expressing wild-type hJAM-A, chimera JCJ, and deletion mutant 
J∆J (Figure 16).  As a control, adenovirus infection also was tested by adsorbing 
transfected cells with Ad 5-GFP.  This Ad5-GFP was constructed from a plasmid which 
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Figure 15. Reovirus engages the D1 domain of hJAM-A. CHO cells were transiently 
transfected with plasmids encoding the indicated receptor constructs.  Following incubation 
for 24 h to permit receptor expression, cells (1 x 106) were stained with hCAR or hJAM-A-
specific antisera or adsorbed with reovirus T1L (1 x 1011 particles).  Cell surface expression 
of receptor constructs and virus binding were assessed by flow cytometry.  
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contained a 2.3-kb, cytomegalovirus (CMV) promoter-driven enhanced green fluorescent 
protein (EGFP) gene (derived from pEGFP-1 [Clontech, Palo Alto, Calif.]) inserted into 
the E3 region of Ad5 (141).   Cells expressing hCAR and CJJ supported infection by 
adenovirus (data not shown), demonstrating that these molecules also can serve as 
functional virus receptors.  To provide further support for the role of hJAM-A D1 in 
reovirus infection, viral replication was assessed 24 h after adsorption by plaque assay.  
T1L produced substantially higher yields in cells expressing hJAM-A, JCJ, and J∆J in 
comparison to yields in cells expressing receptors that lack the hJAM-A D1 domain 
(Figure 16).  Together, these data indicate that the D1 domain of hJAM-A is required for 
reovirus attachment, infection, and growth. 
 
Overall structure of hJAM-A 
 To better understand structure-function relationships of JAM-A which mediate 
binding to reovirus, a GST–hJAM-A fusion protein was constructed.  The extracellular 
portion of hJAM-A was cloned into a vector encoding glutathione S-transferase (GST) 
followed by a thrombin cleavage site to produce a GST-hJAM-A fusion protein.  The protein 
was expressed in bacteria and purified using a glutathione column followed by cleavage with 
thrombin.  The protein was further purified by ion-exchange chromatography and size-
exclusion.   Crystals were obtained by using 8 mg/ml protein and 16% PEG 6K, 18%  
isopropanol, 0.1 M sodium citrate as precipitant.  
 The polypeptide chain of the extracellular region of hJAM-A folds into two 
concatenated Ig-like domains, termed D1 and D2 (Figure 17).  The N-terminal D1 
domain contains two antiparallel β-sheets (strands ABED and GFCC'C"), which classifies  
it as an Ig-like domain of the variable type (V-set).  Although the fold of D2 is very 
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Figure 16. The D1 domain of hJAM-A is required for reovirus infection and replication.
CHO cells were transiently transfected with plasmids encoding the indicated receptor 
constructs and incubated for 24 h to permit receptor expression. (A) Transfected cells (4 x 
105) were infected with reovirus T1L at an MOI of 1 FFU per cell and incubated at 37 °C for 
20 h.  Cells were fixed and stained for reovirus protein, and infected cells were identified by 
indirect immunofluorescence.  Representative images are shown.  (B) transfected cells (2 x 
105) were adsorbed with reovirus T1L at an MOI of 1 PFU per cell. Reovirus growth was 
assessed by plaque assay at 0 and 24 h postadsorption.  Shown are mean viral titers for three 
independent experiments.  The error bars indicate standard deviations.  
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similar to that of D1, this domain has a much shorter C' strand, and it lacks the C'' strand.  
These differences indicate that D2 is an intermediate type (I-set)  Ig-like domain (78) and 
not a V-set Ig-like domain, as reported for mJAM-A D2 (95).  Analysis with DALI (82) 
shows that the prototypical I-set domain, telokin (78), is among the closest structural 
homologs of hJAM-A D2.  Both D1 and D2 of hJAM-A have the classical disulfide bond 
between β-strands B and F.  The hJAM-A structure exhibits a pronounced elbow angle of 
~125° between the two domains.  As expected, the overall structure of each hJAM-A 
D1D2 monomer resembles that of mJAM-A D1D2 (95), although there are 
conformational differences between the two proteins in surface loops and at the 
interdomain interface.  Our structure also allows us to trace a long loop between β-strands 
C' and D (C'D loop) in D2 that was disordered in the model for mJAM-A D1D2. 
 The asymmetric unit of the hJAM-A crystals contains two independent but 
virtually identical chains (termed A and B).  Each chain assembles into a U-shaped 
homodimer with crystallographic 2-fold symmetry.  The dimer interface features an 
extensive contact between the D1 domains and is reminiscent of an arm-wrestling grip, 
with the GFCC' faces of the two N-terminal domains interlocking at an angle of ~90° 
(Figure 17). Two crystallographically independent dimers are observed.  One is formed  
by chain A and its symmetry mate A, and the other is formed by chains B and B.  Two 
observations suggest that the hJAM-A dimer is physiologically relevant: (i) the purified 
protein elutes at the expected molecular mass for a dimer (48 kDa) by size-exclusion 
chromatography and (ii) a similar dimeric structure was seen in the crystals of mJAM-A  
(95).  With the exception of the dimeric interaction, the arrangements of the molecules in 
the hJAM-A and mJAM-A crystals are not related. 
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Figure 17. Structure of hJAM-A.  (A and B) Ribbon drawings of the hJAM-A dimer, with 
one monomer shown in orange and the other in blue.  Two orthogonal views are displayed. 
Disulfide bonds are shown in green.  (C) View of the interface between two hJAM-A 
monomers. The interface is formed by residues on the GFCC' faces of two D1 domains.  The 
view is along a crystallographic dyad.  Hydrogen bonds and salt bridges are represented by 
broken cylinders.  Amino acids are labeled in single-letter code.  
 
 
 
 46
Interaction of hJAM-A with reovirus attachment protein σ1 
 The crystal structure of the reovirus attachment protein σ1 revealed a putative binding 
site for JAM-A at the lower edge of the σ1 head domain (37).  To investigate whether other 
JAM family members serve as reovirus receptors, we transiently transfected CHO cells with 
hJAM-A, hJAM-B, or hJAM-C and assayed transfected cells for the capacity to support 
reovirus infection.  Expression of JAM proteins at the cell surface was confirmed by flow 
cytometry (Figure 20).  In contrast to cells transfected with hJAM-A, cells transfected with 
hJAM-B or hJAM-C were not infected by reovirus (Figure 20).  Our findings clearly 
demonstrate that reovirus recognizes structural features that are present in hJAM-A but not in 
hJAM-B or hJAM-C. 
 To define structural features unique to JAM-A and potentially involved in contacting σ1, 
we identified conserved sequences in hJAM-A and mJAM-A that are not conserved in the 
other two JAM family members (Figure 20).  Both hJAM-A and mJAM-A serve as reovirus 
receptors, whereas hJAM-B and hJAM-C do not.  Because the D1 domain of hJAM-A is 
necessary and sufficient for interaction with σ1 (Figures 15 and 16), our analysis was 
restricted to that domain.  Residues unique to hJAM-A D1 and mJAM-A D1, and therefore 
likely to participate in σ1 binding, cluster in three main areas (Figure 20): a region at the  
dimer interface (shown in orange) and two surface-exposed regions at the "back" of the  
molecule, opposite the dimer interface (shown in green and magenta, respectively).  All three 
areas are candidates for interaction with σ1.  
 Interestingly, the "top" of the hJAM-A dimer does not contain conserved residues, and 
therefore we hypothesize that σ1 either engages the side of the hJAM-A dimer (via the 
magenta or green surfaces) or the JAM-A dimer interface (via the orange surface).  The green 
surface near the top of D1 comprises the BC loop and the beginning of strand C.  This surface 
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is most complementary in shape and size to the proposed JAM-A-binding region of σ1 (37) 
and, thus, it is a good candidate for σ1–JAM-A interactions.  The equivalent regions in JAM-
B and JAM-C likely have a different structure because of two-residue insertions (Figure 20), 
perhaps explaining the inability of these proteins to serve as reovirus receptors.  The magenta-
colored regions at the "back" of the protein contain three solvent-exposed side chains, Lys-
47, Thr-88, and Thr-95, which also could participate in the interaction with σ1.  
 The interdimer interface of JAM-A (the orange surface in Figure 20) is not accessible to 
σ1 in the context of a JAM-A–JAM-A dimer.  However, σ1 might engage this surface in 
monomeric forms of JAM-A.  Such a mechanism of binding is identical to the strategy used 
by the adenovirus fiber knob to bind the monomeric form of CAR (24).  Indeed, comparison 
of the sequences of JAM-A and CAR shows that JAM-A residues highlighted in orange 
cluster in the same region as the CAR residues known to bind fiber (Figure 20).  Although we 
have no evidence to suggest that σ1 binds to JAM-A in a similar manner, the similarities 
exhibited by σ1 and fiber, and between JAM-A and CAR, indicate that such an interaction 
might occur.  The affinity of the σ1 head domain for hJAM-A is in the nanomolar range 
 (6 x 10–8 M) (10).  Although the affinity of JAM-A for itself is not known, studies using 
recombinant mJAM-A demonstrated that a significant portion of this protein is monomeric 
under physiologic conditions (18).  This finding suggests that JAM-A–JAM-A interactions 
are weak.  Therefore, it seems plausible that σ1 binds to monomeric JAM-A, perhaps by 
engaging residues that form the JAM-A–JAM-A interface. 
 
Structure of the dimer 
 Residues involved in hJAM-A homodimer formation are exclusively located on the 
concave GFCC' face of D1.  The dimer interface includes four buried salt bridges (Arg-59– 
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Figure 18.  Comparison of dimeric arrangements in hJAM-A and mJAM-A. (A) 
Superposition of dimeric structures of hJAM-A (colored as in Fig. 14) and mJAM-A (gray). 
The superposition is based on D1 residues of one monomer only (the orange monomer of 
hJAM-A). (B) Conservation of residues at the mJAM-A and hJAM-A D1 domain dimer 
interfaces. One hJAM-A monomer is shown in surface representation, and the other is shown 
as a blue ribbon. Residues that are strictly conserved in mJAM-A are shown in orange and 
cover the entire dimer interface.  
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Figure 19.  Dimeric structures of virus receptors hJAM-A and CAR. The D1 domains of 
hJAM-A (Upper) and CAR (Lower) engage in a conserved mode of dimerization based on 
interactions between the concave GFCC' β-sheets. Disulfide bonds are in green.  
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Figure 20. Interaction of reovirus with hJAM-A. (A) Transiently transfected CHO cells 
display surface expression of JAM family members. CHO cells were transiently transfected 
with hJAM-A, hJAM-B, or hJAM-C and screened for surface expression of JAM proteins by 
flow cytometry.  (B) Transfection of CHO cells with hJAM-A, but not hJAM-B or hJAM-C, 
rescues infection by reovirus strain T1L.  Shown are infected cells as detected by indirect 
immunofluorescence using rabbit antireovirus sera.  (C) Sequence alignment, with residues 
conserved in hJAM-A and mJAM-A, but not in hJAM-B or hJAM-C, highlighted in orange, 
magenta, and green. Arrows indicate β-strands.  CAR residues contacting the adenovirus 
fiber knob in the complex are highlighted in yellow. Residues conserved in all sequences are 
shown in bold.  (D) The hJAM-A D1D2 dimer viewed from opposite angles, with one 
monomer shown in surface representation and the other shown as a blue ribbon. The side 
chains of conserved residues from C were mapped onto the hJAM-A D1D2 surface by using 
the same color code. Residues colored in orange, green, or magenta cluster in three different 
surface areas. Residues shaded gray in C are buried and not visible in this representation.  
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Glu-61, Glu-61–Arg-59, Lys-63–Glu-121, and Glu-121–Lys-63) as well as several 
hydrophobic contacts (Leu-72–Tyr-119, Met-110–Met-110, and Tyr-119–Leu-72) (Figure 
18).  Hydrogen bonds exist between the Tyr-75 and Glu-114 side chains.  
 Although the GFCC' face of D1 also mediates homodimer formation in the mJAM-A 
D1D2 structure (95), the relative arrangements of the D1 domains in the two dimers are 
noticeably different (Figure 18).  The mJAM-A interdomain interface contains only two salt 
bridges and fewer additional contacts (95).  The Lys-63–Glu-121 and Met-110–Met-110 
interactions at the center of the hJAM-A interface are absent in mJAM-A, as are the hydrogen 
bonds involving Tyr-75, Glu-114, and their symmetry-related counterparts.  These differences 
result in a smaller interface in mJAM-A (Figure 18).  Using the program SURFACE and a 
standard probe radius of 1.4 Å, we calculate buried surface areas of 1,380 and 1,200 Å2 for 
the hJAM-A and mJAM-A dimers, respectively. 
 The observed differences in the hJAM-A and mJAM-A dimers are noteworthy 
given the near absolute conservation of residues at the dimer interfaces (Figure 18).  The 
GFCC' faces of hJAM-A and mJAM-A (residues 58–75 and 105–122 of hJAM-A) can be 
superimposed onto each other with an root means squared deviation of 0.4 Å for the 36 
Cα atoms.  There are only six substitutions among these 36 aa, and none of the 
substituted residues engage in dimer contacts (distances >4 Å).  Thus, differences in the 
arrangement of the hJAM-A and mJAM-A dimer interfaces cannot be explained by 
altered contacts mediated by substituted residues.  Instead, these differences are likely 
caused by crystal packing forces involving other regions of the molecules, and they 
indicate that small movements of one monomer with respect to the other can occur.  
 The dynamic nature of the JAM-A dimer interface may result in part from its 
dependence on ionic interactions, which is unusual for protein–protein interfaces.  Low 
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pH and moderately high ionic strength lead to dissociation of the mJAM-A dimer (18), 
indicating that ionic interactions represent the principal means of association.  We note 
that both structures were obtained by using conditions of low ionic strength and at pH 
values at which acidic side chains are expected to be deprotonated.  Thus, salt bridges are 
expected to exist in both cases.  However, the free energy contribution of salt bridges in 
an aqueous environment is small (139).  The JAM-A dimer interface, which is stabilized 
primarily by salt bridges and contains several solvent molecules, is therefore especially 
likely to undergo rearrangement or dissociation. 
 
Discussion 
 Experiments reported here were performed to define the molecular basis of reovirus 
attachment to hJAM-A.  The capacity of reovirus to bind, infect, and replicate to high titers in 
cells expressing chimeric hCAR-hJAM-A receptor constructs and single domain deletion 
mutants demonstrates that the membrane-distal D1 domain of hJAM-A is an essential 
component of the reovirus receptor function of hJAM-A (Figures 18 and 19).  Several viruses 
have been demonstrated to engage cellular receptors via the most distal domain of an Ig 
superfamily receptor, including adenovirus (hCAR) (24, 65), coxsackievirus (hCAR) (79), 
human immunodeficiency virus (CD4) (97), measles virus (SLAM) (119), poliovirus (PVR) 
(21), and rhinovirus (ICAM-1) (94).  Thus, utilization of the membrane-distal D1 domain of 
hJAM-A by reovirus provides additional evidence for a common theme in viral attachment. 
The attachment proteins of adenovirus and reovirus share structural and functional 
properties, which has led to speculation that they have a common ancestor (37).  
Remarkably, the receptors for both viruses, CAR and JAM-A, respectively, also share 
key structural properties.  CAR forms a homodimer (171) that is structurally similar to the 
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hJAM-A homodimer and also is formed by interactions between the GFCC' β-sheets of 
the N-terminal D1 domains (Figure 19).  Although the contacts between CAR monomers 
are somewhat more hydrophobic and do not directly involve salt bridges (171), several 
charged residues are present at the CAR–CAR interface (Glu-56, Asp-68, Lys-121).  It is 
possible that these side chains interact via water molecules.  Moreover, the relative 
arrangement of the two CAR monomers is highly similar to that observed for the two 
hJAM-A monomers (Figure 19).  Both contacts involve concave GFCC' β-sheets that face 
each other at an angle of  ~90° and bury an almost identical amount of solvent (1,300 Å2 
for the CAR–CAR dimer (171) and 1,380 Å2 for hJAM-A–hJAM-A). 
 Homodimeric structures have been observed in a number of other Ig superfamily 
proteins (31, 89, 91, 120, 193), but only one of these proteins, CD2, forms dimers via the 
GFCC' β-sheet of D1 (26, 89).  However, it is noteworthy that several Ig superfamily 
receptors engage viral ligands via the GFCC' β-sheet.  The HIV glycoprotein gp120 binds 
to residues on the GFCC' face of its receptor CD4 (97), and the same region of CD4 also 
interacts with its natural ligand MHC class II (180).  Complexes of rhinoviruses and 
coxsackievirus A21 with their receptor intercellular adhesion molecule-1 (ICAM-1) also 
show that the interactions involve residues at the top of ICAM-1 D1, a region that 
includes part of the GFCC' face (20, 195).  Moreover, the adenovirus fiber knob engages 
the same area of the GFCC' face that mediates formation of the CAR–CAR dimer (24, 
171).  The structure of the complex between fiber knob and CAR shows a trimeric knob 
decorated with three copies of monomeric CAR (24, 171). 
 Analysis of the crystal-packing arrangement of the mJAM-A molecules has led to a 
model of JAM-A interactions at tight junctions (95).  In this model, a JAM-A dimer located 
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at the surface of one cell engages a dimer on the opposing cell via contacts in D1, producing 
an extensive network of contacts between dimers.  Although our crystals contain two 
crystallographically nonequivalent copies of hJAM-A, we do not observe a similar contact 
involving either of these molecules, and thus our structural analysis does not provide 
supporting evidence for the model presented by Kostrewa et al. (95).  In the hJAM-A 
crystals, two alternative contacts between hJAM-A dimers that could form the basis for 
interactions in tight junctions exist.  However, neither of these contacts is observed in the 
mJAM-A crystal lattice.   
One interpretation of the available crystallographic data is that contacts between 
JAM-A dimers in tight junctions involve low-affinity interactions that depend on the 
presence of additional proteins, and these interactions cannot be easily reproduced by 
using conditions that promote crystallization.  Another interpretation is that the JAM-A 
dimer itself, which is observed in the crystals of hJAM-A and mJAM-A, represents a 
physiologic contact present in tight junctions.  In this interpretation, JAM-A monomers 
would engage JAM-A monomers on apposing cells to help mediate homophilic cell–cell 
interactions.  The dimensions for such a model suggest that it deserves consideration, 
because it would lead to a separation of cells of ~85 Å, similar to the observed distances 
between cells at tight junctions of ~100 Å.  CAR is also thought to mediate homophilic 
interactions between cells (43, 83, 179), and the homodimeric structure of CAR has been 
interpreted to depict an interaction between CAR monomers from apposing cells (171). 
 Of the virus receptors whose structures have been solved, only adenovirus receptor 
hCAR and reovirus receptor JAM-A have been demonstrated to form homodimers by 
contacts between the GFCC' β-strands of apposing D1 domains (95, 129, 171).  Moreover, 
there are numerous similarities in the attachment proteins of adenovirus and reovirus: 1) both 
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form trimers; 2) both insert into pentamers of capsid proteins at the virion 5-fold symmetry 
axes; 3) both have fibrous domains formed by unique triple β-spiral structural motifs; and 4) 
both have globular, virion-distal domains formed by β-barrel structures with unique and 
identical β-strand connectivity.  These similarities suggest functionally convergent evolution 
of two large, nonenveloped viruses (151).  Additionally, the observation that hJAM-A and 
hCAR share numerous structural and functional similarities leads to the hypothesis that 
adenovirus and reovirus engage their receptors using similar mechanisms. 
 The crystal structure of the hJAM-A ectodomain provides insights into how JAM-A 
functions in tight junction formation and viral attachment.  A key feature of JAM-A is its 
capacity to form dimers via an extensive interface in its N-terminal domain.  This interface is 
distinguished from traditional protein–protein interfaces by its highly polar character and its 
capacity to accommodate substantial rearrangements.  The latter is evidenced by the different 
dimeric structures of hJAM-A and mJAM-A despite absolute conservation of residues at the 
interface.  We think it possible that the dynamic nature of the interface plays a role in 
mediating and perhaps facilitating transitions between monomeric and dimeric forms of JAM-
A.  Moreover, the dynamic nature of the interface likely distinguishes JAM-A from the other 
JAM family members, JAM-B and JAM-C, both of which contain substitutions that are 
predicted to alter the stability of the interface.  Previous work from our laboratory has shown 
that the adenovirus and reovirus attachment proteins share many structural and functional 
features (37).  Here we show that the similarities also extend to their receptors.  The crystal 
structure of hJAM-A features a dimeric arrangement that closely resembles that seen in the 
adenovirus receptor, CAR.  Parallels in the structures of these molecules are especially 
intriguing in light of the recent observation that CAR, like JAM-A, is a component of cell–
cell junctions (43, 83, 179).  Thus, both viral and cellular determinants of adenovirus and 
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reovirus binding exhibit striking structural similarities, which suggest conserved strategies of 
attachment among these viruses. 
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CHAPTER IV 
 
A CHIMERIC ADENOVIRUS VECTOR ENCODING REOVIRUS ATTACHMENT 
PROTEIN σ1 TARGETS CELLS EXPRESSING JUNCTIONAL ADHESION 
MOLECULE-A 
 
 
Introduction 
 Adenovirus (Ad) vectors are potent gene-delivery vehicles capable of eliciting both 
mucosal and systemic immune responses (142).  Ad vectors are advantageous because the 
can tolerate large fragments of DNA and have a low frequency of nonhomologous 
chromosomal integration (81).  Human Ad serotypes 2 and 5 (Ad2 and Ad5) bind and enter 
cells by using the combined interactions of the fiber and penton base proteins with cellular 
receptors.  The fiber protein is an elongated trimer with an N-terminal fibrous tail domain 
(shaft) and a C-terminal globular head domain (knob).  Ad2 and Ad5 engage the 
coxsackievirus and Ad receptor (CAR) (23, 161) via a binding site located in the knob 
[Roelvink, 1998 #3093].  CAR is a member of the Ig superfamily (23, 161) expressed at 
regions of cell-cell contact (43).  After fiber-mediated attachment, the penton base binds to 
cell surface αv integrins, which mediate internalization (187).  
 Although Ad5 vectors transduce many types of cells, the efficiency of these vectors is 
limited if cells lack one or more Adenovirus receptors (86).  For example, dendritic cells 
(DCs) do not express CAR and are poorly transduced by Ad5 (160).  This relatively poor 
transduction of DCs can be enhanced by engineering the vector to target alternative receptors 
(22, 125).  Ad serotypes that bind to other receptors (e.g., CD46 (67) mediate increased 
transduction of immunologically relevant cells (177), but these vectors are more promiscuous 
than Ad5 and deliver genes into cells that may not contribute to vaccination and thus may 
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increase toxicity.  Therefore, although potent, current Ad vectors lack sufficient specificity to 
function in some applications.  
 The reovirus attachment protein, σ1, plays a key role in targeting the virus to distinct 
cell types, including those at mucosal surfaces (1, 27, 189, 190).  Similar to the Ad fiber, 
reovirus σ1 is an elongated trimer with head-and-tail morphology [Furlong, 1988 
#370;Banerjea, 1988 #77;;Fraser, 1990 #3682].  A domain in the fibrous tail of T3D σ1 binds 
to α-linked sialic acid (9, 35, 36, 49), whereas the head binds to JAM-A (10).   
 The structures of the Ad fiber (172) and reovirus σ1 (37) proteins are strikingly 
similar (Figure 19).  The two proteins are the only structures known to date to form trimers 
by using triple β-spiral motifs.  The fiber shaft most likely is composed entirely of β-spiral 
repeats (172), whereas the σ1 tail is predicted to also contain an α-helical coiled-coil N-
terminal to the β-spiral region (37).  The head domains of both proteins are formed by eight 
antiparallel β-strands with identical interstrand connectivity.  Therefore, although Ad and 
reovirus belong to different virus families and have few overall properties in common, the 
observed similarities between the attachment proteins and receptors of these viruses suggest a 
conserved mechanism of binding. 
 Based on the structural similarities between Ad fiber and reovirus σ1, we engineered 
chimeric fiber-σ1 attachment proteins to exploit the JAM-A and sialic acid-binding properties 
of σ1.  Of those tested, only a near-full-length version of σ1 grafted onto the virion-insertion 
domain of Ad fiber (Fibtail-T3D σ1) formed trimers and assembled onto Ad particles.  We 
show here that when the fiber gene in the Ad5 genome is replaced with Fibtail-T3D σ1, the 
resulting virus, Ad5-T3Dσ1, is capable of infecting intestinal epithelial cells expressing 
JAM-A and sialic acid and primary human DCs expressing JAM-A.  These data provide 
 59
proof of principle for the development of chimeric Ad vectors encoding reovirus σ1 for gene 
delivery to mucosal surfaces.  This work also establishes a foundation for the use of Ad-σ1 
chimeric viruses as a template to enable facile reverse genetic manipulation of the reovirus 
attachment protein for studies of virus–cell and virus–host interactions.  Results presented in 
this chapter were gathered in collaboration with Skip Mercier and Michael Barry at Baylor 
College of Medicine. 
 
Results 
 
Design and Characterization of a Functional Fiber-σ1 Chimera 
 Based on the structural similarities between Ad5 fiber and reovirus σ1 (Figure 21), 
we engineered three Ad fiber-reovirus σ1 chimeras with increasingly larger portions of σ1 
protein replacing structurally homologous regions of fiber (Figure 22A).  Fibshaft-T3Dσ1 
contains the N-terminal 21 β-spiral repeats of fiber fused to the head domain of T3Dσ1.  
Fib8-T3Dσ1 contains the N-terminal eight β-spiral repeats of fiber fused to the T3D σ1 β-
spiral and head domains.  Fibtail-T3Dσ1 contains the N-terminal 44 aa virion-anchoring  
domain (41) fused to T3Dσ1 lacking only the N-terminal 17 amino acids.  After transfection 
of CHO cells, each of the chimeric attachment proteins was expressed, but only Fibtail-
T3Dσ1formed trimers (Figure 22B and data not shown), suggesting that only this chimera 
maintains native folding. 
 
Production and characterization of an Ad vector expressing a chimeric fiber-σ1 
attachment protein 
 
 The Fibtail-T3Dσ1 gene was recombined into an Ad5 genome lacking E1 and E3 to  
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Figure 21. Full-length models of Ad5 fiber (Upper) and reovirus σ1 (Lower). The three 
monomers within each trimer are shown in red, orange, and blue. Both proteins have head-
and-tail morphology, with an eight-stranded β-barrel domain forming the head.  The Ad5 
fiber model was generated by adding 17 β-spiral repeats to the four present in the crystal 
structure of an Ad2 fragment, which also has 21 β-spiral repeats.  Sequence predictions 
suggest that  1 contains an N-terminal  135-residue α-helical coiled coil followed by eight β-
spiral repeats and the globular head domain. The σ1 model was generated by first adding five 
β-spiral repeats to the N terminus of the crystallized fragment.  This model then was joined 
with a 135-residue trimeric coiled coil formed by elongating an existing coiled-coil structure.  
The N-terminal 45 and 39 residues of fiber and σ1, respectively, are not included in the 
model, because they form a virion-anchoring structure (indicated by gray lines).  
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Figure 22.  Design and expression of chimeric fiber-σ1 attachment proteins. (A) 
Schematic diagram of the chimeric fiber-σ1 attachment proteins described in the text. 
Regions corresponding to fiber and σ1 in the diagrams are shaded black and gray, 
respectively (not drawn to scale).  Fiber tail, which mediates virion anchoring, is represented 
as a small cylinder, the α-helical coiled coils as small ovals, the β-spiral repeats as large 
cylinders, and the head domain as three large ovals.  (B) Immunoblots of denatured (boiled) 
and native (unboiled) lysates of CHO cells transfected with plasmid expressing Fibtail-
T3Dσ1 probed with a serum (1561) that recognizes the N-terminal region of Ad5 fiber.  
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replace the fiber gene by using λphage red recombinase (128).  During the cloning process, 
two c-Myc tags (C2) and one hexahistidine tag (H6) were added to the C terminus of Fibtail-
T3Dσ1 (Fibtail-T3Dσ1C2H6) to facilitate protein detection.  The resulting virus, Ad5-
T3Dσ1, was rescued by transfection and production in 633 fiber-expressing cells (178).  After 
amplification in 633 cells, the virus was passaged in 293A cells to eliminate fiber from the 
virions and allow only Fibtail-T3Dσ1C2H6 to be encapsidated.  
 To determine whether Fibtail-T3Dσ1C2H6 was encapsidated onto Ad5 virions, CsCl-
purified Ad5, Ad5-BAP-TR, which contains biotinylated fibers (125), and Ad5T3Dσ1 were 
analyzed by immunoblotting using antibodies specific for either the fiber N terminus or the c-
Myc epitope tag (Figure 23A).  Comparison of the immunoblots demonstrated that Fibtail-
T3Dσ1C2H6 was encapsidated onto Ad5 virions at levels similar to those of fiber on Ad5 
and Ad5-BAP-TR.  As anticipated, the anti-c-Myc antibody recognized both Ad5-BAP-TR 
and Ad5-T3Dσ1, which contain c-Myc tags but not wild-type fiber.  Coomassie blue staining 
demonstrated that relative amounts of the capsid proteins of wild-type Ad5 and Ad5-
T3Dσ1were comparable (Figure 23B).  Thus, Fibtail-T3Dσ1C2H6 is encapsidated onto Ad 
virions and enables normal virion maturation. 
 
Transient transfection of CHO cells with JAM-A rescues infection by Ad5-T3Dσ1 
 To determine whether the chimeric Fibtail-T3Dσ1 attachment protein could bind to 
JAM-A, CHO cells were transfected with plasmids expressing hCAR, hJAM-A, and mJAM-
A and tested for infection by luciferase-expressing Ad5-T3Dσ1.  CHO cells were chosen for 
these studies, because they lack both CAR and JAM-A and are poorly infected by both Ad 
and reovirus (63).  Transduction of CHO cells by Ad5-T3Dσ1 was increased substantially by  
expression of either hJAM-A or mJAM-A but not by expression of hCAR (Figure 24A), the  
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Figure 23. Characterization of Ad5-T3Dσ1. Ad5 virions expressing wild-type fiber 
(Fiberwt), CAR-ablated biotinylated fiber (Fiber-BAP-TR), and Fibtail-T3D 1C2H6 were 
precipitated with trichloroacetic acid.  (A) Precipitated particles (4 x 1010 per lane) were 
resolved by SDS/PAGE and immunoblotted with anti-c-Myc mAb 9E10 or antiserum 1561, 
which recognizes the N-terminal region of Ad5 fiber.  (B) Precipitated particles (1.5 x 1011
per lane) were resolved by SDS/PAGE and stained with Coomassie blue.  
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receptor for Ad5 (23, 161).  These data indicate that the JAM-A-binding domain of Ad5-
T3Dσ1 is functional and can target JAM-A-expressing cells in a species-independent fashion. 
 
Inhibition of binding to JAM-A and sialic acid blocks Ad5-T3Dσ1 infection of Caco-2 
cells 
 
 We next tested the capacity of hJAM-A-specific mAb J10.4 and C. perfringens 
neuraminidase to inhibit transduction by Ad5-T3Dσ1.  Caco-2 intestinal epithelial cells, a 
model for enteric mucosal surfaces (93, 170), were used for these experiments, because these 
cells express CAR, JAM-A, and sialic acid (10, 39).  Transduction by Ad5-T3Dσ1 was 
inhibited 50% by JAM-A-specific mAb J10.4 and 80% by neuraminidase (Figure 24B). 
Combined treatment with both mAb J10.4 and neuraminidase reduced transduction nearly  
95%.  In contrast, isotype-matched hCAR-specific mAb RmcB, used as a negative control, 
did not diminish luciferase transduction (Figure 24B).  
 To ensure that JAM-A-dependent transduction by Ad5-T3Dσ1 depends on σ1 and not 
another Ad protein, we tested the capacity of the T3D σ1-specific mAb 9BG5 [Burstin, 1982 
#362] to block infection of Caco-2 cells.  In contrast to T1L σ1-specific mAb 5C6 (174), 
mAb 9BG5 inhibited transduction in a dose-dependent fashion (data not shown).  We noted a 
similar decrease in transduction efficiency after incubation of Ad5-T3Dσ1 with 
sialoglycophorin, which is known to interact with reovirus T3Dσ1 (49), before infection (data 
not shown).  These results demonstrate that transduction by Ad5-T3Dσ1 requires σ1 and its 
receptors, JAM-A and sialic acid. 
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Figure 24.  Ad5-T3Dσ1 transduction is mediated by JAM-A and sialic acid. (A) CHO cells 
were transiently transfected with plasmids encoding hCAR, hJAM-A, or mJAM-A. After 48 h of 
incubation to permit receptor expression, cells were adsorbed with 5,000 particles per cell of Ad5-
T3Dσ1 and harvested 24 h later for luciferase assay.  Transduction was measured in lumens.  (B) 
Caco-2 cells were either untreated or treated with 10 µg/ml hCAR-specific mAb RmcB (CAR 
mAb), 10 µg/ml hJAM-A-specific mAb J10.4 (JAM-A mAb), 333 milliunits/ml C. perfringens
neuraminidase (NM), or both JAM-A mAb and neuraminidase.  Cells were adsorbed with 5,000 
particles per cell of Ad5-T3Dσ1 and harvested 24 h later for luciferase assay.  Transduction was 
measured in lumens.  The results are presented as the means for three independent experiments.  
Error bars indicate SD.  A paired Student's t test was performed to compare transduction of 
transfected or treated cells versus mock or untreated cells (*, P < 0.01; **, P < 0.05; ns, not 
significant).  
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Ad5-T3Dσ1 Transduces Primary Human DCs 
 DCs play important roles in the induction of adaptive immune responses (8).  To 
determine whether Ad5-T3Dσ1 is capable of transducing DCs, we infected primary cultures 
of human DCs with Ad5 and Ad5-T3Dσ1.  DCs express JAM-A but not CAR (Figure 25A), 
which is consistent with previous observations (132).  Transduction of DCs by Ad5-T3Dσ1 
was substantially more efficient than by Ad5 (Figure 25B).  Moreover, transduction was 
eliminated almost completely by treatment with hJAM-A-specific mAb J10.4 (Figure 25B).  
These findings suggest that Ad5-T3Dσ1 may have utility for transducing CAR-negative DCs 
at mucosal and other sites. 
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Figure 25.  Ad5 and Ad5-T3Dσ1 transduction of primary human DCs. (A) DCs were 
assessed for surface expression of CAR and JAM-A by flow cytometry by using hCAR-
specific mAb RmcB and hJAM-A-specific mAb J10.4, respectively.  (B) DCs were either 
untreated or treated with 10 µg/ml hCAR-specific mAb RmcB (CAR mAb) or hJAM-A-
specific mAb J10.4 (JAM-A mAb) before adsorption with 5,000 particles per cell of either
Ad5 or Ad5-T3Dσ1.  Cells were harvested 24 h later for luciferase assay.  Transduction was 
measured in lumens.  The results are presented as the means for three independent 
experiments.  Error bars indicate SD.  A paired Student's t test was performed to compare 
transduction by Ad5 versus Ad5-T3D 1 (*, P < 0.01; **, P < 0.05).  
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Discussion 
 In this study, we fused two structurally homologous viral attachment proteins, Ad 
fiber and reovirus σ1, to produce a functional chimeric virus, Ad5-T3Dσ1.  Of the three 
fiber-σ1 chimeras tested, only Fibtail-T3Dσ1 bearing the Ad5 fiber virion-insertion 
domain fused to an almost-full-length version of T3D σ1 protein formed trimers and 
assembled onto Ad virions.  The lack of trimerization of Fib8-T3Dσ1 and Fibshaft-
T3Dσ1 was surprising, because both the head and tail regions of σ1 contain trimerization 
domains (69), whereas the fiber knob domain initiates and maintains trimerization (84).  
Because only Fibtail-T3Dσ1 formed trimers, it is likely that the C-terminal trimerization 
domain of σ1 is insufficient for trimerization of the fiber shaft.  Alternatively, it is 
possible that the chimeric Fib8-T3Dσ1 and Fibshaft-T3Dσ1 proteins do not form trimers, 
because the fused β-spiral junctions are imperfectly matched. 
 In Ad5-T3Dσ1 virions, Fibtail-T3Dσ1 was encapsidated at levels comparable with 
wild-type fiber.  Furthermore, the capsid protein profile of Ad5-T3Dσ1 is similar to that 
of wild-type Ad5.  Most importantly, experiments using receptor-transfected cells, 
antibodies, and reagents that block σ1-sialic acid interactions provide compelling 
evidence that Ad5-T3Dσ1 displaying Fibtail-T3Dσ1 retains both the JAM-A and sialic 
acid-binding functions of the T3Dσ1 protein.  
 We envision at least four applications for chimeric Ad vectors in which the CAR-
binding functions of fiber have been replaced with the JAM-A and sialic acid-binding 
functions of σ1.  First, Ad vectors based on fiber-σ1 chimeras may serve to efficiently 
target mucosal sites for enhanced induction of immune responses at mucosal surfaces.  
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Second, because JAM-A and sialic acid are expressed on a variety of cells, Ad5-T3Dσ1 
and its derivatives may have utility for transducing cells deficient in CAR (e.g., DCs and 
certain types of cancer cells).  Third, because σ1 incorporates its own trimerization 
motifs, fiber-σ1 fusions may provide a trimeric scaffold for the display of other cell-
targeting ligands in a manner analogous to fiber-fibritin chimeras (96).  In support of this 
approach, we recently appended single-chain antibodies onto truncated forms of Fibtail-
T3Dσ1 for delivery of Ad vectors to cells expressing antibody targets (unpublished data).  
Fourth, Ad vectors based on Ad5-T3Dσ1 can be used as a simple genetic platform for 
directed mutagenesis of σ1 for studies of reovirus tropism and receptor-linked signaling. 
 Recently, an additional report has been published that characterizes an Ad5 vector 
that produces a mosaic virus expressing both the Ad5 and reovirus attachment proteins 
(162).  This study confirms that Ad5 tropism can be modified by the exchange or addition 
of the Ad5 fiber with σ1 binding properties.  Interestingly, the modified Ad5-σ1 vector 
enhanced infectivity of cancer cell lines that lack CAR expression (162).   
 The opportunity to use Ad vectors encoding fiber-σ1 chimeras for mucosal targeting 
is especially appealing.  Increased delivery of antigens to intestinal epithelial cells and 
Peyer's patch lymphocytes by such vectors might result in more potent and less toxic 
gene-based vaccines.  Reovirus binds to murine microfold cells (1, 189, 190), and the σ1 
protein plays an important role in conferring this tropism (1, 80).  Interactions of Ad5-σ1 
vectors with microfold cells may facilitate efficient delivery to underlying Peyer's patches 
for induction of immune responses in the gut.  Alternatively, σ1-bearing Ad vectors may 
directly infect DCs at the luminal surface, which are known to shuttle bacteria across 
epithelial monolayers by opening tight junctions and sampling the intestinal lumen (132).  
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DCs express tight junction proteins, including JAM-A (132), which are hypothesized to 
facilitate epithelial barrier penetration.  Our finding that Ad5-T3Dσ1 transduces primary 
DCs more efficiently than wild-type Ad5 suggests that Ad5-σ1 vectors may be useful for 
antigen gene delivery to DCs in the intestine and other sites.  
 Findings described in this report indicate that Ad vectors can be efficiently targeted to 
cells expressing JAM-A and sialic acid by the reovirus attachment protein σ1.  By virtue 
of the capacity to infect both intestinal epithelial cells and DCs, Ad5-σ1 vectors may have 
utility in the induction of immune responses at mucosal surfaces and thus prevention of 
infection at the site of pathogen entry.  These vectors also will allow a precise 
determination of the contribution of the JAM-A- and sialic acid-binding properties of σ1 
to interactions of σ1 with cells in vivo.  This approach should lead to improved Ad 
vectors for gene delivery and enhance an understanding of σ1 biology. 
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CHAPTER V 
 
REOVIRUS ENTRY INTO POLARIZED EPITHELIAL CELLS DISRUPTS TIGHT 
JUNCTION INTEGRITY  
 
Introduction 
 JAM-A is essential for reovirus infection of numerous cell types (10, 109, 129).  
However, the biochemical consequences of reovirus interactions with JAM-A in tight 
junctions have not been elucidated.  JAM-A is an important component of tight junctions that 
form between endothelial and epithelial cells (102, 106, 123).  Tight junctions serve as 
a semipermeable barrier between cells, establish distinct apical and basolateral regions in 
polarized epithelia, and function as critical sites for endocytosis and signaling (7, 197). 
 Tight junctions are composed of transmembrane proteins clustered at the apical 
portion of the lateral membrane (112).  These transmembrane proteins are adhesion 
molecules that mediate cell-cell contacts (7, 197).  Scaffolding proteins are tethered to the 
cytoplasmic tails of the transmembrane proteins.  These proteins are involved in the 
recruitment and maintenance of the junctional complex (112).   
The cytoplasmic tail of JAM-A interacts with several tight junction-associated 
proteins, including AF-6 (59), PAR-3 (60, 88), and ZO-1 (19, 59) in a PDZ-domain-
dependent manner.  ZO-1 belongs to the zonula occludens family, which also includes ZO-2 
and ZO-3.  The zonula occludens family of proteins is hypothesized to function in mediating 
protein-protein interactions through modular PDZ domains and participate as components of 
signal transduction pathways (72).  ZO-1 functions as a transcriptional regulator through its 
interactions with ZO-1–associated nucleic acid binding protein (ZONAB) (6). 
  It is not known how reovirus accesses JAM-A on polarized cells, nor whether 
reovirus binding to JAM-A leads to intracellular signaling events that influence viral 
 72
replication or alter tight junction integrity.  In the infected host, reovirus might engage JAM-
A on the apical surface of intestinal epithelial cells.  Since JAM-A is a tight junction protein, 
apical infection by reovirus would require disruption of tight junctions to liberate the 
receptor.  Reovirus also may infect the basolateral surfaces of intestinal cells following 
transcytosis through microfold (M) cells (191).  Current data do not favor one model over the 
other.   
  To determine the route by which reovirus infects polarized cells most efficiently and 
to elucidate whether reovirus alters the tight junction protein complex during viral attachment 
and internalization, we utilized MDCK and Caco-2 cell culture systems, which are well-
established models for studies of tight junctions in polarized epithelium  (144).  We found 
that reovirus preferentially infects the apical surface of polarized cells and that infection is 
dependent on JAM-A.  Reovirus binding to polarized cells alters the distribution of JAM-A 
and tight junction-associated protein ZO-1 and induces disruptions in transepithelial 
resistance (TER) of infected epithelial monolayers.  These results suggest that reovirus 
disrupts tight junction integrity during viral entry.  
 
Results 
 
Reovirus entry into cells disrupts JAM-A distribution 
 To test whether reovirus alters the distribution of JAM-A during entry, we examined 
the intracellular localization of this receptor during a timecourse of reovirus entry into JAM-
A-expressing CHO cells.  Cells were grown on glass coverslips and adsorbed with T1L at 
4oC for 45 min.  The inoculum was replaced with fresh medium, and cells were incubated at 
37oC.   Cells were fixed in methanol and stained for JAM-A at 10 min intervals for 60 min.  
Subcellular distribution of these proteins was determined by using immunofluorescence 
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microscopy (Figure 26).  In the untreated and 0 min timepoints, JAM-A localization was 
tightly confined to regions of cell-cell contact.  At early timepoints following reovirus 
infection, JAM-A was apparent in the cytoplasm.  After 30 minutes of infection the JAM-A 
signal was localized to punctate bodies within the cytoplasm with minimal staining at the cell 
surface.  These results demonstrate that reovirus entry into JAM-A-expressing cells induces 
receptor internalization.    
 
Apical infection of polarized cells by reovirus is JAM-A-dependent 
 To investigate whether reovirus preferentially infects apical or basolateral surfaces of 
polarized cells, Caco-2 cells were grown on transwell supports and allowed to form polarized 
monolayers.  The extent of polarization of the transwells was determined by measuring the 
TER prior to the onset of experimentation.  Cells were adsorbed either apically or 
basolaterally with T1L and incubated at 37oC for 24 h.  Following incubation, infected cells 
were quantified using an immunofluorescence assay (Figure 27).  We found that apical 
infection of Caco-2 cells by T1L was substantially more efficient than basolateral infection.   
 To test the requirement for JAM-A as a receptor in polarized cells, Caco-2 cells were 
grown to confluency on glass coverslips and treated with JAM-A-specific mAb J10.4 prior to 
apical infection with T1L.  Pretreatment of cells with JAM-A-specific mAb J10.4 efficiently 
reduced T1L infection (Figure 28).  These findings suggest that apical infection of Caco-2 
cells by T1L is dependent on utilization of JAM-A as a receptor. 
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Figure 26. Reovirus infection of JAM-A-expressing cells alters JAM-A localization.
JAM-A expressing CHO cells were grown to confluency on glass coverslips.  Monolayers 
were adsorbed T1L at an MOI of 5X103 particles per cell at 4oC for 45 min.  Cells were 
warmed to 37oC for the times shown, stained with JAM-A-specific mAb J10.4, and 
visualized using immunofluorescence microscopy.  
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Figure 27. Reovirus infection is most efficient following adsorption to the apical surface 
of polarized cells. Caco-2 cells were plated to confluency on 0.33-cm2 permeable supports 
and cultured for 14 days.  Monolayers were adsorbed either apically or basolaterally with 
T1L at an MOI of 10 or 60 PFU per cell. Infected cells were detected by indirect 
immunofluorescence and quantified by counting fluorescent cells in three random fields of 
view per well in three wells. Error bars indicate standard deviations.  
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Figure 28.  Apical infection of polarized cells is JAM-A dependent.  Caco-2 cells were 
grown to confluency on glass coverslips.  Monolayers were adsorbed apically with T1L at an 
MOI of 10 PFU per cell in the presence or absence of PBS, anti-ICAM-1 mAb, or anti-
hJAM-A mAb J10.4.  Infected cells were detected by indirect immunofluorescence and 
quantified by counting fluorescent cells in three random fields of view per well in three wells.  
For both experiments, results are presented as the mean FFU per field. Error bars indicate 
standard deviations.  
0
50
100
150
200
250
300
350
400
450
PBS ICAM-1
10 µg/ml Ab
JAM-A
10 µg/ml Ab
In
fe
ct
ed
 c
el
ls
 (F
FU
/fi
el
d)
 
In
fe
ct
ed
 c
el
ls
 (F
FU
/fi
el
d)
 
 
 
 
 
 
 77
Reovirus entry of polarized cells alters ZO-1 localization 
To test whether reovirus alters the distribution of tight junction proteins, we 
examined the intracellular location of ZO-1, which interacts with the JAM-A cytoplasmic 
tail (19, 59), during a timecourse of reovirus entry into epithelial cells.  Confluent MDCK 
cells were adsorbed with reovirus T1L, and ZO-1 location was monitored by 
immunofluorescence microscopy (Figure 29).  ZO-1 was redistributed from regions of 
intercellular contacts to the cytoplasm and nucleus during the 40 min observation 
interval, coincident with reovirus entry and disassembly (5, 153).  Thus, reovirus entry 
into MDCK cells alters the intracellular distribution of JAM-A-associated protein ZO-1, 
suggesting that reovirus perturbs the function of epithelial tight junctions.  
 
Reovirus entry of polarized epithelial cells alters TER 
To test whether reovirus binding to JAM-A disrupts the barrier activity of tight 
junctions in polarized cells, polarized MDCK cells were grown on transwell supports and 
adsorbed with T1L at 37oC.  The monolayers were monitored at 15-min intervals for a total 
of 120 min for changes in TER using an epithelial volt-Ohm meter (Figure 30).  As negative 
controls, cells were treated in the absence of viral adsorption with PBS or pretreatment with  
JAM-A-specific mAb J10.4, which does not disrupt intact tight junctions (102).  
Reovirus induced a time-dependent increase in paracellular permeability with kinetics that 
paralleled the redistribution of ZO-1.  Importantly, reovirus-induced alterations in TER were 
diminished by incubation of cells with J10.4 mAb prior to viral adsorption.  These findings 
suggest that reovirus alters tight junction integrity, which may be important for viral growth 
in certain types of cells and dissemination in the host. 
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Reovirus entry of non-polarized cells alters ZO-1 localization 
Experiments described thus far demonstrate that reovirus binding to JAM-A alters 
the subcellular distribution of ZO-1 during a timecourse of reovirus entry into polarized 
cells.  ZO-1 is also expressed in non-polarized cell types that are permissive for reovirus 
infection (87, 101).  To confirm that ZO-1 redistributes during reovirus entry, HeLa cells 
were adsorbed with reovirus T3D and incubated at 37oC for 0 or 30 minutes.  Nuclear 
and cytoplasmic extracts were prepared after lysis in a hypotonic buffer containing 
10 mM HEPES (pH 7.9), 10 mM KCl, and 1.5 mM MgCl2.  Nuclear and cytoplasmic 
proteins were resolved by SDS-PAGE and immunoblotted using a ZO-1-specific 
polyclonal antiserum (Figure 31).  Following entry of T3D, the relative abundance of 
ZO-1 in the cytoplasm was diminished in comparison to mock infection.  Additionally, a 
cleavage fragment of ZO-1 appears in the nucleus 30 minutes following infection with 
T3D.  These biochemical data compliment the observation of ZO-1 nuclear accumulation 
following reovirus entry using immunofluorescence microscopy and suggest that reovirus 
internalization leads to a redistribution of ZO-1 from the cell surface to the nucleus. 
 
Discussion 
 Although many examples exist of viruses utilizing cell adhesion molecules as 
receptors, little is known about how viral attachment proteins encounter these subcellularly 
restricted proteins and the cellular response of these interactions.  We have previously 
demonstrated that JAM-A is a serotype-independent reovirus receptor and that efficient entry 
of reovirus into numerous cell types including HeLa, CHO, and dendritic cells is dependent 
on JAM-A utilization (10, 109, 129).  Prior to studies in this chapter, it was unknown what 
role JAM-A plays in reovirus infection of polarized cells. 
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Figure 29. Intracellular distribution of ZO-1 following reovirus infection of MDCK 
cells. MDCK cells were plated to confluency and cultured for five days.  Cells were either 
infected with T1L at an MOI of 102 PFU per cell or treated with PBS (mock). Cells were 
incubated at 37oC for the times shown, stained with a polyclonal ZO-1 antiserum, and 
visualized using immunofluorescence microscopy.
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Figure 30. Changes in TER following reovirus infection of MDCK cells. MDCK cells 
were plated to confluency on 0.33-cm2 permeable supports and cultured for 12 days. 
Monolayers were adsorbed apically with PBS (control) or T1L at an MOI of 102  PFU per cell 
in the presence or absence of anti-hJAM-A mAb J10.4 (hJAM-A mAb).  Monolayers were 
monitored for changes in TER for the times shown using an epithelial volt-Ohm meter. The 
results are presented as percent resistance relative to the zero time point (baseline resistance = 
350 Ω).  
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Figure 31. Reovirus entry into HeLa cells alters ZO-1 distribution. HeLa cells were 
plated to confluency and adsorbed with T3D at an MOI of 100 PFU per cell for 0 or 30 
minutes.  At the indicated timepoints, nuclear and cytoplasmic extracts were prepared, 
resolved by SDS-PAGE, and immunoblotted using a polyclonal ZO-1-specific antiserum.  
Positions of MW standards (in kD) are shown. 
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 Results presented here demonstrate that reovirus infection of polarized epithelial cells 
is most efficient following apical adsorption and is dependent on JAM-A utilization.  At early 
time points in reovirus infection, JAM-A redistributes from regions of cell-cell contact to 
punctuate bodies within the cytoplasm.  Concurrently, ZO-1 localization changes from 
regions of intercellular contacts to the cytoplasm and nucleus.  Paracellular permeability as 
assessed by TER is increased with kinetics that parallel the redistribution of ZO-1.  Reovirus-
induced TER alterations are diminished with pretreatment with JAM-A-specific mAb J10.4, 
demonstrating that these effects are JAM-A dependent. 
 The capacity of reovirus to use JAM-A as a receptor has implications for reovirus 
infection and pathogenesis.  Regulation of tight junction formation is important for 
development and maintenance of epithelial and endothelial barriers (17).  JAM-A-specific 
mAbs prevent the reorganization of disrupted tight junctions in cultured intestinal epithelial 
cells (102) and promote tight junction breakdown of the endothelium lining CNS blood 
vessels, resulting in enhanced disease in response to viral or bacterial infections (98).  If 
reovirus-JAM-A interactions lead to a similar destabilization of tight junctions in CNS 
endothelium, this effect might promote disruption of the blood-brain barrier, permitting 
cerebral edema and neural inflammation, conditions associated with reovirus-induced 
encephalitis (10, 71, 165) .   
  Reovirus-induced tight junction dysregulation within the intestinal epithelium might 
promote infection of enteric epithelial cells and underlying Peyer’s patches, thereby 
providing an opportunity for systemic dissemination.  A similar mechanism has been 
proposed for adenovirus interactions of epithelial surfaces.  During adenovirus infection, the 
viral fiber protein is shed from infected cells and binds to its receptor, CAR, which like JAM-
A, is also expressed at tight junctions (43).  Fiber-CAR interactions are hypothesized to 
disrupt tight junctions and allow virus escape (179).  This model fits with data presented in 
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Chapter II demonstrating that σ1 binds to residues involved in JAM-A homodimer formation, 
which provides support for the idea that σ1-JAM-A interactions may disrupt tight junctions.     
 Until recently, ZO-1 was presumed to function primarily as a tight junction regulator 
through its action as an organizational scaffold that tethers transmembrane proteins to 
signaling molecules and the cytoskeleton (61, 62, 110).  The discovery that ZO-1 acts in 
concert with ZONAB as a transcriptional regulator suggests that tight junction proteins serve 
as platforms for cell signaling at both the cell membrane and the nucleus.  To date, the only 
stimuli identified to result in nuclear accumulation of ZO-1 are the remodeling of cell-cell 
contacts of maturing monolayers and wound healing (74).  Our finding that reovirus-JAM-A 
interactions result in a nuclear translocation of ZO-1 suggests that ZO-1 is involved in 
cellular responses elicited by microbes.   
 Utilization or disruption of tight junctions is a common theme for many 
microorganisms including viruses, bacteria, and fungi (38, 143, 179).  This theme of 
disrupting or commandeering tight junction proteins by diverse pathogens may highlight 
common signaling strategies, one of which may be to modulate the transcriptional machinery 
to render the cell more permissive for pathogen replication.  For example, disruption of tight 
junctions and accumulation of ZO-1 in the nucleus could induce cytoskeletal rearrangements, 
induce signal transduction events, and alter the transcriptional program of the cell.  Any of 
these events could result in a more favorable environment for pathogen growth and 
dissemination.  Alternatively, microbial-induced disruption of tight junctions may result in 
induction of innate host defense mechanisms.  Rapid relocalization of ZO-1 or other 
junctional proteins to the nucleus may serve a cellular sensor function in which tight junction 
disruption is an early indicator of cellular invasion. 
 The discovery that reovirus-JAM-A interactions leads to a redistribution of ZO-1, 
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expands our knowledge of the physiologic effects of virus-receptor interactions and 
highlights a potential role for the tight junction in regulating the cellular response to viral 
infection.  This work expands our understanding of viral receptors and highlights that they 
are not simply attachment moieties.  Virus-receptor interactions are capable of disrupting 
cell-cell interactions and induce signal transduction pathways.  It will be fascinating to 
explore the biological consequences of these biochemical events elicited by reovirus receptor 
engagement.  
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CHAPTER VI 
 
SUMMARY AND FUTURE DIRECTIONS 
 
The first step in viral replication is mediated by a specific and structurally 
regulated relationship between the viral attachment protein and its cognate receptor.  
Defining the precise interactions that mediate virus-receptor engagement is crucial for 
understanding the mechanisms underlying viral pathogenesis.  Although many viral 
receptors have been identified, little is known about the biophysical events that mediate 
cellular entry, the involvement of viral replication in signal transduction, and the function 
of these molecules in viral tropism and pathogenesis.  A thorough understanding of 
mechanisms of viral attachment is essential for uncovering the role of receptors in 
pathogenesis at an organismal level and the rational design of antiviral therapeutics 
targeting the virus attachment step.  The work described in this dissertation was performed 
to enhance an understanding of structure-function relationships between σ1 and JAM-A and 
to seek insight into the physiological consequences of reovirus-receptor engagement.   
The data presented in this thesis support the following conclusions: 1) reovirus 
attachment is achieved through binding of the D-E loop of σ1 to the JAM-A dimer 
interface (Chapter II and III); 2) in polarized epithelial cells, the binding of σ1 to the 
JAM-A dimer interface disrupts tight junction integrity (Chapter V); 3) and disruption of 
tight junction integrity by reovirus leads to the internalization of JAM-A and subsequent 
nuclear re-distribution of ZO-1 (Chapter V).  This chapter summarizes the data presented 
in this dissertation and highlights future directions for this research. 
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Molecular mechanisms of reovirus attachment 
  Results from Chapter II demonstrate that JAM-A is a serotype-independent reovirus 
receptor and the only JAM family member capable of mediating reovirus entry.  This work 
led to the identification of a highly conserved cluster of residues found at the base of the σ1 
head termed the D-E loop.  The D-E loop is a logical candidate for a receptor-binding domain 
because it is highly conserved among JAM-A-binding strains, it is surface exposed, and it is 
accessible to a ligand.   
 Future studies should be directed toward definition of the specific interactions that 
govern σ1 engagement of JAM-A.  To test the hypothesis that the D-E loop mediates JAM-A 
binding, mutations can be engineered into a bacterially expressed GST-T3D σ1 head 
construct using PCR-based methods.  The affinities of purified mutant σ1 proteins for JAM-
A can be determined by surface plasmon resonance.  After identification of mutant σ1 
proteins that exhibit a decreased affinity for JAM-A, the biological relevance of these 
mutations should be tested by using the reovirus-Ad5 chimera system (Chapter IV).  Should 
results from experiments using chimeric adenoviruses be difficult to interpret, full-length wt 
and mutant σ1 proteins, along with outer-capsid proteins σ3 and µ1, can be expressed in 
insect cells using recombinant baculoviruses and recoated onto reovirus core particles (33).  
Recoated core particles can be tested for the capacity to bind and infect cells. 
 The experiments described in Chapter III identified the D1 domain of JAM-A to be 
both necessary and sufficient for reovirus binding and infection.  The D1 domain is the 
membrane distal immunoglobulin-like domain that mediates JAM-A homodimerization.  
Subsequent to this work, mutagenesis studies demonstrated that residues intimately 
associated with the JAM-A dimer interface are critical for reovirus interactions with 
JAM-A (63).  This finding suggests that σ1 engages JAM-A using sequences involved in 
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dimer formation.  To test this theory and establish the structural basis of JAM-A interactions 
with σ1, the structures of σ1 in complex with JAM-A should be solved using X-ray 
crystallography.  This work is currently being performed in collaboration with the laboratory 
of Thilo Stehle.   
  
The role of JAM-A in reovirus-induced disruptions of tight junction integrity 
 The experiments described in Chapter V we determined that apical route entry of 
reovirus is most permissive for reovirus infection of polarized epithelial cells.  This infection 
is dependent on binding to JAM-A and results in disruption of JAM-A localization during a 
timecourse of reovirus entry.  Additionally, infection of polarized epithelial cells results in 
alteration of ZO-1 localization and an increase of paracellular permeability, suggesting that 
reovirus entry disrupts tight junction integrity.   
 Immediate future steps should focus on defining the minimal viral components 
necessary for disruption of tight junction integrity and the physiological consequences of this 
alteration.  To determine whether changes in the distribution of tight junction-associated 
proteins are attributable to σ1 interactions with JAM-A, virus should  be treated prior to 
adsorption  T1 σ1-specific mAb which blocks reovirus binding to JAM-A.  I predict that 
antibody treatment will inhibit the capacity of reovirus to alter the intracellular distribution of 
JAM-A and JAM-A-associated proteins.  Additionally, a bacterially expressed T3D σ1 head 
construct should be used in experiments to study the capacity of σ1, in the absence of other 
viral components, to disrupt tight junction integrity.  
  To test whether alterations in tight junction protein distribution require steps in 
reovirus replication subsequent to attachment, cells should be treated with either ammonium 
chloride, which arrests acid-dependent disassembly of virions in cellular endosomes (51, 
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153) or ribavirin, which blocks viral transcription (130).  Given the tempo of the observed 
changes, less than 1h, I anticipate that neither treatment will interfere with the capacity of 
reovirus to alter the distribution of JAM-A and JAM-A-associated proteins following 
attachment. 
To define the dynamics of tight junction disruption and ZO-1 distribution during 
reovirus entry into living cells, we will use a ZO-1-green fluorescent protein (GFP) fusion 
construct can be used (133).   ZO-1-GFP exhibits subcellular colocalization with endogenous 
ZO-1 and has no demonstrable effects on cell growth or TER of transfected cells (133).  
MDCK cells should be transfected with ZO-1-GFP, infected with reovirus, and imaged for 
ZO-1 localization using confocal video microscopy for real-time analysis. 
To investigate the role of ZO-1 in reovirus entry and infection, epithelial cells 
lacking ZO-1 expression should be infected and monitored for alterations in tight junction 
integrity, reovirus entry, and infection (169).  ZO-1 has been demonstrated to alter 
transcriptional regulation following migration to the nucleus (6).  It would be interesting to 
investigate whether reovirus-induced nuclear localization of ZO-1 results in alteration of the 
transcriptional program.  To test this hypothesis, ZO-1 deficient cells can be utilized to 
define gene expression patterns through microarray analysis following reovirus infection 
in the presence and absence of ZO-1 expression.  
 
The role of JAM-A in reovirus pathogenesis 
JAM-A is a receptor for prototype and field-isolate strains of reovirus.  However, the 
function of JAM-A in reovirus-induced disease is unknown.  The dramatic differences 
exhibited by T1 and T3 reovirus strains in viral tropism and disease in mice segregate with 
the σ1-encoding S1 gene [Weiner, 1980 #210;[Weiner, 1977 #189;Weiner, 1980 
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#210;Tardieu, 1982 #212;Dichter, 1984 #147]].  These findings suggest that different 
reovirus serotypes engage unique receptors and that receptor distribution is an important 
determinant of reovirus pathogenesis.  However, all reovirus strains tested to date are capable 
of using JAM-A as a receptor (10, 29).  I think it possible that JAM-A serves as a serotype-
independent reovirus receptor at some sites in the host, and other as yet unidentified receptors 
may confer serotype-dependent tropism in the CNS.  In support of this possibility, a p65/p95 
complex has been suggested to serve as a T3 reovirus receptor in the murine nervous system 
(131).  Alternatively, utilization of coreceptors, perhaps carbohydrate in nature, may permit 
reovirus infection of specific cells or tissues.  In support of this idea, reovirus strains that vary 
in sialic acid binding also vary in cell tropism and disease pathogenesis in the hepatobiliary 
system (11).  To distinguish between these possibilities, JAM-A-null mice should be infected 
with reovirus strains that bind to JAM-A but not sialic acid and monitor infected mice for 
viral growth and disease.  If JAM-A is a tissue-specific reovirus receptor, reovirus should 
infect some sites in JAM-A-null mice but not others.  If coreceptor utilization is required for 
tropism in the context of JAM-A expression, JAM-A-null mice should be resistant to reovirus 
infection. 
 
Conclusions 
 With this research, we seek to establish a precise understanding of virus-receptor 
interactions in reovirus target-cell selection and pathogenesis.  The studies performed in this 
thesis are a blend of molecular genetics, cell imaging, and structural analyses designed to 
provide a comprehensive assessment of the structure and function of reovirus attachment 
protein σ1 and its cell-surface receptors.  The long-term goal of this work is to identify key 
intermolecular interactions between virus and the cell that define obligate, sequential steps 
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leading to tissue- and organ-specific infection and disease.  Knowledge gained fron this 
research also might enable the targeting of vaccine or gene therapy vectors, such as σ1-
expressing chimeric adenoviruses, to specific sites in the host.  Identification of signaling 
pathways activated by reovirus binding would represent a particularly intriguing area of 
future research.  Experiments to extend such observations will be designed to explore how 
receptor-linked signaling pathways influence viral growth and cell death.  Because this work 
affords the opportunity to couple atomic resolution studies of reovirus-receptor interactions 
with studies of reovirus target cell selection in the infected host, it may serve as a general 
model for ligand-receptor binding and aid in the rational design of anti-infective therapies 
based on inhibition of pathogen-receptor interactions. 
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CHAPTER VII 
 
DETAILED METHODS OF PROCEDURE 
 
Cells, viruses, and antibodies 
 Spinner-adapted murine L929 (L) cells were grown in either suspension or 
monolayer cultures in Joklik's modified Eagle's minimal essential medium (Irvine 
Scientific, Santa Ana, Calif.) supplemented to contain 5% fetal bovine serum (Gibco-
BRL, Gaithersburg, Md.), 2 mM L-glutamine, 100 U of penicillin per ml, 100 mg of 
streptomycin per ml, and 0.25 mg of amphotericin per ml (Gibco-BRL).  HeLa, MDCK, 
and Caco-2 cells were maintained in monolayer cultures in Dulbecco's minimal essential 
medium (Gibco-BRL) supplemented to contain 10% fetal bovine serum, L-glutamine, 
and antibiotics as described for L cells.  Chinese hamster ovary (CHO) cells were 
maintained in Ham's F12 medium supplemented with fetal bovine serum, L-glutamine, 
and antibiotics as described for HeLa cells.  
 The prototype reovirus strains T1L/53, T2J/55, and T3D/55 are laboratory stocks. 
The field-isolate reovirus strains used in this study are shown in Table 1.  Variant K, a 
neutralization-resistant variant of T3D/55, was selected and characterized as previously 
described (15, 148, 149).  Green fluorescent protein-encoding serotype 5 adenovirus (Ad 5-
GFP) was provided by Dr. Jeffrey Bergelson (University of Pennsylvania).  Viral stocks 
were prepared by plaque purification and passage in L cells (173).  Purified virions were 
prepared by using second- and third-passage L-cell lysate stocks as previously described 
(66, 135).  Viral particle concentrations were determined by measurements of the optical 
density at 260 nm, using a conversion factor of 2.1 x 1012 viral particles per optical 
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density unit (146).  The particle-to-PFU ratio of stocks used for viral infectivity assays 
was approximately 250 to 1.   
 Rabbit hCAR-specific antiserum was provided by Jeffrey Bergelson (University 
of Pennsylvania).  Rabbit polyclonal hJAM-B- and hJAM-C-specific antisera were 
generated as previously described (70).  The murine hJAM-A-specific monoclonal 
antibody (MAb) J10.4 was purified from mouse ascites by using protein A-Sepharose 
(102).  The immunoglobulin G (IgG) fractions of polyclonal rabbit antisera raised against 
T1L/53 and T3D/55 (186) were purified by using protein A-Sepharose (9).  A mixture of 
these sera was capable of recognizing all strains of reovirus used in this study. 
 
Fluorescent-focus assays of viral infectivity 
  Monolayers of HeLa cells in 96-well plates (Costar, Cambridge, Mass.) (3 x 104 cells 
per well) were pretreated for 1 h with phosphate-buffered saline (PBS), hCAR-specific 
antiserum, or the hJAM-A-specific MAb J10.4 at various concentrations prior to the 
adsorption of virus at room temperature for 1 h.   Following removal of the inoculum, the 
cells were washed with PBS and incubated at 37°C for 20 h to permit the completion of a 
single round of viral replication.  Monolayers were fixed with 1 ml of methanol at –20°C for 
a minimum of 30 min, washed twice with PBS, blocked with 2.5% immunoglobulin-free 
bovine serum albumin (Sigma-Aldrich, St. Louis, Mo.) in PBS, and incubated at room 
temperature for 1 h with protein-A-affinity-purified polyclonal rabbit anti-reovirus serum at a 
1:800 dilution in PBS-0.5% Triton X-100.  The monolayers were washed twice with PBS-
0.5% Triton X-100 and incubated with a 1:1,000 dilution of goat anti-rabbit immunoglobulin 
conjugated with the Alexa Fluor 546 fluorophore (Molecular Probes, Eugene, Oreg.).  The 
monolayers were washed twice with PBS, and infected cells were visualized by indirect 
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immunofluorescence using an Axiovert 200 inverted microscope modified for fluorescence 
microscopy (Carl Zeiss, New York, N.Y.).  Infected cells were identified by the presence of 
intense cytoplasmic fluorescence that was excluded from the nucleus.  No background 
staining of uninfected control monolayers was noted.  Reovirus antigen-positive cells were 
quantified by counting the fluorescent cells in at least three random fields of view per well in 
triplicate at a magnification of x20. 
 
Transient transfection and infection of CHO cells 
 CHO cells were transiently transfected with an empty vector or with plasmids 
encoding receptor constructs by the use of Lipofectamine PLUS reagent (Invitrogen, San 
Diego, Calif.) as previously described (10).  After 24 h of incubation to allow receptor 
expression, transfected cells were allowed to adsorb to the virus at a multiplicity of infection 
(MOI) of 1 fluorescent focus unit (FFU) per cell, incubated for an additional 20 h, fixed with 
methanol, and stained for reovirus proteins by use of an antireovirus serum at a 1:800 
dilution.  Images were captured at a magnification of x20 with a Zeiss Axiovert 200 inverted 
microscope. 
 
Sequence analysis of the S1 gene 
 Viral genomes were extracted from infected L-cell lysates by the use of Trizol (Life 
Technologies, Rockville, Md.) according to the protocol supplied by the manufacturer.  S1 
gene segments were amplified by reverse transcription-PCR (RT-PCR) using 10 U of avian 
myeloblastosis virus reverse transcriptase (Promega Biosciences, San Luis Obispo, Calif.), 
2.5 U Taq DNA polymerase (Promega Biosciences), and primers complementary to the 5' and 
3' nontranslated regions of the S1 genes of the reovirus prototype strains.  The type 1 S1 
forward primer was 5' GGATCCGCTATTCGCGCCTATGGATG, and the reverse primer 
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was 5' GGGTTCGCGCTAGATTCA.  The type 2 S1 forward primer was 5' 
GCTATTCGCACTCATGTCGGATCTAGTGCAGC, and the reverse primer was 5' 
GATGAGTCGCCACTGTGCCGAGTGGA.  The type 1 5' forward primer contained 
nucleotides that resulted in a primer-derived sequence for the first two amino acids (M and 
D), and the type 2 5' forward primer contained nucleotides that resulted in a primer-derived 
sequence for the first six amino acids (M, S, D, L, V, and Q).  The amplification products 
were cloned into the pCR 2.1 vector (Invitrogen).  Sequences of at least two independent RT-
PCR clones for each S1 gene segment were determined by automated sequencing. 
 
Phylogenetic analysis of S1 gene nucleotide sequences 
 Sequences were aligned by using the program ClustalX (159). Phylogenetic trees 
were constructed from variations in the 1-encoding S1 gene nucleotide sequences by the 
maximum parsimony method using the heuristic search algorithm within the program PAUP 
v4.0b10 (154).  Trees were rooted at the midpoint.  The branching orders of the phylograms 
were verified statistically by resampling the data 1,000 times in a bootstrap analysis using the 
branch and bound algorithm as applied in PAUP. 
 
Sequence alignment and structural modeling methods 
 Sequences were aligned by using the program ClustalW 
(http://www.ebi.ac.uk/clustalw/).  Alignments were rendered in ALSCRIPT (12), using 
different colors to highlight different degrees of sequence similarity.  Sequence changes were 
mapped onto the crystal structure of T3D/55 σ1 (37) by using the program GRASP (118). 
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Generation of chimeric and mutant receptor constructs 
 Nomenclature of chimeric and deletion mutant constructs indicates exchanged or 
deleted domains relative to wild-type hCAR or hJAM-A from amino to carboxyl termini.  
Chimeric receptor CJJ (hCAR residues 1-141; hJAM-A residues 133-299) and deletion 
mutants J∆J (hJAM-A residues 133-234 deleted) and ∆JJ (hJAM-A residues 29-132 deleted) 
were generated using PCR to insert a HindIII endonuclease restriction site at the 3' or 5' end 
of respective amino-terminal or carboxyl-terminal receptor fragments.  Chimera JCJ (hJAM-
A residues 1-128, hCAR residues 138-227, hJAM-A residues 235-299) and full-length D1 
point mutant receptors were generated by overlap extension PCR.  All chimeric and mutant 
receptor PCR products were digested with restriction endonucleases and ligated into plasmid 
pcDNA3.1+ (Invitrogen).  The fidelity of cloning was confirmed by automated sequencing.  
 
Flow cytometric analysis of receptor expression and virus binding 
 CHO cells were transiently transfected and incubated for 24 h to allow receptor 
expression.  Cells were detached from plates by incubation with 20 mM EDTA in PBS.  Cells 
(1 x 106) were incubated with hCAR- or hJAM-A-specific antiserum at dilutions of 1:750 or 
1:1000, respectively, or incubated with reovirus T1L or T3SA- (1 x 105 particles/cell) on ice 
for 60 min.  Virus-adsorbed cells were washed with PBS and incubated with clarified, 
combined T1L/T3D antiserum  at 1:1000 dilution on ice for 60 min.  All samples were 
washed with PBS and incubated with phycoerythrin-conjugated goat anti-rabbit IgG 
secondary antiserum (Molecular Probes, Inc.) at a 1:1000 dilution on ice for 30 min. Cells 
were washed twice with PBS and fixed with 2% paraformaldehyde in PBS.  Cells were 
analyzed using a FACScan flow cytometer (Becton-Dickinson). 
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Transient transfection and infection of CHO cells expressing chimeric receptor 
constructs 
 
 CHO cells were transiently transfected with empty vector or plasmids encoding wild-
type, chimeric, or deletion mutant receptors using LipofectAMINE and PLUS reagent 
(Invitrogen) as previously described (129).  Cells were incubated for 24 h to allow receptor 
expression and then infected with reovirus T1L at multiplicities of infection of 1 fluorescent 
focus unit/cell and 1 plaque-forming unit/cell for fluorescent focus and plaque assays, 
respectively.  For fluorescent focus assays, infected cells were processed for indirect 
immunofluorescence as previously above and previously (9).  For plaque assays, viral titers in 
cell lysates were determined at 0 and 24 h after adsorption as previously described (173).  In 
brief, monolayers of L cells were infected in duplicate with serial 10-fold dilutions of sample.  
After viral attachment (37ºC, 1 h), cells were overlayed with a 50%-50% (vol/vol) mixture of 
completed 2X medium 199 and 2% Bacto-Agar dissolved in deionized distilled water.  
Monolayers were overlayed a second time at 3 days post inoculation.  A final overlay with 
2X medium 199 containing 1% agar and .04% neutral red was performed 6 days after 
inoculation.  Plaques were counted 12-24 h after the neutral overlay.  The viral titer is 
reported as plaque forming units per ml of original sample. 
 
Protein expression, purification, and crystallization of hJAM-A 
 A cDNA corresponding to the extracellular region of hJAM-A (residues 27–233) was 
cloned into the pGEX-4T-3 expression vector (Amersham Pharmacia), which encodes N-
terminal GST followed by a thrombin cleavage site.  GST–hJAM-A fusion protein was 
expressed in Escherichia coli and purified by affinity chromatography using glutathione 
beads.  hJAM-A was released from the beads by thrombin cleavage and further purified by 
anion-exchange chromatography.  The cleaved protein contains three additional non-native 
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amino acids (Gly-24, Ser-25, and Met-26) at the N terminus.  A final gel filtration step 
resulted in a homogenous peak that corresponded to a dimer of 48 kDa.  Higher-order 
oligomers were not observed.  Crystals were obtained by using 8 mg/ml protein and 16% 
PEG 6K, 18% isopropanol, 0.1 M sodium citrate as precipitant.  The final pH of the mixture 
was 6.0. 
 
Structure determination of hJAM-A 
 The crystals belong to space group C2 (a = 116.8 Å, b = 61.8 Å, c = 82.9 Å, = 
120.01°) and contain two molecules in their asymmetric unit.  Before data collection, 
crystals were cryoprotected with 15% glycerol and then flash-frozen in liquid nitrogen. 
Diffraction data were collected at NSLS beamline X25 and processed with HKL (121).  
The structure was determined by molecular replacement using the structure of mJAM-A 
(95).  Rotation and translation searches were performed separately with the N- and C-
terminal domains of mJAM-A in AMORE , which yielded two clear solutions for each 
domain.  The free R factor (28) for the combined solutions was 45.1% (8–3.5 Å) after 
rigid body refinement.  Alternating rounds of model building in O (90) and refinement in 
X-PLOR (28) produced a model with good refinement statistics.  Bulk solvent correction 
and noncrystallographic symmetry constraints were used throughout the refinement.  The 
final model contains residues 25–233 of both chains and 124 water molecules.  
PROCHECK  analysis shows no residues in disallowed regions in the Ramachandran 
plot. 
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Generation of chimeric fiber-σ1 attachment proteins 
 Fiber-σ1 fusion constructs were generated by using phage red recombinase (128) 
expressed in Escherichia coli strain BW25113/pKD46 (46) obtained from the E. coli Genetic 
Stock Center (http://cgsc.biology.yale.edu) as follows: Fibshaft-T3Dσ1, consisting of the N-
terminal 396 aa of Ad5 fiber fused to amino acid 292 of T3D σ1; Fib8-T3Dσ1, consisting of 
the N-terminal 170 aa of Ad5 fiber fused to amino acid 167 of T3D σ1; and Fibtail-T3Dσ1, 
consisting of the N-terminal 44 aa of Ad5 fiber fused to amino acid 18 of T3Dσ1.  Sequences 
encoding the reovirus T3Dσ1 protein flanked by a bovine growth hormone polyadenylation 
signal and a zeocin-resistance gene were amplified by using Pfu polymerase (Stratagene) and 
primers containing 39-nt overhangs homologous to the pCMVfiber plasmid.  The pCMVfiber 
plasmid, containing the Ad5 fiber gene expressed from a CMV immediate-early promoter, 
was cotransformed with the PCR product into the phage red strain BW25113/pKD46.  
Recombinants were selected by using zeocin-containing agar plates.  
 Fibtail-T3Dσ1 was subcloned into a plasmid containing sequences homologous to E4 
and then recombined into the Ad5 genome to replace the fiber gene using red recombinase.  
To aid in detection of the chimeric protein, two c-Myc tags (C2), and one hexahistidine tag 
(H6) were added to the C terminus of the chimera (Fibtail-T3DσC2H6) before 
recombination.  The recombinants were screened for loss of the fiber gene by restriction 
endonuclease mapping and sequencing. 
 Ad vectors used are based on the AdEasy system (Q-BIOgene) and carry the full E1- 
and E3-deleted Ad5 genome with the firefly luciferase gene, an internal ribosome entry site, 
and the humanized Renilla GFP expressed from a cytomegalovirus (CMV) immediate-early 
promoter in the E1 region.  CHO cells were transfected with plasmids encoding fiber- 1 
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chimeras by using Lipofectamine-PLUS (Invitrogen), and cell extracts were harvested for 
SDS/PAGE.  Immunoblots were performed as described (125). 
 
Generation of a chimeric Ad vector 
 Linearized Ad genome encoding the Fibtail-T3D 1C2H6 chimera was transfected 
into 633 cells and maintained in the presence of 0.3 µM dexamethasone and 4 µg/ml 
polybrene.  Virus was propagated, purified by CsCl gradient centrifugation, and quantitated 
as described (47).  The resultant recombinant virus, Ad5-T3Dσ1, was amplified for a final 
round by using 293A cells to remove any residual fiber from newly assembled virions.  
 CsCl-banded Ad5, CAR-ablated biotinylated Ad [Ad5-BAP-TR [Parrott, 2003 
#5103] ], and Ad5-T3Dσ1 were precipitated with trichloroacetic acid.  Pellets were 
resuspended in loading buffer, and 4 x 1010 particles per lane were resolved by SDS/PAGE 
and immunoblotting.  For total protein analysis, precipitated virus (1.5 x 1011 particles per 
lane) was resolved by SDS/PAGE, and gels were stained with Coomassie blue. 
 
Transduction of CHO cells transfected with receptor constructs 
 CHO cells were transfected with plasmids expressing hCAR, hJAM-A, or murine 
(m)JAM-A (24, 63).  After 48 h, the cells were washed once with Hanks' balanced salt 
solution (GIBCO) with 1% BSA (HBSS-BSA) and adsorbed with 5,000 particles per cell of 
Ad5-T3D 1 at 4°C for 30 min.  Cells were washed twice with HBSS-BSA, and fresh medium 
was added.  After incubation at 37°C for 24 h, cells were lysed, and luciferase activity (in 
lumens) was measured as described (125). 
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Transduction of Caco-2 cells and primary DCs after receptor blockade 
 Cells were harvested, washed with HBSS-BSA, and incubated in suspension with 
10 µg/ml of either hCAR-specific mAb RmcB or hJAM1-specific mAb J10.4 at 4°C for 
30 min.  Alternatively, cells were treated with 333 milliunits/ml of Clostridium 
perfringens neuraminidase type X (Sigma) at 37°C for 30 min to remove cell-surface 
sialic acid, followed by two washes with HBSS-BSA.  Cells then were adsorbed with 
5,000 particles per cell of Ad5-T3D 1 at 4°C for an additional 30 min, washed twice, and 
seeded onto 24-well plates in fresh medium.  After incubation at 37°C for 24 h, cells were 
harvested for determination of luciferase activity. 
 
Reovirus infection assays of polarized epithelial cells 
 MDCK cells were plated to confluency on 0.33-cm2 permeable supports and cultured 
for 12 days.  Monolayers were adsorbed apically with PBS (control) or T1L at an MOI of 102 
PFU per cell in the presence or absence of anti-hJAM-A mAb J10.4.  Monolayers were 
monitored for changes in TER for the times shown using an epithelial volt-Ohm meter.  The 
results are presented as percent resistance relative to the zero time point (baseline resistance = 
350 Ω). 
 
Localization of TJ-associated proteins in polarized epithelial cells as determined by 
microscopy 
 Intracellular distribution of ZO-1 following reovirus infection of MDCK cells. 
MDCK cells were plated to confluency and cultured for five days.  Cells were either infected 
with T1L at an MOI of 102 PFU per cell or treated with PBS (mock).  Cells were incubated at 
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37oC for the times shown, stained with a polyclonal ZO-1 antiserum (Zymed), and visualized 
using immunofluorescence microscopy. 
 
Biochemical examination of TJ-associated proteins in HeLa cells 
 HeLa cells were adsorbed with reovirus T3D at an MOI of 100 PFU per cell and 
incubated at 37oC for 0 or 30 minutes.  Nuclear and cytoplasmic extracts were prepared 
after lysis in a hypotonic buffer containing 10 mM HEPES (pH 7.9), 10 mM KCl, and 
1.5 mM MgCl2.  Nuclear and cytoplasmic proteins were resolved by SDS-PAGE and 
immunoblotted using a ZO-1-specific polyclonal antiserum (Zymed). 
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Reovirus infections are initiated by the binding of viral attachment protein 1 to receptors on the surface
of host cells. The 1 protein is an elongated fiber comprised of an N-terminal tail that inserts into the virion
and a C-terminal head that extends from the virion surface. The prototype reovirus strains type 1 Lang/53
(T1L/53) and type 3 Dearing/55 (T3D/55) use junctional adhesion molecule A (JAM-A) as a receptor. The
C-terminal half of the T3D/55 1 protein interacts directly with JAM-A, but the determinants of receptor-
binding specificity have not been identified. In this study, we investigated whether JAM-A also mediates the
attachment of the prototype reovirus strain type 2 Jones/55 (T2J/55) and a panel of field-isolate strains
representing each of the three serotypes. Antibodies specific for JAM-A were capable of inhibiting infections
of HeLa cells by T1L/53, T2J/55, and T3D/55, demonstrating that strains of all three serotypes use JAM-A as
a receptor. To corroborate these findings, we introduced JAM-A or the structurally related JAM family
members JAM-B and JAM-C into Chinese hamster ovary cells, which are poorly permissive for reovirus
infection. Both prototype and field-isolate reovirus strains were capable of infecting cells transfected with
JAM-A but not those transfected with JAM-B or JAM-C. A sequence analysis of the 1-encoding S1 gene
segment of the strains chosen for study revealed little conservation in the deduced 1 amino acid sequences
among the three serotypes. This contrasts markedly with the observed sequence variability within each
serotype, which is confined to a small number of amino acids. Mapping of these residues onto the crystal
structure of 1 identified regions of conservation and variability, suggesting a likely mode of JAM-A binding
via a conserved surface at the base of the 1 head domain.
Mammalian orthoreoviruses (referred to as reoviruses in
this article) are nonenveloped viruses with genomes of 10 dis-
crete segments of double-stranded RNA (reviewed in refer-
ence 41). There are at least three serotypes of reoviruses,
which can be differentiated by the capacity of antireovirus
antisera to neutralize viral infectivity and inhibit hemaggluti-
nation (47, 50). Each of the reovirus serotypes is represented
by a prototype strain, namely, type 1 Lang/53 (T1L/53), type 2
Jones/55 (T2J/55), and type 3 Dearing/55 (T3D/55). Reovi-
ruses appear to infect most mammalian species, but disease is
restricted to the very young (reviewed in reference 63). Reo-
virus infections of newborn mice have been used as the pre-
ferred experimental system for studies of reovirus pathogene-
sis. Sequence polymorphisms in reovirus attachment protein
1 play an important role in determining sites of reovirus
infection in the infected host (4, 32, 69, 70).
The 1 protein is an elongated trimer with a head-and-tail
morphology. The N-terminal 1 tail partially inserts into the
virion via “turrets” formed by the pentameric 2 protein, while
the C-terminal 1 head projects away from the virion surface
(1, 25, 26). A crystal structure of the C-terminal half of T3D/55
1 revealed that the head contains three -barrel domains
(one from each trimer), each of which is constructed from
eight antiparallel -strands (16). Sequence analysis and struc-
tural modeling have suggested that the N-terminal half of the
tail is formed from an -helical coiled coil (6, 21, 40) and the
C-terminal half is formed from a triple -spiral (16, 56). The
overall structural topology of the -spiral and head domains of
1 is strikingly similar to that of the adenovirus attachment
protein, fiber (16, 37, 56).
There are two distinct receptor-binding regions in 1. A
region in the fibrous tail domain of type 3 1 binds to -linked
sialic acid (2, 14, 15, 18). A distinct region in the type 1 1 tail
domain also binds to cell surface carbohydrates (14), and re-
cent evidence suggests that sialic acid may be involved in the
binding of T1L/53 to intestinal cells (30). A second receptor-
binding site is located in the head domains of both the type 1
and type 3 1 proteins (3, 39).
An expression-cloning approach was used to identify junc-
tional adhesion molecule A (JAM-A) as a receptor for the
prototype strains T1L/53 and T3D/55 (3). JAM-A is a 35-kDa
type I transmembrane protein that is a member of the immu-
noglobulin superfamily (34, 36). JAM-A contains two immu-
noglobulin-like domains, a single transmembrane region, and a
short cytoplasmic tail. JAM-A is expressed in a variety of
* Corresponding author. Mailing address: Lamb Center for Pediat-
ric Research, D7235 MCN, Vanderbilt University School of Medicine,
Nashville, TN 37232. Phone: (615) 343-9943. Fax: (615) 343-9723.
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tissues, including epithelial and endothelial barriers (34, 36,
43), where it is thought to regulate tight-junction permeability
and mediate leukocyte trafficking (17, 34, 36, 43).
The crystal structures of the murine (m) and human (h)
homologs of JAM-A, both of which are functional reovirus
receptors (3), indicate that JAM-A forms homodimers via ex-
tensive hydrophobic and ionic contacts between apposing
membrane-distal (D1) immunoglobulin-like domains (33, 44).
Residues that facilitate interdimer interactions are strictly con-
served between mJAM-A and hJAM-A (33, 44). JAM-A
dimers are thought to be physiologically relevant, perhaps
functioning in tight-junction barrier integrity or the diapedesis
of inflammatory cells (8, 33, 44). Recent biochemical studies of
reovirus–JAM-A interactions suggested that 1 binds to a mo-
nomeric version of JAM-A and contacts residues in the vicinity
of the JAM-A dimer interface (24). This strategy of cell at-
tachment is strikingly similar to that used by adenovirus fiber
to bind to the coxsackievirus and adenovirus receptor (CAR)
(10, 66), an immunoglobulin superfamily member that shares
considerable structural homology with JAM-A (57).
For this study, we determined whether JAM-A serves as a
receptor for the prototype type 2 strain T2J/55 and a panel of
four type 1, two type 2, and four type 3 field-isolate strains. The
results indicate that JAM-A, but not the related JAM family
members JAM-B and JAM-C, is a receptor for prototype and
field-isolate strains of the three reovirus serotypes. An analysis
of conserved and variable sequences in the 1 head, together
with existing structural information for 1 and JAM-A, sug-
gested an especially high tolerance for surface variation in the
protein while maintaining the specificity for receptor utiliza-
tion. These findings enhance our understanding of the molec-
ular basis of reovirus binding to JAM-A and provide clues
about the mechanisms of reovirus attachment.
MATERIALS AND METHODS
Cells, viruses, and antibodies. Spinner-adapted murine L929 (L) cells were
grown in either suspension or monolayer cultures in Joklik’s modified Eagle’s
minimal essential medium (Irvine Scientific, Santa Ana, Calif.) supplemented to
contain 5% fetal bovine serum (Gibco-BRL, Gaithersburg, Md.), 2 mM L-
glutamine, 100 U of penicillin per ml, 100 mg of streptomycin per ml, and 0.25
mg of amphotericin per ml (Gibco-BRL). HeLa cells were maintained in mono-
layer cultures in Dulbecco’s minimal essential medium (Gibco-BRL) supple-
mented to contain 10% fetal bovine serum, L-glutamine, and antibiotics as
described for L cells. Chinese hamster ovary (CHO) cells were maintained in
Ham’s F12 medium supplemented with fetal bovine serum, L-glutamine, and
antibiotics as described for HeLa cells.
The prototype reovirus strains T1L/53, T2J/55, and T3D/55 are laboratory
stocks. The field-isolate reovirus strains used in this study are shown in Table 1.
Variant K, a neutralization-resistant variant of T3D/55, was selected and char-
acterized as previously described (7, 54, 55). Viral stocks were prepared by
plaque purification and passage in L cells (67). Purified virions were prepared by
using second- and third-passage L-cell lysate stocks as previously described (26,
49). Viral particle concentrations were determined by measurements of the
optical density at 260 nm, using a conversion factor of 2.1  1012 viral particles
per optical density unit (52). The particle-to-PFU ratio of stocks used for viral
infectivity assays was approximately 250 to 1.
Rabbit hCAR-specific antiserum was provided by Jeffrey Bergelson (Univer-
sity of Pennsylvania). Rabbit polyclonal hJAM-B- and hJAM-C-specific antisera
were generated as previously described (28). The murine hJAM-A-specific
monoclonal antibody (MAb) J10.4 was purified from mouse ascites by using
protein A-Sepharose (34). The immunoglobulin G (IgG) fractions of polyclonal
rabbit antisera raised against T1L/53 and T3D/55 (71) were purified by using
protein A-Sepharose (2). A mixture of these sera was capable of recognizing all
strains of reovirus used in this study.
Fluorescent-focus assays of viral infectivity. Monolayers of HeLa cells in
96-well plates (Costar, Cambridge, Mass.) (3  104 cells per well) were pre-
treated for 1 h with phosphate-buffered saline (PBS), hCAR-specific antiserum,
or the hJAM-A-specific MAb J10.4 at various concentrations prior to the ad-
sorption of virus at room temperature for 1 h. Following removal of the inocu-
lum, the cells were washed with PBS and incubated at 37°C for 20 h to permit the
completion of a single round of viral replication. Monolayers were fixed with 1 ml
of methanol at 20°C for a minimum of 30 min, washed twice with PBS, blocked
with 2.5% immunoglobulin-free bovine serum albumin (Sigma-Aldrich, St.
Louis, Mo.) in PBS, and incubated at room temperature for 1 h with protein-
A–affinity-purified polyclonal rabbit antireovirus serum at a 1:800 dilution in
PBS–0.5% Triton X-100. The monolayers were washed twice with PBS–0.5%
Triton X-100 and incubated with a 1:1,000 dilution of goat anti-rabbit immuno-
globulin conjugated with the Alexa Fluor 546 fluorophore (Molecular Probes,
Eugene, Oreg.). The monolayers were washed twice with PBS, and infected cells
were visualized by indirect immunofluorescence using an Axiovert 200 inverted
microscope modified for fluorescence microscopy (Carl Zeiss, New York, N.Y.).
Infected cells were identified by the presence of intense cytoplasmic fluorescence
that was excluded from the nucleus. No background staining of uninfected
control monolayers was noted. Reovirus antigen-positive cells were quantified by
counting the fluorescent cells in at least three random fields of view per well in
triplicate at a magnification of 20.
Transient transfection and infection of CHO cells. CHO cells were transiently
transfected with an empty vector or with plasmids encoding receptor constructs
by the use of Lipofectamine PLUS reagent (Invitrogen, San Diego, Calif.) as
previously described (3). After 24 h of incubation to allow receptor expression,
transfected cells were allowed to adsorb to the virus at a multiplicity of infection
(MOI) of 1 fluorescent focus unit (FFU) per cell, incubated for an additional
20 h, fixed with methanol, and stained for reovirus proteins by use of an anti-
reovirus serum at a 1:800 dilution. Images were captured at a magnification of
20 with a Zeiss Axiovert 200 inverted microscope.
Flow cytometric analysis of receptor expression. CHO cells were transiently
transfected with receptor constructs, incubated for 24 h, and detached from the
plates by incubation with 20 mM EDTA in PBS. Cells (106) were incubated with
the hCAR-specific antiserum, the hJAM-A-specific MAb J10.4, or an antibody
specific for hJAM-B or hJAM-C (28), washed with PBS, and incubated with a
phycoerythrin-conjugated goat anti-rabbit or anti-rat IgG secondary antibody
(Molecular Probes) at a 1:1,000 dilution on ice for 30 min. The cells were washed
twice with PBS and analyzed with a FACScan flow cytometer (Becton-Dickinson,
Palo Alto, Calif.).
Sequence analysis of the S1 gene. Viral genomes were extracted from infected
L-cell lysates by the use of Trizol (Life Technologies, Rockville, Md.) according
to the protocol supplied by the manufacturer. S1 gene segments were amplified
by reverse transcription-PCR (RT-PCR) using 10 U of avian myeloblastosis virus
reverse transcriptase (Promega Biosciences, San Luis Obispo, Calif.), 2.5 U Taq
DNA polymerase (Promega Biosciences), and primers complementary to the 5
and 3 nontranslated regions of the S1 genes of the reovirus prototype strains.
The type 1 S1 forward primer was 5 GGATCCGCTATTCGCGCCTATGG
TABLE 1. Strains used for studies of JAM-A utilization
by reoviruses
Virus straina Abbreviation
GenBank
accession
no.
Reference
T1/Human/Ohio/Lang/1953 T1L/53 M35963 45, 50
T1/Bovine/Maryland/clone23/1959 T1C23/59 AY862134 31
T1/Bovine/Maryland/clone50/1960 T1C50/60 AY862133 31
T1/Human/Netherlands/1/1984 T1Neth/84 AY862136 29
T1/Human/Netherlands/1/1985 T1Neth/85 AY862135 29
T2/Human/Ohio/Jones/1955 T2J/55 M35964 46, 50
T2/Human/Netherlands/1/1973 T2Neth/73 AY862137 29
T2/Human/Netherlands/1/1984 T2Neth/84 AY862138 29
T3/Human/Ohio/Dearing/1955 T3D/55 NC_004277 46, 50
T3/Human/Wash.D.C./clone93/1955 T3C93/55 L37675 31
T3/Human/Wash.D.C./clone87/1957b T3C87/57 L37677 48
T3/Bovine/Maryland/clone18/1961 T3C18/61 L37684 31
T3/Murine/France/clone9/1961 T3C9/61 L37676 31
a Strain nomenclature is as follows: serotype/species of origin/place of origin/
strain designation/year of isolation.
b This strain has also been designated T3/Human/Wash.D.C./Abney/1957.
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ATG, and the reverse primer was 5 GGGTTCGCGCTAGATTCA. The type 2
S1 forward primer was 5 GCTATTCGCACTCATGTCGGATCTAGTGC
AGC, and the reverse primer was 5 GATGAGTCGCCACTGTGCCGAGT
GGA. The type 1 5 forward primer contained nucleotides that resulted in a
primer-derived sequence for the first two amino acids (M and D), and the type
2 5 forward primer contained nucleotides that resulted in a primer-derived
sequence for the first six amino acids (M, S, D, L, V, and Q). The amplification
products were cloned into the pCR 2.1 vector (Invitrogen). Sequences of at least
two independent RT-PCR clones for each S1 gene segment were determined by
automated sequencing.
Phylogenetic analysis of S1 gene nucleotide sequences. Sequences were
aligned by using the program ClustalX (62). Phylogenetic trees were constructed
from variations in the 1-encoding S1 gene nucleotide sequences by the maxi-
mum parsimony method using the heuristic search algorithm within the program
PAUP v4.0b10 (58). Trees were rooted at the midpoint. The branching orders of
the phylograms were verified statistically by resampling the data 1,000 times in a
bootstrap analysis using the branch and bound algorithm as applied in PAUP.
Sequence alignment and structural modeling methods. Sequences were
aligned by using the program ClustalW (http://www.ebi.ac.uk/clustalw/). Align-
ments were rendered in ALSCRIPT (5), using different colors to highlight
different degrees of sequence similarity. Sequence changes were mapped onto
the crystal structure of T3D/55 1 (16) by using the program GRASP (42).
RESULTS
JAM-A serves as a receptor for prototype strains of the
three reovirus serotypes. Our previous work indicated that
JAM-A serves as a receptor for the prototype reovirus strains
T1L/53 and T3D/55 (3). To confirm these observations and to
test whether JAM-A is used as a receptor by T2J/55, we treated
HeLa cells with PBS, an hCAR-specific antiserum as a control,
or the hJAM-A-specific MAb J10.4 prior to viral adsorption.
Infected cells were quantified by indirect immunofluorescence
using an antireovirus serum (Fig. 1A). The treatment of cells
with the CAR-specific antiserum had no effect on the capacity
of the prototype strains to infect HeLa cells. In sharp contrast,
the treatment with MAb J10.4 resulted in a concentration-
dependent inhibition of infection for all three strains. The
minimum concentrations of MAb J10.4 required to reduce the
infectivities of these strains by 50% were between 0.1 and 1.0
	g per ml (Fig. 1B). The infectivities of all three strains were
reduced approximately 90% following the treatment of cells
with 100 	g per ml MAb J10.4.
JAM-B and JAM-C do not serve as receptors for prototype
strains of reovirus. JAM-A is the only JAM family member
tested to date that functions as a receptor for T1L/53 (44). To
determine whether other JAM family members in addition to
JAM-A serve as reovirus receptors for other reovirus proto-
type strains, we transfected CHO cells, which are poorly per-
missive for reovirus infection (24), with a cDNA encoding
hJAM-A, hJAM-B, or hJAM-C. Cells also were transfected
with hCAR as a negative control. After confirmation of the cell
surface expression of the receptor constructs (Fig. 2A), the
transfected cells were tested for the capacity to support reovi-
rus infection. Infected cells were quantified by indirect immu-
nofluorescence using an antireovirus serum (Fig. 2B). Only
CHO cells transfected with hJAM-A were capable of support-
ing an efficient infection of each of the three prototype reovirus
strains, whereas cells transfected with hJAM-B and hJAM-C
did not support the infection of any of these strains in excess of
that supported by cells transfected with hCAR (Fig. 2C).
Therefore, the JAM family member JAM-A, but not JAM-B
or JAM-C, functions as a receptor for prototype strains of
reovirus.
JAM-A serves as a receptor for field-isolate strains of reo-
virus. Strains of each of the three reovirus serotypes have been
isolated from many mammalian hosts over a period in excess of
50 years (29, 31). A type 3 reovirus strain isolated from the
cerebrospinal fluid of a child with meningitis is capable of using
JAM-A as a receptor (64). However, the receptor-binding
properties of other field-isolate strains have not been reported.
To determine whether JAM-A is used as a receptor by other
field-isolate strains of reovirus, we transfected CHO cells with
hJAM-A, hJAM-B, or hJAM-C and tested them for the capac-
ity to support reovirus infection. Ten strains, encompassing
four type 1, two type 2, and four type 3 viruses (Table 1), were
used in these experiments. In parallel with the findings for
prototype reovirus strains, each of the field-isolate strains
tested was capable of utilizing hJAM-A, but not hJAM-B or
hJAM-C, as a receptor (Fig. 3).
Analysis of deduced 1 amino acid sequences for JAM-A-
binding reovirus strains. To gain insight into the 1 residues
that mediate interactions between reoviruses and JAM-A, we
analyzed the amino acid sequences of the 1 proteins of the 3
prototype and 10 field-isolate strains chosen for study. For
these experiments, we determined the 1-encoding S1 gene
sequences of the strains T1C23/59, T1C50/60, T1Neth/84,
T1Neth/85, T2Neth/73, and T2Neth/84 and compared these
sequences to those reported previously (Table 1). RT-PCR
primers complementary to the nontranslated regions of the
type 1 and type 2 S1 genes were designed to facilitate the
amplification of entire S1 genes from infected L-cell lysates.
To define the evolutionary relationships of the S1 gene se-
quences determined for this study with those of the other
reovirus strains sequenced to date, we constructed phyloge-
netic trees by using variation in the 1-encoding S1 gene nu-
cleotide sequences and the maximum parsimony method as
applied in the program PAUP (Fig. 4). The most noteworthy
feature of the S1 phylogenetic tree is that the strains clustered
into distinct lineages based on their serotypes. A phylogenetic
tree generated by using the same data set and the neighbor-
joining algorithm of the phylogenetic analysis program
MacVector (MacVector 2001, version 7.1.1) had a topology
identical to that of the tree generated by PAUP (data not
shown). Therefore, our phylogenetic analysis indicates that the
S1 genes of reovirus strains cluster tightly into three lineages
defined by serotype. Concordantly, changes in the deduced
amino acid sequences of the 1 protein within a given serotype
are confined to a small number of residues. Since each of the
strains investigated for this study was capable of using JAM-A
as a receptor, the locations of these changes provide clues
about areas that can vary in surface structure without impeding
the capacity to engage this molecule. Thus, these changes de-
fine areas that are unlikely to interact with JAM-A.
Sequence variability within type 3 1 protein. Structural
information is available for the T3D/55 1 protein (16). We
therefore carried out a structure-based comparison of the de-
duced amino acid sequences of the 1 proteins of type 3
field-isolate strains with that of the prototype T3D/55 to define
regions of conserved and variable sequences within a serotype
(Fig. 5). Substantial variability is seen between residues 240
and 250, a region that lies just N-terminal to the first -spiral
repeat in the crystallized fragment and is disordered in the
crystal structure. The 1 fragment was obtained by trypsin
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cleavage of a longer construct after residue Arg245 (16). The
fact that trypsin cleaves 1 at only this position suggests that
Arg245 lies in an exposed loop that likely possesses some
flexibility. Exposed areas in the second and third -spiral re-
peats of the crystallized fragment also contain several substi-
tutions. Because these areas are variable, they are unlikely to
contribute significantly to JAM-A binding.
Most of the remaining substitutions are located at the top of
the 1 trimer, forming a highly variable “plateau” that is also
unlikely to bind to JAM-A. Some of the observed variations on
FIG. 1. JAM-A blockade reduces infection of prototype reovirus strains. HeLa cells at equivalent degrees of confluence were pretreated with
PBS, an hCAR-specific antiserum as a control, or the hJAM-A-specific MAb J10.4 prior to adsorption with T1L/53, T2J/55, or T3D/55 at an MOI
of 0.1 FFU per cell. After incubation for 20 h, the cells were fixed and permeabilized with methanol. Newly synthesized viral proteins were detected
by the incubation of cells with a polyclonal rabbit antireovirus serum followed by incubation with an anti-rabbit immunoglobulin–Alexa-546 serum
for the visualization of infected cells by indirect immunofluorescence. (A) Representative fields of view. (B) Reovirus-infected cells were quantified
by counting fluorescent cells in a minimum of three random fields of view per well for three wells at a magnification of 20. The results are
presented as the mean FFU per field. Error bars indicate standard deviations.
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the plateau are anticipated to alter the structure of the mole-
cule. For example, the replacement of Ser435 with Met in
T3D9/61 and T3D18/61 is likely to cause significant structural
changes, as Ser435 is partially buried in the T3D/55 structure
(16). Because they are exposed at the protein surface, the
polymorphisms seen on the plateau may allow viral escape
from antibody recognition. In contrast, the lower portion of the
head domain is highly invariant, suggesting that the base of the
1 head is primarily responsible for interactions with JAM-A.
Sequence variability within 1 proteins of the three reovirus
serotypes. An alignment of the deduced 1 amino acid se-
quences for all of the strains chosen for study showed that only
36 of the 210 residues in the crystallized fragment of T3D/55
1 (16) are conserved (Fig. 6). There is substantially more
variability among the serotypes than that within each serotype.
Mapping of the conserved residues onto the crystal structure of
T3D/55 1 showed that many of these residues are buried,
especially those located at the base of the 1 head-trimer
interface (Fig. 6). A large fraction of the remaining conserved
residues cluster in a single, solvent-exposed region at the lower
edge of the -barrel. Again, the regions that are most variable
within type 3 1 (the -spiral region and the “top” of the
trimer) are also most variable among the different serotypes. In
contrast, an extended, contiguous area of conserved residues is
located at the base of the head domain, and additional, smaller
areas of conservation are found along the side of this domain.
Because these regions are conserved in the JAM-A-binding
strains investigated here, they mark potential contact points for
this receptor.
The large conserved area at the base of the head domain is
formed primarily by a stretch of residues (Asn369 to Glu384 in
T3D/55 1) within a 310 helix and a long loop between
-strands D and E (16) (Fig. 6). This region also includes
Trp421 at the end of -strand F. The conserved region is fairly
hydrophobic, with the side chains of Val371, Leu379, and
Trp421 accounting for a large portion of the surface area
predicted to be involved in JAM-A binding. A second, smaller
cluster of conserved residues (Leu331, Trp333, Ile360, and
His438 in T3D/55 1) lies above this putative JAM-A-binding
surface, near the top of the trimer (Fig. 6). While most of the
side chains of these residues are buried, the structural features
of this cluster may contribute to receptor engagement. The
remaining surface area of the 1 trimer, especially near the top
of the head and the head-to-head contacts, is almost entirely
devoid of conserved residues.
A neutralization-resistant variant of reovirus T3D/55 uses
JAM-A as a receptor. Variants of T3D/55 selected for their
resistance to neutralization by the use of MAb 9BG5 (55) have
a mutation at Asp340 or Glu419 in the 1 head (7) (Fig. 5B).
These variants have alterations in central nervous system
(CNS) tropism following infections of newborn mice (54). The
single mutation in variant K of 1, Glu419 to Lys (7), segre-
gates genetically with the altered growth and tropism of this
virus in the murine CNS (32). To determine whether a neu-
tralization-resistant variant of T3D/55 retained the capacity to
use JAM-A as a receptor, we treated HeLa cells with PBS, an
hCAR-specific antiserum as a negative control, or the hJAM-
A-specific MAb J10.4 prior to infection with variant K. In-
fected cells were quantified by indirect immunofluorescence
using an antireovirus serum (Fig. 7). The treatment of cells
with increasing concentrations of the JAM-A-specific MAb
J10.4 resulted in a dose-dependent inhibition of viral infection,
while the CAR-specific antiserum had no effect on viral infec-
tivity. At the maximal concentration of MAb J10.4 used (100
	g per ml), infectivity was nearly abolished, demonstrating that
variant K is capable of using JAM-A as a receptor (Fig. 7).
FIG. 2. CHO cells transfected with hJAM-A support growth of
prototype reovirus strains. (A) CHO cells were transiently transfected
with a plasmid encoding hCAR, hJAM-A, hJAM-B, or hJAM-C. Fol-
lowing incubation for 24 h to permit receptor expression, cells were
incubated with receptor-specific MAbs, and the cell surface expression
of receptor constructs was assessed by flow cytometry. (B) Transfected
CHO cells at equivalent degrees of confluence were adsorbed with
T1L/53, T2J/55, or T3D/55 at an MOI of 0.1 FFU per cell. Reovirus
proteins were detected by indirect immunofluorescence at 20 h postin-
fection. Representative fields of view are shown. Magnification, 20.
(C) Reovirus-infected cells were quantified by counting fluorescent
cells in five random fields of view per well for three wells. The results
are presented as the mean FFU per field. Error bars indicate standard
deviations.
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Thus, the mechanism of the altered pathogenicity of variant K
appears to be independent of JAM-A utilization.
DISCUSSION
An examination of receptor usage by diverse virus families,
including arenaviruses (11, 53), adenoviruses (9, 27, 51, 72),
and measles virus (20, 35, 61), has led to the discovery that
receptor usage by some viruses varies based on the viral clade,
serotype, or adaptation to passaging in cell culture. We under-
took this study to determine whether JAM-A is used as a
receptor by both prototype and field-isolate strains of reovi-
ruses. The results demonstrate that each of the prototype and
field-isolate reovirus strains tested, regardless of their sero-
type, species, or geographical region of isolation, is capable of
utilizing JAM-A as a receptor.
Prior to this work, sequence information for the S1 gene
segments of type 1 and type 2 reovirus strains was limited to
the prototype strains T1L/53 and T2J/55. In this study, we
determined the S1 sequences of four type 1 and two type 2
field-isolate strains. A phylogenetic analysis of the deduced
1-encoding S1 gene sequences revealed that these reovirus
field-isolate strains are associated with discrete lineages de-
fined by serotype. Given that all reovirus strains tested to date
FIG. 3. Expression of JAM-A confers infectivity on field-isolate reovirus strains. CHO cells were transiently transfected with a plasmid
encoding hCAR, hJAM-A, hJAM-B, or hJAM-C. Following incubation for 24 h to permit receptor expression, the cells were adsorbed with the
indicated field-isolate strains at an MOI of 1 FFU per cell. Reovirus proteins were detected by indirect immunofluorescence at 20 h postinfection
and quantified by counting of the fluorescent cells in three random fields of view per well for three wells. The results are presented as the mean
FFU per field. Error bars indicate standard deviations.
FIG. 4. Phylogenetic relationships among S1 gene nucleotide sequences of 13 reovirus strains. A phylogenetic tree for the 1-encoding S1 gene
sequences of the strains shown in Table 1 was constructed by using the maximum parsimony method as applied in the program PAUP. The tree
is rooted at its midpoint. Bootstrap values of 
50% (indicated as a percentage of 1,000 repetitions) for major branches are shown at the nodes.
Bar, distance resulting from 10 nucleotide changes.
7972 CAMPBELL ET AL. J. VIROL.
FIG. 5. Sequence conservation and structural variability within the type 3 1 protein. (A) Alignment of deduced amino acid sequences of the
1 proteins of prototype strain T3D/55 and four type 3 field-isolate strains. The alignment was generated by using the program ALSCRIPT (5),
with default conservation parameters applied according to the following color scheme: red, identical residues; orange, conserved residues at 80%
conservation; yellow, conserved residues at 60% conservation; white, nonconserved residues. The 80% conservation threshold identifies closely
related amino acids (e.g., Ile and Leu), whereas the 60% threshold identifies more distantly related amino acids (e.g., Ser and Ala, both of which
have small side chains). The amino acid positions in the alignment are numbered above the sequences. The gray line indicates residues present
in the crystallized fragment of T3D/55 1 (16). (B) Structure of the 1 trimer, with residues colored according to the same color code as that
used for panel A. Four different views are shown. For each of the views, two 1 monomers are shown in surface representation, and the other
is depicted as a blue ribbon tracing corresponding to the -carbon backbone. The first three views each differ by 90° along a vertical axis; the
fourth view shows the molecule in the third view after rotation by 90° along a horizontal axis. The positions of residues 340 and 419 are marked
in the third panel from the left.
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are capable of using JAM-A as a receptor, it seems plausible
that 1 interacts with JAM-A through residues that are con-
served among the serotypes, including the newly characterized
type 1 and type 2 field-isolate strains. The observation that
JAM-A is used as a receptor by all reovirus strains tested was
unexpected since the 1 protein is highly divergent among the
three serotypes. For example, a sequence analysis of the pro-
totype strains revealed that the 1 head domains of T1L/53
and T2J/55 share 50% identical residues, while those of T1L/53
and T3D/55 share only 27% of their residues.
Substantial evidence has accumulated to suggest that the 1
head domain binds to cellular receptors. Truncated forms of
1 containing only the head domain are capable of specific cell
interactions (22, 23). Concordantly, proteolysis of T3D/55 viri-
ons leads to the release of a C-terminal receptor-binding frag-
ment of 1 (residues 246 to 455) (13) and a resultant loss in
infectivity (39). This fragment of 1 is capable of binding to
JAM-A on a biosensor surface with an affinity in the nanomo-
lar range (3). Preliminary findings from our laboratory indicate
that an even smaller fragment of T3D/55 1, corresponding to
the head domain and a single -spiral repeat, is capable of
binding to JAM-A (K. M. Guglielmi, P. Schelling, T. Stehle,
and T. S. Dermody, unpublished observations). Thus, the 1
head promotes interactions with JAM-A that are distinct from
the interactions with sialic acid mediated by the 1 tail.
While most of the residues conserved among the 1 proteins
of the strains tested are scattered throughout the molecule, an
examination of the 1 surface revealed a single extended patch
of conserved residues at the lower edge of the 1 head. We
think that this region may form part of a JAM-A-binding
surface. This conserved region is formed mostly by residues in
the vicinity of a long loop connecting -strands D and E of the
eight-stranded -barrel that forms the 1 head. Although it is
easily accessible to ligands, this site is somewhat recessed into
FIG. 7. JAM-A is used as a receptor for a neutralization-resistant
variant of reovirus T3D/55. HeLa cells at equivalent degrees of con-
fluence were pretreated with PBS, an hCAR-specific antiserum, or the
hJAM-A-specific MAb J10.4 prior to adsorption with variant K at an
MOI of 1 FFU per cell. Reovirus proteins were detected by indirect
immunofluorescence at 20 h postinfection. (A) Representative fields of
view. (B) Reovirus-infected cells were quantified by counting fluores-
cent cells in three random fields of view per well for three wells. The
results are presented as the mean FFU per field. Error bars indicate
standard deviations.
FIG. 6. Sequence conservation and structural variability within the 1 proteins of the three reovirus serotypes. (A) Alignment of deduced
amino acid sequences of the 1 proteins of 3 prototype and 10 field-isolate reovirus strains. The alignment was generated by using ALSCRIPT
and the scheme described in the legend to Fig. 5. Gaps in the aligned sequences are indicated by dots. (B) Mapping of residues onto the 1
structure, using the same color code as that depicted in Fig. 5. The four views correspond to those in Fig. 5B.
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the protein surface and is surrounded by protruding, noncon-
served residues on all three edges of the trimer. Only residues
from a single monomer contribute to the putative JAM-A-
binding region and its borders, and the regions are not involved
in 1 intersubunit contacts. Thus, the location of conserved
residues within the trimer suggests that each 1 monomer can
independently bind to a JAM-A molecule.
Although it may serve as the primary contact point for the
receptor, the putative JAM-A-binding site in 1 is relatively
small, measuring about 15 Å long and 10 Å wide. Most other
interactions between viral ligands and proteinaceous receptors
cover somewhat larger areas. It is therefore likely that addi-
tional regions of 1 contribute to interactions with JAM-A. We
noted that the putative JAM-A-binding site lies at the lower
edge of a large, concave surface formed by -strands B, A, D,
and G of 1. Residues on this surface, which almost entirely
covers one side of the -barrel, would easily be accessible to a
receptor and do not participate in intersubunit contacts. The
top of the 1 head is formed by three prominent protrusions,
with one coming from each -barrel. These protrusions are
entirely devoid of conserved residues among the serotypes and
also exhibit significant sequence drift within type 3 1 proteins.
It is therefore highly unlikely that the top of the 1 head
participates in receptor binding, again implicating regions on
the side of each -barrel as the most likely areas of contact
with JAM-A.
Neutralization-resistant variants of the reovirus T3D/55 se-
lected by using the 1-specific MAb 9BG5 contain mutations
in the 1 head that segregate genetically with alterations in
neural tropism (7, 32, 54, 55). Since reovirus tropism in the
murine CNS is determined at least in part by 1-receptor
interactions (19, 60), it is possible that the antibody-selected
mutations in the 1 head alter receptor binding. However, we
found that variant K, which has a Glu-to-Lys mutation at
amino acid 419, uses JAM-A as a receptor. This observation
suggests that the mutation in 1 of variant K alters the inter-
actions of this strain with cell surface receptors other than
JAM-A or influences a postattachment step in reovirus repli-
cation. It is noteworthy that amino acid 419 is adjacent to the
1 head trimer interface in the vicinity of amino acid 340 (16)
(Fig. 5), which is also targeted for mutation in neutralization-
resistant variants of T3D/55 (7). It is possible that mutations at
these sites alter 1 subunit interactions required for viral as-
sembly or disassembly.
Reovirus serotypes exhibit striking differences in tropism
and pathogenesis in the murine CNS. Type 1 reoviruses spread
to the CNS hematogenously and infect ependymal cells (65,
70), resulting in subacute hydrocephalus (69). In contrast, type
3 reoviruses spread to the CNS by neural routes and infect
neurons (38, 65, 70), causing lethal encephalitis (59, 69). An
analysis of reassortant viruses containing gene segments de-
rived from T1L/53 and T3D/55 demonstrated that the pathway
of viral spread in the host (65) and tropism for neural tissues
(19, 70) segregate with the 1-encoding S1 gene. These find-
ings suggest that 1 determines the CNS cell types that serve as
targets for reovirus infection, presumably by its capacity to
bind to receptors expressed by specific CNS cells. Since all
strains of reovirus tested are capable of utilizing JAM-A as a
receptor, the engagement of JAM-A alone does not explain
the differences in tropism and virulence displayed by the dif-
ferent reovirus serotypes in the murine CNS. It is possible that
JAM-A serves as a serotype-independent reovirus receptor at
some sites within the host and that other receptors, perhaps
carbohydrate in nature, confer serotype-dependent tropism. In
support of a role for cell surface carbohydrates in reovirus
disease, the capacity to bind sialic acid enhances the spread of
type 3 reoviruses within the host and targets the virus to bile
duct epithelial cells, leading to obstructive jaundice (4). It is
also possible that serotype-dependent differences in pathogen-
esis are influenced by one or more postbinding events.
The role of JAM-A utilization in reovirus infections in vivo
is not known. JAM-A is expressed on many cell types, includ-
ing intestinal epithelium, bile duct epithelium, lung epithelium,
leukocytes, and CNS endothelial cells (36), which serve as sites
of reovirus infection in mice (68). It will be interesting to
determine whether JAM-A functions as a reovirus receptor at
these sites in infected animals. Mice with a targeted disruption
of the JAM-A gene are viable and fertile (12). These mice
exhibit an accelerated migration of dendritic cells to lymph
nodes, which is associated with enhanced contact hypersensi-
tivity (12). No other developmental or immune abnormalities
have been noted. Studies of reovirus infections using JAM-A-
deficient animals should clarify the function of JAM-A in re-
ovirus pathogenesis and disease.
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Mammalian reoviruses are nonenveloped viruses that contain a segmented, double-stranded RNA genome.
Reoviruses infect most mammalian species, although infection with these viruses in humans is usually asymp-
tomatic. We report the isolation of a novel reovirus strain from a 6.5-week-old child with meningitis. Hem-
agglutination and neutralization assays indicated that the isolate is a serotype 3 strain, leading to the designation
T3/Human/Colorado/1996 (T3C/96). Sequence analysis of the T3C/96 S1 gene segment, which encodes the
viral attachment protein, j1, confirmed the serotype assignment for this strain and indicated that T3C/96 is
a novel reovirus isolate. T3C/96 is capable of systemic spread in newborn mice after peroral inoculation and
produces lethal encephalitis. These results suggest that serotype 3 reoviruses can cause meningitis in humans.
Mammalian reoviruses are nonenveloped viruses that
contain a genome of 10 discrete segments of double-
stranded RNA (dsRNA) [1]. There are 3 major reovirus
serotypes, which are differentiated by the capacity of
antisera to neutralize viral infectivity and inhibit hem-
agglutination [2, 3]. Reoviruses have a wide geographic
distribution and can infect virtually all mammals, in-
cluding humans [4].
Reoviruses were originally called respiratory enteric
orphans on the basis of their repeated isolation from
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respiratory and enteric tracts of children with asymp-
tomatic illness [2]. Only mild respiratory or gastro-
intestinal symptoms are observed when infection is
symptomatic [4–7]. There are few studies of human
reovirus-associated neurological disease [8]. These stud-
ies generally relied on serological analysis or isolation
of reovirus from stool samples for diagnosis, which is
diagnostically inconclusive, because of the frequency of
asymptomatic reovirus infections. Three studies have
described the isolation of reovirus directly from cere-
brospinal fluid (CSF) or neural tissue samples obtained
from individuals with meningitis or encephalitis, as de-
scribed elsewhere [9–11]. In these studies, there was no
molecular or virological analysis of the isolated strain
performed. Therefore, little is known about the biologic
characteristics of reovirus strains that cause human
CNS disease.
In contrast to human reovirus infection, infection of
newborn mice is highly pathogenic. After oral inocu-
lation in mice, reovirus is taken up by intestinal M cells
[12] and undergoes primary replication in lymphoid
tissue of Peyer’s patches. T1 reovirus spreads to the
CNS hematogenously and infects ependymal cells [13,
14], which results in hydrocephalus [15]. In contrast,
T3 reovirus spreads to the CNS neurally, infects neurons
[13, 14, 16], and causes lethal encephalitis [15, 17]. The
pathways of viral spread in the host [13] and pattern
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Table 1. Reovirus strains used for T3C/96 S1 gene sequence analysis.
Virus straina Abbreviation GenBank accession no. Reference(s)
T1/Human/Ohio/Lang/1953 T1L/53 M35963 [2, 66]
T2/Human/Ohio/Jones/1955 T2J/55 M35964 [2, 67]
T3/Human/Ohio/Dearing/1955 T3D/55 NC_004277 [2, 67]
T3/Human/Washington, DC/clone 93/1955 T3C93/55 L37675 [68]
T3/Human/Washington, DC/Abney/1957 T3A/57 L37677 [69]
T3/Human/Washington, DC/clone 84/1957 T3C84/57 L37678 [44]
T3/Bovine/Maryland/clone 31/1959 T3C31/59 L37683 [68]
T3/Bovine/Maryland/clone 43/1960 T3C43/60 L37682 [68]
T3/Bovine/Maryland/clone 44/1960 T3C44/60 L37681 [44]
T3/Bovine/Maryland/clone 45/1960 T3C45/60 L37680 [44]
T3/Human/Tahiti/clone 8/1960 T3C8/60 L37679 [68]
T3/Bovine/Maryland/clone 18/1961 T3C18/61 L37684 [68]
T3/Murine/France/clone 9/1961 T3C9/61 L37676 [68]
T3/Human/Colorado/1996 T3C/96 AY 302467 Present study
a Strains are named according to the following scheme: serotype/species of origin/place of origin/strain designation/
year of isolation [70].
of neurotropism [14, 18] segregate with the viral S1 gene, which
encodes the viral attachment protein [19, 20]. The j1 protein
which determines the CNS cell types that serve as targets for
reovirus infection, presumably by its capacity to bind receptors
expressed on specific CNS cells.
The j1 protein is a fibrous trimer with an elongated tail
domain that inserts into the virion and a globular head domain
that projects away from the virion surface [21–23]. T1 and T3
j1 contain receptor-binding domains in both the tail and head
regions. A domain in the T3 j1 tail binds a-linked sialic acid
[24, 25], and another domain in the head of both T1 and T3
j1 binds junctional adhesion molecule 1 (JAM1) [26]. The T1
j1 tail also binds cell-surface carbohydrate [25]. As a conse-
quence of a sequence polymorphism in the tail of T3D/55 j1,
the sialic acid– and JAM1-binding domains are dissociable by
treatment of virions with intestinal proteases, such as trypsin
or chymotrypsin [27, 28], which may determine the attenuated
virulence of T3D/55 after oral inoculation [29].
Engagement of reovirus receptors also induces postbinding
signaling events that influence disease pathogenesis. Reovirus
induces apoptosis in cultured cells [30–33], including neurons
[34], and in vivo [35, 36]. Neurovirulent strains induces ap-
optosis to a greater extent than nonneurovirulent strains [30,
31, 34, 37]. Analysis of T1L/ /55 reassortant viruses53T3D
indicates that differences in apoptosis efficiency are determined
primarily by the j1-encoding S1 gene [30, 31, 37], which sug-
gests that receptor engagement influences the magnitude of the
apoptotic response. In concordance with this idea, the most
apoptogenic reovirus strains bind to both sialic acid [37] and
JAM1 [26].
In the present study, we report the isolation of a T3 reovirus
designated T3/Human/Colorado/1996 (T3C/96) from the CSF
of a 6.5-week-old child with meningitis. The T3C/96 S1 gene
sequence was determined and compared to all previously re-
ported T3 reovirus S1 gene sequences. The capacity of T3C/96
to bind sialic acid and JAM1 and to cause encephalitis in mice
was assessed. The results indicate that T3C/96 is a novel T3
reovirus capable of systemic spread to the CNS after peroral
inoculation of newborn mice and provide direct evidence that
T3 reovirus can be neurovirulent in humans.
MATERIALS AND METHODS
Cells, viruses, and antibodies. Spinner-adapted murine L929
(L) cells grown in suspension or on monolayer cultures and
HeLa cell monolayers were maintained as described elsewhere
[30, 32]. Prototype reovirus strains T1L/53 and T3D/55 and
reovirus field isolate strains (table 1) are laboratory stocks. Virus
titers were determined by use of plaque assay [38], and purified
virus and particle concentrations were determined, as described
elsewhere [21, 39]. Antibodies used included murine j1-specific
monoclonal antibody (MAb) 5C6 (T1 j1) [40], MAb 9BG5
(T3 j1) [41], and JAM1-specific MAb J10.4 [42].
Electron microscopy. Supernatant of infected rhesus mon-
key kidney (RMK) cells was clarified by centrifugation at 1000
g for 10 min at 22C. Clarified supernatant was placed in an
Airfuge EM-90 rotor (Beckman Coulter) containing a Formvar-
coated grid (Electron Microscopy Sciences) and was centrifuged
at 100,000 g for 30 min at 22C. The grid was stained with 2%
phosphotungstic acid (1 min) and was examined by use of a
Zeiss EM10 electron microscope.
Hemagglutination (HA) assays. Purified reovirus virions
(1011 particles) were serially diluted in 50 mL of PBS in 96-well
round-bottom microtiter plates (Corning-Costar). Calf eryth-
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rocytes (Colorado Serum) were washed twice with PBS and were
resuspended at a concentration of 1% (vol/vol) in PBS. Eryth-
rocytes (50 mL) were added to wells containing virus and in-
cubated for 2 h at 4C.
Neutralization assays. T1 and T3 j1-specific MAbs were
serially diluted 2-fold in gelatin saline and were incubated with
103 pfu/mL of T3C/96 virions for 1 h at 37C. Samples were
titrated in duplicate on L-cell monolayers by use of plaque
assay [38]. Data are presented as the percentage of control
plaque-forming units (virions untreated by antibody).
Sequence analysis of the S1 gene. The S1 gene segment
of T3C/96 was amplified by use of reverse-transcriptase poly-
merase chain reaction (RT-PCR), using primers complemen-
tary to the 5′ and 3′ nontranslated regions (NTRs) [43], and
then was cloned into the pCR 2.1 vector (Invitrogen) and se-
quenced by use of T4 DNA polymerase (Sequenase 2.0; United
States Biochemical). Sequences of the NTRs were determined
by use of direct dsRNA sequencing, using purified viral genomic
RNA [44]. The S1 gene nucleotide sequences of independent
isolates of T3C/96 were determined in independent laboratories
and were found to be identical.
Phylogenetic analysis of S1 gene nucleotide sequences.
Phylogenetic trees were constructed from variation in the j1-
encoding S1 gene nucleotide sequences by use of the neighbor-
joining algorithm (phylogenetic analysis program; MacVector
2001, version 7.1.1; Accelrys). Branching orders of the phylo-
grams were verified statistically by resampling the data 1000
times in a bootstrap analysis, using the branch and bound al-
gorithm (MacVector).
Fluorescent-focus assays of viral infectivity. HeLa cell
monolayers ( cells/well) were pretreated with PBS, cox-52 10
sackie and adenovirus receptor (CAR)–specific MAb RmcB (20
mg/mL) [45, 46], Arthrobacter ureafaciens neuraminidase (40
mU/mL; ICN Biomedicals), or JAM1-specific MAb J10.4 (20
mg/mL) [42] before adsorption of virus for 1 h at room tem-
perature. Inoculum was removed, and cells were washed with
PBS and were incubated for 20 h at 37C, to permit completion
of a single round of viral replication. Cells were fixed with 1
mL of methanol for 30 min at 20C. Fixed monolayers were
washed twice with PBS, blocked with 5% immunoglobulin-free
bovine serum albumin (Sigma-Aldrich) in PBS, and incubated
for 30 min at 37C with protein-A–affinity–purified polyclonal
rabbit antireovirus serum [47] at a 1:800 dilution in PBS/0.5%
Triton X-100. Monolayers were washed twice with PBS/0.5%
Triton X-100 and were incubated with a 1:1000 dilution of goat
anti–rabbit immunoglobulin serum conjugated with Alexa Fluor
546 fluorophore (Molecular Probes). Monolayers were washed
twice with PBS/0.5% Triton X-100, and infected cells were vi-
sualized by indirect immunofluorescence by use of a Zeiss Pho-
tomicroscope III microscope modified for fluorescence micros-
copy. Infected cells were identified by the presence of intense
cytoplasmic fluorescence that was excluded from the nucleus. No
background staining of uninfected control monolayers was de-
tected. Reovirus antigen-positive cells were quantitated bycounting
fluorescent cells in 3 random fields of view/well in triplicate at a
20 magnification.
Mice and inoculations. ND4 Swiss Webster mice aged 2–
3 days with an average weight of 2 g (Harlan) were inoculated
either intracranially or perorally with purified virus. Before in-
oculation, all mice from simultaneously delivered litters were
pooled and randomly subdivided into litters of 8–11 mice/dam.
For intracranial inoculations, 5 mL of purified virus diluted in
gelatin saline was delivered into the right cerebral hemisphere
by use of a Hamilton syringe and a 30-gauge needle [48]. For
peroral inoculations, 50 mL of purified virus diluted in gelatin
saline was delivered into the stomach by passage of a polyeth-
ylene catheter 0.61 mm in diameter (BD Biosciences) through
the esophagus [49]. At various times after inoculation, mice were
killed, and brains were harvested into 2 mL of gelatin saline.
Brains were homogenized by freezing (70C) and thawing
(37C), which was then followed by sonication. Virus titer in
brain homogenates was determined by plaque assay [38].
The LD50 of reovirus was determined by use of ND4 Swiss
Webster mice aged 2–3 days. Litters of mice were inoculated
either intracranially or perorally with a single dose of reovirus
and were checked daily for survival. Moribund mice were killed.
The LD50 of reovirus was calculated by use of the method of
Reed and Muench [50]. All animal experiments were performed
under institutionally approved protocols in Association for As-
sessment and Accreditation of Laboratory Animal Care–ap-
proved facilities.
Histological and immunohistochemical staining for reovi-
rus antigen. At various times after intracranial inoculation
of neonatal mice, mice were killed. Brains were fixed in 10%
buffered formaldehyde for 24–48 h at 4C, paraffin embedded,
and thin sectioned. Deparaffinized tissue samples were stained
with hematoxylin-eosin.
For immunohistochemical staining, deparaffinized tissue
samples were rehydrated by incubation in PBS for 20 min at
room temperature. Endogenous peroxidase was quenched by
incubation in 0.3% peroxide in methanol for 30 min. Tissue
samples were blocked by incubation in PBS containing 1.5%
normal goat serum for 20 min. After the blocking solution was
removed, tissue samples were incubated for 30 min in rabbit
antireovirus serum (1:800 in blocking solution) that was first
purified by protein-A affinity chromatography and was pread-
sorbed against methanol-fixed L-cell monolayers. Antigen-pos-
itive cells were visualized by use of avidin-biotin–conjugated
horseradish peroxidase (Vectastain ABC) and 3,3′-diamino-
benzadine (DAB) substrate, according to the manufacturer’s
instructions (Vector Laboratories). After DAB staining, tissue
samples were rinsed in deionized water and were counterstained
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Figure 1. Strain characterization of T3C/96. A, Electron micrograph
of T3C/96 after growth in primary rhesus monkey kidney cells. B, Elec-
trophoretic analysis of reovirus strains T1L/53, T3C/96, and T3D/55. Ap-
proximately equal numbers of reovirus particles were resolved by acryl-
amide gel electrophoresis. Viral double-strand RNA (dsRNA) gene
segments were visualized after staining of the gel with ethidium bromide.
Position of the serotype-determining S1 gene segment is indicated for
each strain. C, Neutralization of T3C/96 with j1-specific monoclonal an-
tibodies (MAbs). T3C/96 virions were incubated for 1 h at 37C with
either the T1j1-specific MAb 5C6 or the T3 j1-specific MAb 9BG5 at
the concentrations shown. Viral titer was determined by plaque assay,
using L cells. Data are the mean of 2 experiments.
for 45 s with hematoxylin, dehydrated in 95% ethanol, air dried,
and mounted under coverslips by use of Accu-Mount 60 re-
agent (Baxter Healthcare).
RESULTS
Case report. A 6.5-week-old female infant who was delivered
vaginally at 35 weeks gestation had a 3-day history of irritability,
decreased appetite, vomiting, and high-pitched cry. After vital
signs were notable for temperature of 38.8C (pr), heart rate
of 166 beats/min, respiratory rate of 36 breaths/min, and blood
pressure of 72/30 mmHg. The child was in mild respiratory
distress, with grunting while breathing room air. Her neck was
supple, chest and cardiac examinations were normal, and her
abdomen was soft and nontender. Neurological examination
was remarkable for lethargy, normal cranial nerves, muscle
tone, and reflexes. An episode consistent with a generalized
seizure was noted in the emergency department.
Her hematocrit was 27.7%, white blood cell (WBC) count
was 9500 cells/mm3, and platelet count was 412,000 platelets/
mm3. CSF contained a WBC count of 22 cells/mm3 (77% neu-
trophils, 9% bands, and 14% lymphocytes), a protein level of
67 mg/dL, and a glucose level of 44 mg/dL. The serum glu-
tamate oxaloacetate transaminase level was 64 IU/L (normal,
!60 IU/L), and the conjugated bilirubin level was 0.5 mg/dL
(normal, !0.3 mg/dL). Alkaline phosphatase, serum glutamate
pyruvate transaminase, and gamma glutamyltransferase levels
were normal. Bacterial cultures of blood and CSF were sterile.
CSF PCR assay was negative for enteroviruses and herpes sim-
plex virus. During her 5 days of hospitalization, the patient
developed transient abdominal distension and watery diarrhea.
No erythrocytes or leukocytes were observed after microscopy
of stool samples, and stool cultures were negative for enteric
pathogens, as were tests for rotavirus antigen and electron mi-
croscopy for rotavirus particles. She gradually recovered and
was discharged from the hospital without obvious neurological
sequelae.
Isolation and virological characterization of a novel T3 re-
ovirus strain. CSF was inoculated onto primary human dip-
loid fibroblast (MRC-5), human epithelial carcinoma (Hep-2),
and primary RMK cell monolayers. The RMK cell cultures
developed a granular, nonsloughing pattern of cytopathic effect
(CPE). Supernatant of these cells was used to infect MRC-5
cells, which developed similar CPE. Electron microscopy of
infected cells demonstrated icosahedral nonenveloped viral par-
ticles characteristic of mammalian reovirus (figure 1A).
The original RMK cell lysate was used to inoculate flasks of
murine L cells, which developed a characteristic reovirus CPE.
Plaque assay of lysates demonstrated round 1–2 mm plaques.
Electrophoretic analysis of infected L-cell lysates demonstrated
the presence of 10 viral gene segments (figure 1B). The largest
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Figure 2. Phylogenetic tree based on S1 gene nucleotide sequences of 14 reovirus strains. Phylogenetic tree for 1416 nt of the S1 gene (nt 12–
1370) of the strains shown in table 1 was constructed by use of the neighbor-joining algorithm of MacVector (version 7.1.1; Accelrys). Bootstrap
values 150% (indicated as a percentage of 1000 repetitions) for major branches are shown at the nodes. The tree is unrooted.
of the S-class gene segments (S1) migrated slowly in the ac-
rylamide gel, a characteristic of T3 reovirus strains (figure 1B).
Virus produced after infection of L cells agglutinated bovine
erythrocytes (HA observed at virus concentrations6.25104
pfu/well), which is characteristic of HA produced by T3 reo-
virus (data not shown) [51, 52]. The CSF isolate was efficiently
neutralized by T3 j1-specific MAb 9BG5 (150% plaque re-
duction at 5 ng/mL), but not by T1 j1-specific MAb 5C6 (no
plaque reduction at500 mg/mL) (figure 1C). The new reovirus
isolate was designated T3C/96.
Sequence analysis of the T3C/96 S1 gene. The reovirus
S1 gene, encoding viral attachment protein j1 [19, 20], is the
major genetic determinant of neurovirulence in infected mice
[14, 15]. Therefore, we determined the sequence of the T3C/
96 S1 gene (GenBank accession no. AY302467). The 5′ and 3′
NTRs of all T3 reovirus S1 genes sequenced to date are highly
conserved [44]. RT-PCR primers complementary to the NTRs
were designed to permit amplification of the entire T3C/96 S1
gene from infected L-cell lysates. A PCR product of the expected
size (∼1.4 kb) was obtained. The S1 gene cDNA was cloned
and sequenced. NTRs of the T3C/96 S1 gene were directly
sequenced by use of dsRNA as template. Nucleotide sequences
of the prototype T3D/55 and the novel T3C/96 S1 genes shared
69% positional identity, which provided sequence confirmation
of the assignment of this new isolate as a T3 strain.
To define the evolutionary relationship of the T3C/96 S1
gene with the S1 genes of other reovirus strains sequenced to
date, we constructed phylogenetic trees by use of variation in
the S1 gene nucleotide sequences and the neighbor-joining al-
gorithm (figure 2). The most noteworthy feature of the S1
phylogenetic tree is that the S1 gene sequence of T3C/96 is
substantially divergent from all other T3 strains analyzed. How-
ever, the T3C/96 S1 gene is more closely related to the S1 genes
of the other T3 strains than to those of either T1 or T2 strains.
A phylogenetic tree generated by use of the maximum likeli-
hood method (Phylogeny Inference Package) [53] had a to-
pology identical to the tree generated by using the neighbor-
joining algorithm (data not shown). Therefore, T3C/96 is the
first member of a highly divergent clade of T3 reovirus.
Comparison of the deduced amino acid sequences of the
T3D/55 and T3C/96 j1 proteins confirms their evolutionary
relationship, with the sequences sharing 74.3% positional iden-
tity (figure 3A). Secondary structure predictions for the 2 pro-
teins are strikingly similar (data not shown). Notably, both
T3D/55 and T3C/96 j1 possess amino-terminal regions with
high a-helical predictions and contain regions of sequence be-
tween amino-terminal residues 200–300 with high b-sheet
predictions.
The deduced aa sequence of T3C/96 j1 protein was com-
pared with that of T3D/55 across known functional domains
(figure 3B). The region between aa residues 198 and 204 has
been linked genetically [24, 52, 54] and biochemically [25] to
the capacity of T3D/55 to bind sialic acid. The sequence of
T3C/96 j1 was identical to that of T3D/55 across this region,
which is consistent with the capacity of T3C/96 to produce HA
and suggests that T3C/96 uses a-linked sialic acid as a corecep-
tor. Sequence polymorphism at aa 249 influenced the suscep-
tibility of T3 j1 protein to cleavage by intestinal proteases [28].
T3C/96 encoded a hydrophobic isoleucine at aa 249, which is
a characteristic of all T3 strains that possess protease-resistant
Novel Type 3 Reovirus • JID 2004:189 (1 May) • 1669
Figure 3. Sequence analysis of the T3C/96 j1 protein. A, Alignment
of deduced amino acid sequences of the j1 proteins of T3D/55 and T3C/
96. T3D/55 j1 protein aa residues 1–455 are shown by use of the single-
letter aa code. aa Residues in T3C/96 j1 that are identical to the T3D/
55 sequence are indicated by dashes. aa Positions are numbered above
the sequences. aa Residues in the predicted sialic acid–binding domain
[24, 25, 52, 54] are underlined. A sequence that confers sensitivity to
cleavage by intestinal proteases [28] is circled. aa Residues identified to
be important for neuronal tropism [55, 56] are boxed. B, Functional do-
mains of j1 protein. JAM1, junctional adhesion molecule 1.
j1 proteins [28]. Two aa residues in the j1 head domain (aa
340 and 419) have been genetically implicated in reovirus neu-
rotropism [55, 56]. These aa residues are identical in the T3D/
55 and T3C/96 j1 proteins, and aa residues in the immediate
vicinity of these 2 sites are highly conserved. Thus, the divergent
strain T3C/96 conserves several domains of j1 known to be
important for reovirus neurovirulence.
T3C/96 receptor utilization. To determine whether T3C/
96 is capable of using sialic acid and JAM1 as functional re-
ceptors, HeLa cells were treated with neuraminidase, JAM1-
specific MAb J10.4, or both neuraminidase and MAb J10.4
before adsorption with T3C/96. Infected cells were quantitated
by use of indirect immunofluorescence, using an antireovirus
serum (figure 4). Compared to either untreated cells or cells
treated with CAR-specific MAb RmcB as a control, treatment
of cells with neuraminidase to remove cell-surface sialic acid
resulted in a 61% reduction in the number of infected cells.
Treatment of cells with JAM1-specific MAb J10.4 resulted in a
47% reduction in the number of infected cells. However, when
cells were treated with both neuraminidase and MAb J10.4,
infection by T3C/96 was virtually abolished. Therefore, T3C/
96 is capable of using both sialic acid and JAM1 as receptors,
which confirms predictions made by analysis of its j1 protein
sequence.
Pathogenesis of T3C/96 in mice. To test the capacity of
T3C/96 to infect CNS tissue, newborn mice were inoculated
intracranially with either T3C/96 or T3D/55 and were killed at
various times after inoculation. Infectious virus present in ho-
mogenized brain tissue samples was quantitated by use of plaque
assay (figure 5). Similar to T3D/55, T3C/96 replicated efficiently
in CNS tissues, producing yields 10,000-fold greater than input
4 days after inoculation and sustaining high titers in the brain
up to 12 days after infection. These data indicate that T3C/96
can infect and grow to high titer in the murine CNS.
To assess the neurovirulence of T3C/96, litters of newborn
mice were inoculated intracranially with increasing doses (101–
104 pfu/mouse) of either T3D/55 or T3C/96, and mortality was
monitored daily for 21 days after inoculation (figure 6A). T3D/
55 is neurovirulent after intracranial infection, displaying an
LD50 of ∼100 pfu, which is consistent with previously studies,
as described elsewhere [38, 57, 58]. Infection with T3C/96 also
resulted in lethality, although with somewhat reduced virulence,
compared with T3D/55 (LD50, ∼ 3000 pfu). These results in-
dicate that T3C/96 is virulent after direct inoculation of the
virus into the brain.
To determine whether T3C/96 is virulent after a natural route
of infection, newborn mice were inoculated perorally with 105,
106, or 107 pfu/mouse of either T3D/55 or T3C/96 and were
monitored daily for mortality (figure 6B). In contrast to results
obtained after intracranial inoculation, we found that only T3C/
96 was virulent after peroral inoculation. At the highest dose
of virus used, no mice survived infection with T3C/96, whereas
90% of T3D-infected mice survived. Thus, T3C/96 can dissem-
inate from the murine intestine to the CNS and produce a
lethal infection.
To assess pathologic changes associated with T3C/96 infec-
tion in the CNS, brain section samples derived from mice killed
2, 4, and 6 days after intracranial inoculation with either 104
Figure 4. Effect of neuraminidase and junctional adhesion molecule 1 (JAM1)–specific monoclonal antibody (MAb) on growth of T3C/96. HeLa
cells ( cells) were pretreated with PBS, coxsackie and adenovirus receptor (CAR)–specific MAb RmcB (20 mg/mL) [45, 46], neuraminidase (4052 10
mU/mL), JAM1-specific MAb J10.4 (20 mg/mL) [42], or neuraminidase and MAb J10.4 before adsorption with T3C/96 at an MOI of 1 fluorescent focus
unit (ffu)/cell. After incubation for 20 h, cells were fixed and permeabilized with methanol. Newly synthesized viral proteins were detected by incubating
cells with polyclonal rabbit antireovirus serum, followed by incubation with anti–rabbit immunoglobulin Alexa-546 serum for visualization of infected
cells by indirect immunofluorescence. A, Representative fields of view are shown. B, Reovirus antigen–positive cells were quantitated by enumerating
fluorescent cells in 3 random fields of view/well in triplicate. Data are mean fluorescent focus units for 3 wells. Error bars indicate SDs. ffu, Fluorescent-
forming units.
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Figure 5. Growth of T3C/96 in mice after intracranial inoculation. ND4
Swiss Webster mice (aged 2–3 days) were inoculated intracranially with
100 plaque-forming units (pfu) of either T3C/96 or T3D/55. At the indicated
days after inoculation, mice were killed, and brains were collected. Brain
tissue samples were homogenized by sonication, and titers of virus present
in homogenates were determined by use of plaque assay. Each data point
represents the average virus titer of 2–4 brains. Error bars indicate SD.
Figure 6. Lethality of T3D/55 and T3C/96 after either intracranial
(A) or peroral inoculation (B). ND4 Swiss Webster mice (2–3 days) were
inoculated with various doses of either T3D/55 or T3C/96. Each dose was
inoculated into single litters of mice. Survival was monitored daily for 21
days. pfu, Plaque-forming units.
pfu of T3C/96 or gelatin saline were examined after staining
with hematoxylin-eosin (figure 7A, 7C, 7E, and 7G; data not
shown). Brain section samples derived from mice infected with
T3C/96 demonstrated evidence of meningoencephalitis (figure
7A and 7E; data not shown). Inflammatory infiltrates were
detected primarily in the cerebral cortex, hippocampus, dien-
cephalon, and brain stem. Morphologically, inflammatory cells
were mostly lymphocytes and macrophages/microglia, with
some plasma cells and neutrophils. The extent of inflammation
increased with time after virus inoculation, with the most ex-
tensive inflammation observed 6 days after inoculation (data
not shown).
To define the extent and location of reovirus antigen in the
CNS of T3C/96-infected mice, section samples derived from
mice killed 2, 4, and 6 days after inoculation with either 104
pfu of T3C/96 or gelatin saline were examined after staining
with a reovirus-specific antiserum (figure 7B, 7D,7F, and 7H;
data not shown). Immunohistochemical staining for reovirus
protein demonstrated immunoreactive neurons in brain section
samples derived from T3C/96-infected, but not mock-infected,
mice. Antigen-positive neurons were detected primarily in the
cerebral cortex, hippocampus, diencephalon, and brain stem.
Similar to the observed inflammatory changes, the number of
antigen-positive cells increased with time after virus inoculation
(data not shown). Most cells demonstrating immunohisto-
chemical evidence of reovirus protein were detected in inflamed
foci. These observations indicate that intracranial inoculation
of T3C/96 leads to encephalitis and reovirus protein expression
in newborn mice. Therefore, T3C/96 is capable of neurovirulent
infection.
DISCUSSION
The present study is the first molecular characterization of a
reovirus strain isolated directly from the CSF of an infant with
symptoms and signs consistent with meningitis. The strain iso-
lated, T3C/96, is a novel T3 reovirus, as determined by its HA
capacity, neutralization profile, and S1 gene sequence. Molec-
ular analysis of the T3C/96 S1 gene indicates that this strain is
the most divergent T3 reovirus isolated to date. Despite this
divergence, key functional domains of j1 are conserved in this
strain. T3C/96 encodes an isoleucine at position 249 in j1, a
polymorphism that has been linked to the capacity of T3 re-
ovirus strains to infect the murine intestine and to spread from
the intestine to the CNS [28]. In addition, key aa residues in
the j1 head domain implicated in T3 neural tropism and neu-
Figure 7. Inflammation and reovirus protein expression in the brain of newborn mice infected with T3C/96. ND4 Swiss Webster mice (2–3 days) were
inoculated intracranially with either 104 pfu of T3C/96 (A, B, E, and F) or gelatin saline (C, D, G, and H). At 6 days after inoculation, brain tissue samples
were harvested, paraffin embedded, sectioned, and stained with hematoxylin-eosin (A, C, E, and G) or stained for reovirus antigen by use of a polyclonal
antireovirus serum (B, D, F, and H). Sections are from the upper brain stem (A–D) and the cortex (E–H). Brown staining indicates reovirus antigen.
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rovirulence [55, 56] are conserved. The conservation of aa res-
idues involved in sialic acid binding [24, 25, 52, 54] in T3C/96
j1 suggests that binding to this carbohydrate may be important
in neurovirulence, a hypothesis supported by the finding that
the capacity to bind sialic acid enhances reovirus spread from
the murine intestine to the CNS [59].
Experimental infections of mice indicate that T3C/96 is neu-
rotropic and neurovirulent. T3C/96 productively infects the
murine CNS, producing lethal infection after direct intracranial
inoculation. However, in striking contrast to T3D/55, T3C/96
is also virulent after peroral inoculation, which may be related
to a sequence polymorphism in j1 at aa 249.
Why do reovirus infections of humans rarely produce dis-
ease? Analysis of the T3C/96 S1 sequence suggests that the low
incidence of serious illness associated with reovirus infection
may be caused, in part, by a requirement for a discrete set of
viral biochemical characteristics that permit neural spread of
enteric reovirus infections. Specifically, a protease-resistant j1
molecule may be required for both efficient growth in the in-
testine and spread to secondary sites of replication, including
the CNS. In addition, the capacity to bind sialic acid also may
function to enhance spread to the CNS in infected humans
[59]. Finally, specific sequences may be required in receptor-
binding domains of the j1 head to permit efficient infection
of CNS neurons. It is conceivable that viral strains lacking any
of these characteristics would be nonpathogenic in humans.
Host factors also play an important role in determining the
outcome of reovirus infection. Studies using mice indicate that
reovirus virulence strongly correlates with host age. Newborn
mice are exquisitely susceptible to reovirus CNS infection,
whereas adult mice support limited viral growth and show no
histopathological evidence of CNS injury even after intracranial
inoculation of large doses of virus [17]. The capacity of reovirus
to invade the CNS from a peripheral site of inoculation also
declines rapidly with age [60]. In addition to host age, host
immune responses can influence susceptibility to reovirus in-
fection. Administration of reovirus-specific antibodies by either
transplacental transfer [61] or intraperitoneal inoculation [38,
57, 58] protects newborn mice against fatal reovirus infection of
the CNS. The rarity of human neurological infection with reo-
viruses could reflect the fact that exposure to nonneurovirulent
reovirus generates protective immune responses, which, in turn,
prevent neurological disease after subsequent exposure to “neu-
rovirulent” strains. Neurological disease would occur only when
a nonimmune susceptible individual was exposed to a virus con-
taining the appropriate set of neurovirulence determinants.
In addition to reovirus, other members of the Reoviridae
family have been associated with CNS disease in humans. Ro-
tavirus, an important cause of gastroenteritis in children (re-
viewed in [62]) has been implicated in a few cases of enceph-
alitis [63, 64], as has Colorado tick fever virus, a member of
the Coltivirus genus of the Reoviridae [65]. The patient reported
in the present study provides evidence that reovirus also can
cause human CNS disease.
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Mammalian reoviruses are nonenveloped viruses with
a long, filamentous attachment protein that dictates dis-
ease phenotypes following infection of newborn mice
and is a structural homologue of the adenovirus attach-
ment protein. Reoviruses use junctional adhesion mole-
cule 1 (JAM1) as a serotype-independent cellular recep-
tor. JAM1 is a broadly expressed immunoglobulin
superfamily protein that forms stable homodimers and
regulates tight-junction permeability and lymphocyte
trafficking. We employed a series of structure-guided
binding and infection experiments to define residues in
human JAM1 (hJAM1) important for reovirus-receptor
interactions and to gain insight into mechanisms of reo-
virus attachment. Binding and infection experiments
using chimeric and domain deletion mutant receptor
molecules indicate that the amino-terminal D1 domain
of hJAM1 is required for reovirus attachment, infection,
and replication. Reovirus binding to hJAM1 occurs
more rapidly than homotypic hJAM1 association and is
competed by excess hJAM1 in vitro and on cells. Cross-
linking hJAM1 diminishes the capacity of reovirus to
bind hJAM1 in vitro and on cells and negates the com-
petitive effects of soluble hJAM1 on reovirus attach-
ment. Finally, mutagenesis studies demonstrate that
residues intimately associated with the hJAM1 dimer
interface are critical for reovirus interactions with
hJAM1. These results suggest that reovirus attachment
disrupts hJAM1 dimers and highlight similarities be-
tween the attachment strategies of reovirus and
adenovirus.
Mammalian reoviruses are prototype members of the Reo-
viridae family of viruses. They are nonenveloped viruses that
contain a genome of 10 double-stranded RNA segments (1).
Reoviruses have been isolated from many mammalian species,
including humans; however, severe disease is rare and usually
restricted to the very young (2). Neonatal mice are exquisitely
susceptible to reovirus infection and have been employed for
studies of viral pathogenesis with particular emphasis on cen-
tral nervous system tropism and corollary disease phenotypes.
Following oral inoculation of newborn mice, serotype 1 (T1)
reovirus strains spread hematogenously from the intestine to
the central nervous system and demonstrate tropism for
ependymal cells (3–5). In contrast, serotype 3 (T3) reoviruses
spread via neural routes to the central nervous system, where
they infect neurons (3–6). As a result of these differences in cell
tropism, T1 strains cause nonlethal hydrocephalus, whereas T3
strains cause lethal encephalitis. Reassortant genetics defined
the viral S1 gene segment as the primary genetic correlate of
these tropism and disease phenotypes (3–5).
The S1 gene segment encodes the reovirus attachment pro-
tein, 1 (7, 8). The trimeric 1 protein exhibits head-and-tail
morphology (9–13) and inserts into the virion capsid at the
icosahedral 5-fold symmetry axes. The adenovirus attachment
protein, fiber, exhibits similar morphology and virion insertion
(14). A major portion of the 1 tail, including residues impor-
tant for carbohydrate binding (15), folds into a triple -spiral
structural motif (13). This motif consists of repeating units of
short -strands that previously had only been seen in the
“shaft” domain of adenovirus fiber (16). Similarities also exist
between the “knob” domain of fiber and the 1 head, which
both form globular structures composed of unique eight-
stranded -barrels (13). Evidence gathered from biochemical
and genetic studies previously defined the 1 head as the viral
determinant of proteinaceous cellular receptor engagement
(3–5, 17). The strong association of the S1 gene segment with
serotype-dependent differences in reovirus tropism and disease
led to the hypothesis that reovirus serotypes usurp distinct cell
surface molecules for attachment and infection.
To better understand the contributions of cellular receptors
in reovirus pathogenesis, we used an expression-cloning ap-
proach to identify junctional adhesion molecule 1 (JAM1)1 as a
receptor for reovirus and demonstrated that reovirus directly
engages JAM1 in a bimolecular interaction via the head do-
main of 1 (17). JAM1 is a receptor for both T1 and T3 reovirus
strains in culture (17); however, the in vivo roles of JAM1 in
reovirus tropism and pathogenesis have not been defined.
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JAM1 is a type 1 transmembrane protein consisting of two
extracellular Ig-like domains, termed D1 and D2, a single
transmembrane segment, and a short cytoplasmic tail (18, 19).
JAM1 is expressed in a variety of tissues, including epithelial
and endothelial barriers (18–20), where it is thought to regu-
late tight junction permeability and mediate lymphocyte traf-
ficking (18–21). The crystal structures of murine and human
homologues of JAM1 (mJAM1 and hJAM1, respectively), both
of which are functional reovirus receptors (17), indicate that
JAM1 forms homodimers via extensive hydrophobic and ionic
contacts between apposing D1 domains (22, 23). Residues that
facilitate interdimer interactions are strictly conserved be-
tween mJAM1 and hJAM1 (22, 23). JAM1-JAM1 dimers are
highly stable and thought to be physiologically relevant, per-
haps functioning in tight junction barrier integrity or diapede-
sis of inflammatory cells (22–24).
The contacts that facilitate JAM1 dimerization are interest-
ing in that they occur via the GFCC face of the D1 Ig-like
domain (22, 23). The only other molecules demonstrated to
form homodimers using similar interdimer contacts are the
human coxsackievirus and adenovirus receptor (hCAR) and
CD2 (25–27). The structure of hCAR in complex with the ade-
novirus fiber knob revealed that fiber engages the D1 domain of
hCAR using residues involved in hCAR homodimer formation
and that knob mimics the hCAR-hCAR interaction (16, 25).
Biophysical evidence suggests that fiber-hCAR interactions are
thermodynamically favored over hCAR-hCAR interactions,
providing support for a model in which residues in the hCAR
dimer interface preferentially bind fiber over hCAR (28). The
structural similarities between the reovirus and adenovirus
attachment proteins and between their cognate receptors,
paired with the absolute conservation of residues in mJAM1
and hJAM1 that mediate homodimer formation, suggest that
reovirus engages the D1 domain of hJAM1 and that residues
involved in hJAM1 dimerization are important for reovirus
attachment (23). This hypothesis was formally tested in the
current study.
For these experiments, we generated chimeric receptor mol-
ecules consisting of reciprocal domain exchanges between
hCAR and hJAM1 and single domain hJAM1 deletion mutants
and tested the capacity of these constructs to support reovirus
binding and infection. We performed complementary in vitro
and cellular competition binding studies and hJAM1 dimer
cross-linking experiments to assess the effects on reovirus at-
tachment. Finally, we generated a series of hJAM1 point mu-
tants to define specific residues important for reovirus-hJAM1
interactions. The results of these structure-guided approaches
reveal that residues in the hJAM1 D1 domain within and
proximal to the dimer interface are critical for reovirus-hJAM1
interactions. These findings more clearly define the molecular
basis of reovirus binding to hJAM1 and highlight potential
mechanisms of reovirus attachment. Moreover, they provide
biological and biophysical evidence that reovirus and adenovi-
rus use remarkably similar attachment strategies.
EXPERIMENTAL PROCEDURES
Cells, Viruses, and Antibodies—Spinner adapted L929 (L) cells were
maintained in Joklik’s modified essential medium supplemented to
contain 5% fetal bovine serum, 2 mM L-glutamine, 100 units/ml peni-
cillin, 100 g/ml streptomycin, and 0.25 g/ml amphotericin B. HeLa
cells were maintained in Dulbecco’s modified Eagle’s medium, and
Chinese hamster ovary (CHO) cells were maintained in Ham’s F-12
medium, both supplemented to contain 10% fetal bovine serum, 2 mM
L-glutamine, 100 units/ml penicillin, and 100 g/ml streptomycin. Re-
ovirus strain type 1 Lang (T1L) is a laboratory stock. Strain T3SA is
a non-sialic acid-binding monoreassortant virus (29). Reoviruses were
purified from infected L cells as previously described (9). Particle con-
centrations were determined by spectrophotometry at 260 nm using a
conversion factor of 2.1  1012 particles/ml/A260. Particle/plaque-form-
ing unit ratios for T1L were 100:1. Particle/fluorescent focus unit ratios
for T1L were 10,000:1. Green fluorescent protein-encoding serotype 5
adenovirus (Ad 5-GFP) was provided by Dr. Jeffrey Bergelson (Univer-
sity of Pennsylvania). hJAM1-specific monoclonal antibody (mAb) J10.4
and rabbit polyclonal hJAM1 antiserum were provided by Dr. Charles
Parkos (Emory University).
Generation of Chimeric and Mutant Receptor Constructs—Nomencla-
ture of chimeric and deletion mutant constructs indicates exchanged or
deleted domains relative to wild-type hCAR or hJAM1 from amino to
carboxyl termini. Chimeric receptor CJJ (hCAR residues 1–141; hJAM1
residues 133–299) and deletion mutants JJ (hJAM1 residues 133–234
deleted) and JJ (hJAM1 residues 29–132 deleted) were generated
using PCR to insert a HindIII endonuclease restriction site at the 3 or
5 end of respective amino-terminal or carboxyl-terminal receptor frag-
ments. Chimera JCJ (hJAM1 residues 1–128, hCAR residues 138–227,
hJAM1 residues 235–299) and full-length D1 point mutant receptors
were generated by overlap extension PCR. All chimeric and mutant
receptor PCR products were digested with restriction endonucleases
and ligated into plasmid pcDNA3.1 (Invitrogen). The fidelity of clon-
ing was confirmed by automated sequencing. The PCR primers used to
generate chimeric and deletion mutant receptors are shown in Table I.
The PCR primers used for point mutant coding changes are shown in
Table II.
Transient Transfection and Infection of CHO Cells—CHO cells were
transiently transfected with empty vector or plasmids encoding wild-
type, chimeric, or deletion mutant receptors using LipofectAMINE and
PLUS reagent (Invitrogen) as previously described (23). Cells were
incubated for 24 h to allow receptor expression and then infected with
reovirus T1L at multiplicities of infection of 1 fluorescent focus unit/cell
and 1 plaque-forming unit/cell for fluorescent focus and plaque assays,
respectively. For fluorescent focus assays, infected cells were processed
for indirect immunofluorescence as previously described (29). Images
were captured at 20 magnification using a Leica DM IRB inverted
microscope. For plaque assays, viral titers in cell lysates were deter-
mined at 0 and 24 h after adsorption as previously described (30).
Flow Cytometric Analysis of Receptor Expression and Virus Bind-
ing—CHO cells were transiently transfected and incubated for 24 h to
allow receptor expression. Cells were detached from plates by incuba-
tion with 20 mM EDTA in PBS. Cells (1  106) were incubated with
hCAR- or hJAM1-specific antiserum at dilutions of 1:750 or 1:1000,
respectively, or incubated with reovirus T1L or T3SA (1  105 parti-
cles/cell) on ice for  60 min. Virus-adsorbed cells were washed with
PBS and incubated with clarified, combined T1L/T3D antiserum (31) at
1:1000 dilution on ice for 60 min. All samples were washed with PBS
and incubated with phycoerythrin-conjugated goat anti-rabbit IgG sec-
ondary antiserum (Molecular Probes, Inc.) at a 1:1000 dilution on ice for
30 min. Cells were washed twice with PBS and fixed with 2%
paraformaldehyde in PBS. Cells were analyzed using a FACScan flow
cytometer (Becton-Dickinson).
Expression and Purification of Soluble Receptor Constructs—Soluble
ectodomains of wild-type and point mutant hJAM1 constructs were
fused to an amino-terminal glutathione S-transferase affinity tag via a
thrombin cleavage site and purified as described (23). Nucleotide se-
quences corresponding to residues 27–233 of wild-type hJAM1 and
FIG. 1. Chimeric and deletion mutant receptor constructs for
studies of reovirus binding and growth. Ig superfamily proteins
hCAR (red) and hJAM1 (blue) were used to generate chimeric receptor
constructs in which Ig-like domains were reciprocally exchanged. Single
Ig-like domains of hJAM1 also were deleted. Nomenclature indicates
origin or deletion of domains D1, D2, and cytoplasmic tail (left to right)
relative to wild-type hCAR or hJAM1.
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hJAM1 point mutants were cloned by PCR, digested with restriction
endonucleases, and ligated into pGEX-4T-3 (Amersham Biosciences) for
bacterial transformation. Bacteria were cultured in Luria-Bertani
broth at 37 °C with shaking, and protein expression was induced with
0.1 mM isopropyl--D-thiogalactoside (Amersham Biosciences). Bacteria
were harvested by centrifugation and lysed by sonication in the pres-
ence of protease inhibitor mixture (Roche Molecular Biochemicals).
Glutathione S-transferase-hJAM1 constructs were purified from bacte-
rial lysates by glutathione affinity chromatography. Soluble wild-type
and point mutant hJAM1 ectodomains were liberated from the gluta-
thione resin by thrombin cleavage (20 units/ml) at room temperature
overnight.
In Vitro hJAM1 and Reovirus Binding Analysis—hJAM1 (500 g/ml)
and reovirus T1L (1.1  1013 particles/ml) in PBS were biotinylated by
incubation in 200 g/ml EZ-Link Sulfo-NHS-LC-biotin (Pierce) at room
temperature for 60 min. Unincorporated biotin was removed by exhaus-
tive dialysis against PBS. ELISA plates were coated with 20 nM solu-
tions of soluble hJAM1, cross-linked hJAM1, point mutant hJAM1, or
bovine serum albumin (2 g/ml) in pH 9.6 carbonate-bicarbonate buffer
(Sigma). Plates were blocked by incubation with 2% (w/v) bovine serum
albumin, 0.05% Triton X-100, PBS. For kinetic analyses, biotinylated
hJAM1 (20, 40, 80, or 160 nM) in blocking buffer was incubated with
hJAM1-coated plates for 0, 5, 15, 30, 60, 120, 180, 240, or 300 min, and
biotinylated reovirus (2.5  1010, 5.0  1010, 1.0  1011, or 2  1011
particles/ml or 0.042, 0.083. 0.16, or 0.33 nM, respectively) in blocking
buffer was incubated with hJAM1-coated plates for 0, 5, 15, 30, 60, 120,
180, and 240 min at 37 °C. As controls for specificity, binding of 80 nM
biotinylated hJAM1 in the presence of a 100-fold excess of unlabeled
hJAM1 at 180 min and binding of 0.33 nM reovirus (2  1011 particles/
ml) in the presence of 20 g/ml hJAM1-specific mAb J10.4 or hCAR-
specific mAb RmcB (32) were assessed. For competition and equilibrium
analyses, biotinylated reovirus (2  1011 particles/ml; 0.33 nM) in block-
ing buffer was incubated with hJAM1-, cross-linked hJAM1-, or point
mutant hJAM1-coated plates in the presence or absence of excess sol-
uble hJAM1 or cross-linked hJAM1 at 37 °C for 180 min. Binding in the
presence of 20 g/ml hJAM1-specific mAb J10.4 was tested as a control
for specificity. All plates were washed twice with 0.05% Triton X-100/
PBS and once with PBS and incubated with 2 g/ml horseradish per-
oxidase (HRP)-conjugated streptavidin (Amersham Biosciences) in
blocking buffer at room temperature for 30 min. Plate-bound biotiny-
lated hJAM1 or reovirus was detected following incubation with HRP
substrate (ABTS (2,2-azino-bis(3-ethylbenz-thiazoline-6-sulfonic acid),
Sigma) and analysis by spectrophotometry at 405 nm. For all conditions
tested, no binding to bovine serum albumin-coated plates was detected.
Virus Radioligand Binding Assays—Radioligand binding assays
were performed as previously described (29). Reovirus T1L was meta-
bolically labeled with Easy Tag TM EXPRE35S35S (PerkinElmer Life
Sciences) and purified as described (9). HeLa cells were detached from
plates by incubation with 20 mM EDTA, resuspended in Dulbecco’s PBS
(Invitrogen) supplemented with metabolic inhibitors (10 mM NaN3, 5
mM 2-deoxyglucose, and 2 mM NaF), and incubated at 37 °C for 30 min
to deplete cellular ATP and block receptor-mediated endocytosis (29,
33). Cells (1  106) were incubated with 35S-labeled reovirus T1L (1 
105 particles/cell) for 180 min in the presence or absence of excess
soluble hJAM1. Cells were collected by vacuum filtration, and virus
binding was assessed by liquid scintillation.
Cross-linking Analysis—Soluble hJAM1 (500 g/ml) was incubated
with a 50-fold molar excess of the water-soluble cross-linking reagent
bis(sulfosuccinimidyl) suberate (BS3) in PBS at room temperature for
60 min. Unreacted BS3 was quenched by the addition of 20 mM Tris-HCl
(pH 7.5). HeLa cells (1  107) were incubated with PBS or 2 mM BS3 at
4 °C for 120 min, followed by washing with PBS to remove excess BS3.
The efficiency of cross-linking was assessed following lysis of cells in 1%
Triton X-100/PBS on ice for 30 min. Lysates were clarified by centrif-
ugation, and hJAM1 was immunoprecipitated using 10 g/ml hJAM1-
specific mAb J10.4. Immunoprecipitates and soluble hJAM1 were re-
solved by SDS-PAGE. Resolved proteins were transferred to
nitrocellulose and immunoblotted with hJAM1-specific antiserum (1:
1000). Proteins were detected by ECL. Soluble hJAM1 was tested for
the capacity to bind reovirus and compete virus binding in vitro, and
HeLa cells were tested for the capacity to bind virus in a radioligand
binding assay.
RESULTS
Identification of hJAM1 Domains Required for Reovirus At-
tachment—We previously have shown that JAM1 is a serotype-
independent reovirus receptor (17). However, specific se-
quences in JAM1 required for reovirus attachment are not
known. To identify domains in JAM1 required for reovirus
binding and infection, we generated receptor chimeras using
hJAM1 and Ig superfamily relative hCAR (Fig. 1 and Table I).
hCAR is incapable of supporting reovirus binding and infection
(17) and was selected as the chimera partner for these studies
due to its structural similarities to JAM1 (23). A PCR-based
approach was used to reciprocally exchange sequences encod-
ing either the D1 or D2 Ig-like domains of wild-type receptor
TABLE I
PCR primers for chimeric and deletion mutant receptors
T7 and BGH primers were used as 5 forward and 3 reverse primers for all constructs. Underlined nucleotides denote HindIII restriction
endonuclease site.
1 These primers were used to generate the upstream (5) J-C junction in chimera JCJ using JCJ2 PCR product as template.
2 These primers were used to generate the downstream (3) C-J junction in chimera JCJ.
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cDNAs. We also generated single-domain deletion mutants of
hJAM1 to complement data obtained using the chimeric recep-
tor molecules. CHO cells, which lack expression of both JAM1
and CAR (see Refs. 19 and 32 and Fig. 2), were transiently
transfected with plasmids encoding wild-type hJAM1 and
hCAR, chimeric receptor molecules CJJ and JCJ, and hJAM1
deletion mutants JJ and JJ. Cell surface expression of each
construct and the capacity of reovirus to bind transfected cells
were assessed by flow cytometry (Fig. 2). All constructs were
detected at the cell surface. Chimera-transfected cells stained
with both hJAM1- and hCAR-specific antisera, indicating that
the molecules are indeed chimeric (Fig. 2). Prototype reovirus
strain T1L bound cells expressing wild-type hJAM1, chimera
JCJ, and deletion mutant JJ but failed to bind cells express-
ing hCAR, chimera CJJ, or deletion mutant JJ (Fig. 2). T3
reovirus strain T3SA also bound cells expressing constructs
that contained the D1 domain of hJAM1 (data not shown).
These data demonstrate that both T1 and T3 reoviruses engage
the membrane-distal D1 domain of hJAM1.
Reovirus Infection and Growth in CHO Cells Expressing
Chimeric and Deletion Mutant Receptors—To determine the
role of specific JAM1 domains in reovirus infection, CHO cells
were transiently transfected with plasmids encoding the
hCAR-hJAM1 chimeras or hJAM1 domain-deletion mutants.
Transfected cells were adsorbed with T1L, and the capacity of
reovirus to infect these cells was assessed by indirect immuno-
fluorescence. Consistent with the binding experiments, reovi-
rus protein expression was detected after infection of cells
expressing wild-type hJAM1, chimera JCJ, and deletion mu-
tant JJ (Fig. 3A). As a control, adenovirus infection also was
tested by adsorbing transfected cells with Ad 5-GFP. Cells
expressing hCAR and CJJ supported infection by adenovirus
(data not shown), demonstrating that these molecules also can
serve as functional virus receptors. To provide further support
for the role of hJAM1 D1 in reovirus infection, viral replication
was assessed 24 h after adsorption by plaque assay. T1L pro-
duced substantially higher yields in cells expressing hJAM1,
JCJ, and JJ compared with cells expressing receptors that
lack the hJAM1 D1 domain (Fig. 3B). Together, these data
indicate that the D1 domain of hJAM1 is required for reovirus
attachment, infection, and growth.
Competitive Reovirus-hJAM1 Binding Analysis—To assess
the capacity of reovirus and hJAM1 to compete for engagement
of hJAM1, a series of complementary in vitro and cell binding
studies were performed. Due to the apparent high affinity and
slow dissociation rate of hJAM1 dimers (23),2 we first estab-
lished an experimental system in which equilibrium could be
achieved over an extended time course to provide evidence that
hJAM1-hJAM1 interactions are saturable and specific and,
therefore, support the use of soluble hJAM1 as a competitor for
virus binding studies. For these experiments, ELISA plates
were coated with 20 nM solutions of soluble hJAM1 ectodomain.
This concentration facilitated maximal hJAM1 immobilization
(data not shown). Increasing concentrations of biotinylated
hJAM1 were then tested for the capacity to bind immobilized
hJAM1 in a kinetic binding assay (Fig. 4A). Homophilic hJAM1
interactions occurred in a concentration- and time-dependent
manner, approaching equilibrium following incubation for in-
tervals greater than 240 min at 80 and 160 nM concentrations.
Furthermore, hJAM1-hJAM1 interactions are specific, since
incubation in the presence of 100-fold excess concentrations of
unlabeled hJAM1 resulted in no detectable binding following
incubation for 180 min (data not shown).
To gather further evidence for the validity of in vitro binding
assays for studies of reovirus-hJAM1 interactions, we per-
formed kinetic virus-binding analyses. Binding of biotinylated
reovirus T1L to immobilized hJAM1 was assessed over time
(Fig. 4B). Reovirus exhibited concentration- and time-depend-
ent binding to hJAM1-coated plates, achieving equilibrium
more rapidly than hJAM1 (180 min) and at lower concentra-
tions (particle concentrations of 1.0  1011/ml (6.2 nM 1) and
2.0  1011/ml (12 nM 1)). Reovirus binding to immobilized
hJAM1 was abolished in the presence of 20 g/ml hJAM1-
specific mAb J10.4 but not affected by 20 g/ml hCAR-specific
mAb RmcB at the highest virus concentration tested, indicat-
ing the specificity of the reovirus-hJAM1 interaction (data not
shown). Together, these results demonstrate that hJAM1 and
reovirus specifically engage immobilized hJAM1 and provide
confidence that this in vitro binding assay is a valid method for
assessing whether hJAM1 and reovirus compete for overlap-
ping binding sites.
We next used the in vitro binding assay to test the capacity
of soluble hJAM1 to compete for reovirus binding to immobi-
lized hJAM1 (Fig. 4C). Biotinylated reovirus T1L particles (2
1011/ml) were mixed with fold molar excess concentrations of
soluble hJAM1, calculated to account for 36 copies of 1 per
virion particle, and tested for the capacity to bind immobilized
hJAM1. Reovirus binding was inhibited in a dose-dependent
fashion, with a 50% inhibitory concentration (IC50) between 20-
2 J. C. Forrest and T. S. Dermody, unpublished results.
FIG. 2. Reovirus engages the D1 domain of hJAM1. CHO cells
were transiently transfected with plasmids encoding the indicated re-
ceptor constructs. Following incubation for 24 h to permit receptor
expression, cells (1  106) were stained with hCAR- or hJAM1-specific
antisera or adsorbed with reovirus T1L (1 1011 particles). Cell surface
expression of receptor constructs and virus binding were assessed by
flow cytometry.
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and 50-fold molar excess soluble hJAM1. At 100-fold molar
excess hJAM1, virus binding was reduced to near background
levels, which were determined by assessing virus binding in the
presence of hJAM1-specific mAb J10.4.
To provide a more complete assessment of reovirus-hJAM1
interactions, we tested the capacity of soluble hJAM1 to com-
pete for reovirus binding to HeLa cells (Fig. 4D). HeLa cells
were incubated with radiolabeled T1L virions in the presence of
increasing fold molar excess of soluble hJAM1. Similar to re-
sults obtained using the in vitro binding assay, reovirus bind-
ing to HeLa cells was inhibited by soluble hJAM1 in a dose-de-
pendent fashion, with an IC50 between 20- and 50-fold molar
excess hJAM1 and nearly complete inhibition by 100-fold molar
excess. These data provide additional support for the primary
role of hJAM1 in reovirus attachment to cells. Moreover, the
large excess of hJAM1 required for competition suggests a
higher affinity for reovirus-hJAM1 interactions than those of
hJAM1-hJAM1 (35).
Effect of Cross-linking on Reovirus Binding to hJAM1—To
more directly assess the importance of residues involved in
hJAM1 dimerization for reovirus attachment, we tested the
effect of hJAM1 cross-linking on reovirus binding. Soluble
hJAM1 was cross-linked by incubation with the water-soluble
cross-linking agent BS3. This treatment resulted in the forma-
tion of higher order oligomers whose Mr values correspond to
hJAM1 dimers (Fig. 5A). Similar results were observed previ-
ously for cross-linked mJAM1 (24), suggesting that cross-link-
ing hJAM1 and mJAM1 covalently join the dimeric structures
FIG. 3. The D1 domain of hJAM1 is required for reovirus infection and replication. CHO cells were transiently transfected with
plasmids encoding the indicated receptor constructs and incubated for 24 h to permit receptor expression. A, transfected cells (4  105) were
infected with reovirus T1L at a multiplicity of infection of 1 fluorescent focus unit/cell and incubated at 37 °C for 20 h. Cells were fixed and stained
for reovirus protein, and infected cells were identified by indirect immunofluorescence. Representative images are shown. B, transfected cells (2 
105) were adsorbed with reovirus T1L at a multiplicity of infection of 1 plaque-forming unit (PFU)/cell. Reovirus growth was assessed by plaque
assay at 0 and 24 h postadsorption. Shown are mean viral titers for three independent experiments. The error bars indicate S.D.
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elucidated for both molecules. To assess the effects of cross-
linking on reovirus attachment, ELISA plates were coated with
20 nM solutions of either untreated or BS3-treated hJAM1 and
tested for the capacity to bind biotinylated T1L virions (Fig.
5B). Cross-linking resulted in a reduction of reovirus binding to
immobilized hJAM1 to near background levels, suggesting that
reovirus binds a monomeric form of hJAM1 via residues in the
dimer interface. To corroborate these results, we tested the
capacity of 100-fold excess BS3-treated hJAM1 to compete for
reovirus binding to untreated hJAM1 (Fig. 5B). In sharp con-
trast to untreated hJAM1 at 100-fold molar excess, 100-fold
molar excess cross-linked hJAM1 was an inefficient competitor
of reovirus binding. These data strongly suggest that the
hJAM1 dimer interface is involved in reovirus attachment.
To define the effect of hJAM1 cross-linking on reovirus bind-
ing to cells, HeLa cell surface proteins were cross-linked by
incubation with BS3. Cross-linked hJAM1 was captured by
immunoprecipitation using hJAM1-specific mAb J10.4 and de-
tected by immunoblotting using hJAM1-specific antiserum
(Fig. 5C). BS3 treatment of cells resulted in the formation of a
very large Mr species (97 kDa). Following BS
3 treatment, the
binding capacity of radiolabeled T1L was diminished, with
cross-linking resulting in50% reduction in virus binding (Fig.
5D). Virus binding in the presence of 20 g/ml hJAM1-specific
mAb J10.4 was completely abolished in vitro (Fig. 5B) and on
cells (Fig. 5D), indicating that residual binding following BS3 is
dependent on hJAM1. Therefore, the consistent reduction in
reovirus binding due to cross-linking and the failure of BS3-
treated hJAM1 to compete for viral attachment to untreated
hJAM1 suggest that reovirus engages hJAM1 using residues
within the hJAM1 dimer interface. However, it is also possible
that cross-linking alters the conformation of hJAM1 in such a
manner to prevent efficient reovirus binding or the cross-link-
ing agent covers a region in the hJAM1 dimer that otherwise
would be engaged by reovirus. The apparent inefficiency of
cross-linking relative to the effects on virus binding may reflect
a loss of antibody-binding epitopes due to BS3 treatment, with
resultant diminished band intensity by immunoblotting rela-
tive to the untreated species.
Mutational Analysis of Reovirus Binding to hJAM1—To pre-
cisely define the region of hJAM1 bound by 1 and to identify
residues critical for reovirus attachment, we used a PCR-based
approach to generate mutant forms of hJAM1 containing single
amino acid substitutions. Guided by the hJAM1 crystal struc-
FIG. 4. Soluble hJAM1 competes for reovirus binding to hJAM1. A, kinetic analysis of hJAM1-hJAM1 interactions. ELISA plates were
coated with 20 nM solutions of soluble hJAM1. Increasing concentrations of biotinylated soluble hJAM1 were incubated with immobilized hJAM1
at 37 °C for the indicated times. Binding was detected by spectrophotometry at 405 nm following incubation with streptavidin-HRP. Results are
the means of quadruplicate experiments. The error bars indicate S.D. B, kinetic analysis of reovirus-hJAM1 interactions. Increasing concentrations
of biotinylated reovirus T1L particles were incubated with immobilized hJAM1 at 37 °C for the indicated times. Binding was detected following
incubation with streptavidin-HRP. Results are the means of quadruplicate experiments. The error bars indicate S.D. C, competition by hJAM1 for
reovirus binding in vitro. The binding of biotinylated T1L reovirus (2  1011 particles/ml) to immobilized hJAM1 was assessed in the presence of
the indicated fold molar excess of hJAM1. After incubation at 37 °C for 180 min, binding was detected following incubation with streptavidin-HRP.
The dashed line indicates background binding in the presence of 20 g/ml hJAM1-specific mAb J10.4. Results are the means of quadruplicate
experiments. The error bars indicate S.D. D, competition by hJAM1 for reovirus binding to cells. HeLa cells (1  106) were incubated with
35S-labeled reovirus T1L particles (1  1011) at 37 °C for 180 min in the presence of the indicated fold molar excess of hJAM1. Virus binding was
detected by liquid scintillation. The dashed line indicates background binding in the presence of 20 g/ml hJAM1-specific mAb J10.4. Results are
the means of duplicate experiments. The error bars indicate the range of data.
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ture (23), mutations were targeted to solvent-exposed residues
in regions of the molecule that are highly conserved between
hJAM1 and mJAM1 (Fig. 6 and Table II). Soluble ectodomains
of hJAM1 mutants were liberated from glutathione S-transfer-
ase-hJAM1 fusion proteins via treatment with thrombin, and
20 nM solutions of the cleavage products were immobilized onto
ELISA plates. Biotinylated T1L virions (2.0  1011 particles/
ml) were then tested for the capacity to bind the immobilized
hJAM1 mutants (Fig. 7). Virus-binding data were normalized
for hJAM1 immobilization efficiency, and binding was not de-
tected for any constructs in the presence of 20 g/ml hJAM1-
specific mAb J10.4 (data not shown). Most of the mutations
resulted in only minor or modest reductions in virus binding.
However, substitution of Ser57 with lysine or Tyr75 with ala-
nine substantially reduced the efficiency of reovirus binding.
Ser57 is a solvent-accessible residue at the apex of hJAM1
adjacent to the dimer interface, and Tyr75 is a core residue at
the top of the dimer interface (Fig. 6). Neither of these muta-
tions alters the dimeric nature of the molecule in solution (data
not shown), indicating that the observed effects of these muta-
tions on reovirus binding are not attributable to alterations in
the capacity of the mutant proteins to form dimers. Thus, these
findings suggest that Ser57 and Tyr75 play critical roles in
reovirus attachment and highlight the importance of a region
at the top of the homodimer interface in reovirus binding to
hJAM1.
DISCUSSION
Experiments reported here were performed to define the
molecular basis of reovirus attachment to hJAM1. The capacity
of reovirus to bind, infect, and replicate to high titers in cells
expressing chimeric hCAR-hJAM1 receptor constructs and sin-
gle domain deletion mutants demonstrates that the membrane-
distal D1 domain of hJAM1 is an essential component of the
reovirus receptor function of hJAM1 (Figs. 2 and 3). Several
viruses have been demonstrated to engage cellular receptors
via the most distal domain of an Ig superfamily receptor, in-
cluding adenovirus (hCAR) (16, 36), coxsackievirus (hCAR)
(37), human immunodeficiency virus (CD4) (38), measles virus
(SLAM) (39), poliovirus (PVR) (40), and rhinovirus (ICAM-1)
(41). Thus, utilization of the membrane-distal D1 domain of
hJAM1 by reovirus provides additional evidence for a common
theme in viral attachment.
Of the virus receptors whose structures have been solved,
only adenovirus receptor hCAR and reovirus receptor JAM1
have been demonstrated to form homodimers by contacts be-
tween the GFCC -strands of apposing D1 domains (22, 23,
25). Moreover, there are numerous similarities in the attach-
FIG. 5. Cross-linking hJAM1 inhibits reovirus binding. A, soluble hJAM1 (500 g/ml) was cross-linked by incubation with 50-fold molar
excess BS3 at room temperature for 1 h. Untreated hJAM1 (PBS) and BS3-treated hJAM1 were resolved by SDS-PAGE and detected by
immunoblotting using hJAM1-specific antiserum. Monomeric hJAM1 is indicated by an arrow. A larger Mr hJAM1 species is indicated by an
asterisk. B, ELISA plates were coated with 20 nM solutions of untreated or BS3-treated hJAM1. The capacity of biotinylated reovirus T1L (2 1011
particles/ml) to bind hJAM1 and BS3-treated hJAM1 was assessed in the presence or absence of the competitors shown. Samples were incubated
at 37 °C for 180 min, and binding was detected by spectrophotometry at 405 nM following incubation with streptavidin-HRP. Results are the means
of quadruplicate experiments. The error bars indicate S.D. C, HeLa cells were treated with PBS or 2 mM BS3 on ice for 2 h. Cells were lysed using
1% Triton X-100/PBS, and hJAM1 was immunoprecipitated using hJAM1-specific mAb J10.4. Immunoprecipitates were resolved by SDS-PAGE
and immunoblotted using hJAM1-specific antiserum. Monomeric hJAM1 is indicated by an arrow. A larger Mr hJAM1 species is indicated by an
asterisk. D, untreated or BS3-treated HeLa cells (1  106) were incubated with 35S-labeled reovirus T1L virions (1  1011) at 37 °C for 180 min in
the presence or absence of 20 g/ml hJAM1-specific mAb J10.4. Virus binding was detected by liquid scintillation. Results are the means of
duplicate experiments. The error bars indicate the range of data.
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ment proteins of adenovirus and reovirus: 1) both form trimers;
2) both insert into pentamers of capsid proteins at the virion
5-fold symmetry axes; 3) both have fibrous domains formed by
unique triple -spiral structural motifs; and 4) both have glob-
ular, virion-distal domains formed by -barrel structures with
unique and identical -strand connectivity. These similarities
suggest functionally convergent evolution of two large, nonen-
veloped viruses (14). Additionally, the observation that hJAM1
and hCAR share numerous structural and functional similari-
ties leads to the hypothesis that adenovirus and reovirus en-
gage their receptors using similar mechanisms.
Structural and biophysical evidence indicates that adenovi-
rus engages the D1 domain of hCAR using sequences involved
in hCAR homodimerization. Specifically, adenovirus fiber knob
engages the GFCC face of hCAR (16) in a manner thermody-
namically favored over hCAR-hCAR interactions (28). To test
the hypothesis that reovirus engages hJAM1 using residues
involved in hJAM1 homodimerization, we developed an in vitro
binding assay and tested the capacity of hJAM1 to compete for
reovirus binding to hJAM1. We first established that hJAM1-
hJAM1 and reovirus-hJAM1 interactions are saturable and
specific (Fig. 4, A and B). Interestingly, reovirus achieved equi-
librium more rapidly in these experiments and at molarities
much lower than those of hJAM1 (equilibrium in 180 min at
0.16 nM for reovirus versus 300 min at 80 nM for hJAM1).
Limitations of the experimental system do not permit accurate
calculations of equilibrium binding constants. Nonetheless, it
is likely that reovirus-hJAM1 interactions are thermodynami-
cally favored over hJAM1-hJAM1 interactions.
The calculated KD of mJAM1 for mJAM1 (15 nM) (24)
approximates that of the purified T3D 1 head domain for
hJAM1 (60 nM) (17). However, the multivalent nature of 1
FIG. 6. Orientation of mutagenized hJAM1 residues. The structure of the hJAM1 dimer is shown in three orientations: back (A), dimer
interface or front (B), and top (C). In each image, one monomer is depicted as a space-filling model and the other as an -carbon tracing. Conserved
residues selected for mutagenesis are shown in red. Other conserved residues in hJAM1 and mJAM1 are shown in orange. Mutations are
summarized in Table II. This figure was prepared with GRASP (47).
TABLE II
PCR primers for point mutant hJAM1 constructs
T7 and BGH primers were used as 5 forward and 3 reverse primers for all constructs.
Point mutation
Primer
Forward Reverse
S49A 5-GTGAAGTTGGCATGTGCCTAC-3 5-GTAGGCACATGCCAACTTCAC-3
A51K 5-TTGTCCTGTAAATACTCGGGC-3 5-GCCCGAGTATTTACAGGACAA-3
S53A 5-TGTGCCTACGCCGGCTTTTCT-3 5-AGAAAAGCCGGCGTAGGCACA-3
S56K 5-TCGGGCTTTAAATCTCCCCGT-3 5-ACGGGGAGATTTAAAGCCCGA-3
S57K 5-GGCTTTTCTAAACCCCGTGTG-3 5-CACACGGGGTTTAGAAAAGCC-3
Y75A 5-CTCGTTTGCGCCAATAACAAG-3 5-CTTGTTATTGGCGCAAACGAG-3
T80A 5-AACAAGATCGCCGCTTCCTAT-3 5-ATAGGAAGCGGCGATCTTGTT-3
Y83A 5-ACAGCTTCCGCCGAGGACCGG-3 5-CCGGTCCTCGGCGGAAGCTGT-3
T88A 5-GACCGGGTGGCATTCTTGCCA-3 5-TGGCAAGAATGCCACCCGGTC-3
T92A 5-TTCTTGCCAGCGGGTATCACC-3 5-GGTGATACCCGCTGGCAAGAA-3
S98A 5-ACCTTCAAGGCAGTGACACGG-3 5-CCGTGTCACTGCCTTGAAGGT-3
E113K 5-ATGGTCTCTAAAGAAGGCGGC-3 5-GCCGCCTTCTTTAGAGACCAT-3
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on reovirus particles probably mediates cooperative binding
effects that enhance the on rate and stability of reovirus bind-
ing to hJAM1. Additionally, soluble hJAM1 competes for reo-
virus binding to hJAM1 in vitro and on cells with comparable
IC50 values between 20- and 50-fold molar excess hJAM1 rel-
ative to particle-associated 1 and nearly complete inhibition
at 100-fold excess concentrations (Fig. 4, C and D). The rela-
tively high concentration of hJAM1 necessary to detect soluble
hJAM1 binding to immobilized hJAM1 precludes the converse
competition experiment using reovirus as competitor (100-fold
molar excess  1.3  1014 particles/ml or 4.8  1015 copies of
1/ml). Nonetheless, these data further establish the specificity
of reovirus binding to hJAM1 and suggest that reovirus and
hJAM1 utilize identical or overlapping sites for attachment
and dimerization, respectively. Moreover, the high concentra-
tion of hJAM1 necessary to compete reovirus binding provides
additional support for virus-hJAM1 associations being thermo-
dynamically favored over homotypic hJAM1 interactions.
To further assess the role of the hJAM1 dimer interface in
reovirus binding, we tested the effect of chemically cross-link-
ing hJAM1 on reovirus binding to hJAM1 in vitro and on cells.
We found that cross-linking substantially reduced the effi-
ciency of reovirus binding (Fig. 5). Furthermore, cross-linked
hJAM1 exhibited only minimal competition for reovirus bind-
ing to hJAM1 (Fig. 5B). The most likely interpretation of these
data is that access to the hJAM1 dimer interface is required for
efficient reovirus binding, although it is also possible that
cross-linking induces structural changes in hJAM1 that inhibit
viral attachment or that the bound cross-linking reagent pre-
vents access to the hJAM1 dimer. In these experiments, cross-
linking HeLa cell surface proteins induced the formation of a
very large Mr band recognized by antiserum specific for hJAM1
following immunoprecipitation with an hJAM1-specific mAb
(Fig. 5C). It is possible that formation of a large Mr hJAM1-
containing species following cross-linking indicates the tight
association of hJAM1 with additional cellular proteins that
facilitate reovirus entry following attachment to hJAM1 in a
manner analogous to the attachment and entry strategy of
adenovirus (42). The presence of such proteins also might offer
an explanation for the inefficient viral growth in CHO cells
observed in the absence of hJAM1 D1 expression (Fig. 3B).
We previously demonstrated that both hJAM1 and mJAM1
function as reovirus receptors (17). Since this observation, two
additional human and murine JAM proteins (JAM2 and JAM3)
have been identified. However, only JAM1 is capable of sup-
porting reovirus infection (23). Comparative sequence and
structural analysis identified regions of conserved residues in
hJAM1 and mJAM1, but not hJAM2 or hJAM3, which sug-
gested roles for these conserved regions in reovirus attachment
(23). To define residues critical for reovirus binding, mutations
were introduced in several solvent-accessible residues covering
most of the hJAM1 D1 surface (Fig. 6), and these mutant
constructs were tested for the capacity to bind reovirus in vitro.
Using this approach, we found that residues Ser57 and Tyr75
are important for efficient reovirus binding (Fig. 7). Interest-
ingly, these residues localize to a region at the very top of the
hJAM1 dimer interface (Figs. 6 and 8). Mutagenesis of Glu113,
another residue localized to the top of the dimer interface (Figs.
6 and 8), also diminished reovirus binding, but to a lesser
extent than mutations at Ser57 or Tyr75 (Fig. 7). In contrast,
mutation of the other residues chosen for study had little effect
on binding, suggesting that the surface opposite to the dimer
interface (the exposed “back” of hJAM1) does not participate in
interactions with reovirus.
Of the hJAM1 residues important for reovirus attachment,
Ser57 presents the most accessible potential contact point, and
as such, the exposed serine hydroxyl group may provide a
hydrogen bond donor for 1 binding. It is also possible that the
S57K mutation introduces a structural change at the top of
hJAM1. A lysine side chain could potentially interact with
nearby acidic residues Glu113 and Glu114, thereby distorting
the reovirus-binding surface. However, this possibility is un-
likely, given that mutagenesis of Ser56 to lysine does not elicit
a similar inhibitory effect on reovirus binding. We note that
several mutations in a region adjacent to or in the dimer
interface (S49A, A51K, S56K, Y83A, and T92A) modestly in-
hibit binding (Fig. 7). Most of these mutations (Ser49, Ala51,
and Ser56) are in close proximity to and form part of the
FIG. 7. Ser57 and Tyr75 facilitate efficient reovirus attachment to hJAM1. ELISA plates were coated with 20 nM solutions of wild-type or
point mutant forms of soluble hJAM1. Binding of biotinylated reovirus T1L (2  1011 particles/ml) to immobilized hJAM1 constructs was assessed
after incubation at 37 °C for 180 min. Virus binding was detected following incubation with streptavidin-HRP. The dashed line indicates reovirus
binding to wild-type hJAM1. Results are the means of quadruplicate experiments. The error bars indicate S.D. Data are normalized for
immobilization efficiency.
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contiguous -strand leading to Ser57. It is conceivable that
mutagenesis of some of these residues slightly alters the ori-
entation of the Ser57 side chain in a manner that diminishes
the efficiency of reovirus attachment. Residue Tyr75 is buried
in the dimer interface. The drastic effect of Y75A on reovirus
attachment suggests that disruption of hJAM1 homodimers is
required for efficient reovirus binding and, furthermore, that
reovirus interacts with residues at the hJAM1 dimer interface.
An alternative explanation, given the location of Tyr75 at the
hJAM1-hJAM1 interface, might be that the Y75A mutation
adversely affects the dimeric structure, thereby preventing
reovirus binding to dimeric hJAM1. However, mutant Y75A
maintains its dimeric nature in solution (data not shown),
making this explanation less likely. Moreover, our competitive
binding and cross-linking experiments (Figs. 4 and 5, respec-
tively) strengthen the argument against this second possibility.
Our experiments preclude an exact determination of the
mechanism by which Y75A diminishes reovirus binding. Mu-
tagenesis of Tyr75 may alter the dissociation capacity of hJAM1
dimers or remove a potential reovirus contact point. We also
consider it possible that reovirus engages hJAM1 using a two-
step mechanism that facilitates dimer dissolution and efficient
reovirus binding. If so, initial contact with Ser57 may induce a
conformational change in reovirus particles, hJAM1, or both
molecules to promote the formation of a higher affinity binding
state, perhaps by exposing Tyr75. We note that, in the hJAM1
dimer structure, Ser57 is very close to Tyr75 of the apposed
hJAM1 monomer (Y75 in Fig. 8); thus, interaction with Ser57
could easily trigger rearrangements at the JAM1-JAM1 inter-
face. Several lines of evidence lend support to this hypothesis.
First, the localization of closely apposed aspartic acid residues
in the interior of the 1 head trimer interface suggests that 1
is a metastable protein primed for structural rearrangements
(13). Second, although homotypic hJAM1 association cannot be
detected in real time by surface plasmon resonance (data not
shown), in similar experiments reovirus engages hJAM1 with
rapid and saturable kinetics to form a highly stable complex
(17). Third, reovirus binding to cell surfaces or cell membrane
preparations alters the sensitivity of the virus to proteolysis in
a 1-dependent fashion (43), suggesting a role for 1 in parti-
cle-associated structural changes. Ongoing biophysical and
structural approaches will facilitate a further understanding of
the mechanism of reovirus-hJAM1 interactions.
Studies reported in this manuscript provide evidence for
possible mechanisms of reovirus binding to hJAM1. They also
highlight common mechanisms of attachment for reovirus and
adenovirus in which structurally analogous attachment pro-
teins disrupt dimers of structurally analogous receptors to en-
gage and infect target cells. Intriguingly, hJAM1 and hCAR, as
well as several other viral receptors, localize to epithelial bar-
riers (44), suggesting that aspects of these physiologic locations
provide permissive sites for viral infection. Both hJAM1 and
hCAR have been reported to regulate tight junction barrier
function (18–20, 45), and adenovirus may usurp this property
to facilitate release and spread of progeny virions into the
environment (46). Whether reovirus disregulates hJAM1 in a
similar manner is not known. It is also possible that hJAM1
and hCAR were simply selected as abundant and convenient
attachment moieties that are readily accessible by natural
routes of inoculation, which raises the question of why these
particular molecules were chosen. An interesting explanation
would be that particular receptors associate with additional
cellular molecules that contribute to viral replication by facil-
itating cell entry or activating intracellular signaling to induce
a virus-permissive state. Differential requirements for entry or
replication may offer an explanation for why reoviruses and
adenoviruses have selected distinct molecules for amazingly
similar mechanisms of attachment.
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Reovirus attachment to cells is mediated by the binding of viral
attachment protein 1 to junctional adhesion molecule 1 (JAM1).
The crystal structure of the extracellular region of human JAM1
(hJAM1) reveals two concatenated Ig-type domains with a pro-
nounced bend at the domain interface. Two hJAM1 molecules form
a dimer that is stabilized by extensive ionic and hydrophobic
contacts between the N-terminal domains. This dimeric arrange-
ment is similar to that observed previously in the murine homolog
of JAM1, indicating physiologic relevance. However, differences in
the dimeric structures of hJAM1 and murine JAM1 suggest that the
interface is dynamic, perhaps as a result of its ionic nature. We
demonstrate that hJAM1, but not the related proteins hJAM2 and
hJAM3, serves as a reovirus receptor, which provides insight into
sites in hJAM1 that likely interact with 1. In addition, we present
evidence that the previously reported structural homology be-
tween 1 and the adenovirus attachment protein, fiber, also
extends to their respective receptors, which form similar dimeric
structures. Because both receptors are located at regions of cell–
cell contact, this similarity suggests that reovirus and adenovirus
use conserved mechanisms of entry and pathways of infection.
A ttachment to specific host molecules is the initial step inviral infection and plays a key role in target-cell selection in
the infected host. In the case of mammalian reoviruses, this is
accomplished by interactions between the viral attachment
protein, 1, and junctional adhesion molecule 1 (JAM1) (1).
Reoviruses are nonenveloped, icosahedral viruses that infect
most mammalian species, including humans. The capacity of
reovirus strains to engage distinct types of receptors in the host
strongly influences tissue tropism and disease after reovirus
infection (2). JAM1 is a member of the Ig superfamily with two
extracellular Ig-like domains, a single transmembrane region,
and a short cytosolic tail. The crystal structure of the extracel-
lular region of murine JAM1 (mJAM1) revealed a dimer
stabilized by interactions involving the membrane-distal Ig-like
domain (3). The protein is expressed in a variety of tissues and
cell types, including circulating platelets and lymphocytes, and it
has been postulated to function as a regulator of endothelial and
epithelial tight junction formation (4–6). The human homolog of
JAM1 (hJAM1) serves as a ligand for the integrin L2 (LFA-1)
(7), an interaction that likely plays an important role in host
inflammatory responses by mediating transmigration of leuko-
cytes. Two hJAM1 homologs, hJAM2 and hJAM3, have been
recently identified (8–13). Additional evidence that JAM family
members are involved in the inflammatory response is provided
by the observations that hJAM2 interacts with 41 integrins
(14), and hJAM3 interacts with M2 (MAC-1) integrins (15).
Reovirus attachment protein 1 is a long, fibrous molecule
with head-and-tail morphology and several defined regions of
flexibility within its tail (16, 17). The 1 tail inserts into the 12
vertices of the icosahedral virion, whereas the JAM-binding 1
head extends away from the particle surface (18, 19). Labora-
tory-adapted and field-isolate strains of all three reovirus sero-
types bind JAM1 (ref. 1; J.A.C. and T.S.D., unpublished obser-
vations). Some reoviruses also use additional carbohydrate-
based coreceptors for cell attachment (20, 21). For type 3
reoviruses, this coreceptor is -linked sialic acid (22), and its
binding site has been mapped to a region close to the midpoint
of the 1 tail (20, 23). The finding that reoviruses bind to
different receptors by using distinct domains within the 1
protein has led to the suggestion that reoviruses use a multiple-
step adhesion-strengthening mechanism to engage the cell sur-
face (21). In this scenario, reovirus binding to carbohydrate
facilitates viral attachment through low-affinity adhesion. This
interaction places the virus on the cell surface where access to
the higher affinity, but lower abundance, JAM1 protein is
thermodynamically favored.
The recently determined crystal structure of a JAM1-binding
fragment of 1 revealed numerous structural and functional
similarities to the adenovirus attachment protein, fiber, suggest-
ing an evolutionary link in the receptor-binding strategies of
reoviruses and adenoviruses (17). Most adenovirus serotypes
initiate infection by binding to the coxsackievirus and adenovirus
receptor (CAR) (24). The crystal structure of the adenovirus
fiber knob in complex with CAR is known (25). Although no
structural information is currently available for a reovirus-
receptor complex, analysis of the crystallized 1 fragment re-
vealed a region that is likely involved in the interaction with
JAM1 (17). This putative JAM1-binding site forms a recessed
groove at the lower edge of the 1 head that contains many of
the residues conserved in prototype strains of the three reovirus
serotypes. The location of this site suggests that each 1 mono-
mer can independently interact with a JAM1 molecule.
To enhance an understanding of how reovirus mediates cell
tropism and initiates organ-specific disease, we determined the
crystal structure of the hJAM1 ectodomain. Analysis of this
structure allows us to identify regions of the receptor that are
most likely involved in the binding of 1. Moreover, comparison
of the structures of hJAM1 and mJAM1 reveals differences in
the dimeric arrangements of the molecules despite absolute
conservation of residues at the interface, suggesting that the
JAM1 dimer is dynamic and can undergo rearrangement and
perhaps dissociation. Finally, we show that the structure of the
JAM1 dimer closely resembles that of the CAR dimer, mirroring
the close resemblance of the reovirus and adenovirus attachment
proteins and suggesting that the similarities extend beyond
conservation of structure toward conserved strategies of attach-
ment and entry.
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Methods
Protein Expression, Purification, and Crystallization. A cDNA cor-
responding to the extracellular region of hJAM1 (residues
27–233) was cloned into the pGEX-4T-3 expression vector
(Amersham Pharmacia), which encodes N-terminal GST fol-
lowed by a thrombin cleavage site. GST–hJAM1 fusion protein
was expressed in Escherichia coli and purified by affinity chro-
matography using glutathione beads. hJAM1 was released from
the beads by thrombin cleavage and further purified by anion-
exchange chromatography. The cleaved protein contains three
additional non-native amino acids (Gly-24, Ser-25, and Met-26)
at the N terminus. A final gel filtration step resulted in a
homogenous peak that corresponded to a dimer of 48 kDa.
Higher-order oligomers were not observed. Crystals were ob-
tained by using 8 mgml protein and 16% PEG 6K, 18%
isopropanol, 0.1 M sodium citrate as precipitant. The final pH of
the mixture was 6.0.
Structure Determination. The crystals belong to space group C2
(a  116.8 Å, b  61.8 Å, c  82.9 Å,   120.01°) and contain
two molecules in their asymmetric unit. Before data collection,
crystals were cryoprotected with 15% glycerol and then flash-
frozen in liquid nitrogen. Diffraction data were collected at
NSLS beamline X25 and processed with HKL (26). The structure
was determined by molecular replacement using the structure of
mJAM1 (3). Rotation and translation searches were performed
separately with the N- and C-terminal domains of mJAM1 in
AMORE (27), which yielded two clear solutions for each domain.
The free R factor (28) for the combined solutions was 45.1%
(8–3.5 Å) after rigid body refinement. Alternating rounds of
model building in O (29) and refinement in X-PLOR (30) pro-
duced a model with good refinement statistics (Table 1). Bulk
solvent correction and noncrystallographic symmetry con-
straints were used throughout the refinement. The final model
contains residues 25–233 of both chains and 124 water molecules.
PROCHECK (27) analysis shows no residues in disallowed regions
in the Ramachandran plot.
Infectivity Assay. Chinese hamster ovary (CHO) cells (60–80%
confluence) were transfected with 0.4 g of plasmid encoding
hJAM1, hJAM2, hJAM3, or pEGFP-N1 (transfection control)
by using Lipofectamine Plus (GIBCOBRL). Surface expression
was confirmed by flow cytometry using antibodies specific for
hJAM1 (31), hJAM2 (M.A.L. and B.A.I., unpublished observa-
tions), or hJAM3 (32). Transfected cells were infected with
reovirus type 1 Lang (T1L) at a multiplicity of infection of 1
fluorescent focus unit per cell in a total volume of 150 l.
Adsorptions were terminated after incubation at room temper-
ature for 1 h by washing with PBS. Infected cells were identified
18 h after adsorption by indirect immunofluorescence using
rabbit antireovirus sera (1).
Results and Discussion
Overall Structure. The polypeptide chain of the extracellular
region of hJAM1 folds into two concatenated Ig-like domains,
termed D1 and D2 (Fig. 1 A and B). The N-terminal D1 domain
contains two antiparallel -sheets (strands ABED and
GFCCC), which classifies it as an Ig-like domain of the variable
type (V-set). Although the fold of D2 is very similar to that of
D1, this domain has a much shorter C strand, and it lacks the
C strand. These differences indicate that D2 is an intermediate
type (I-set) Ig-like domain (33) and not a V-set Ig-like domain,
as reported for mJAM1 D2 (3). Analysis with DALI (34) shows
that the prototypical I-set domain, telokin (33), is among the
closest structural homologs of hJAM1 D2. Both D1 and D2 of
hJAM1 have the classical disulfide bond between -strands B
and F. The hJAM1 structure exhibits a pronounced elbow angle
of 125° between the two domains. As expected, the overall
structure of each hJAM1 D1D2 monomer resembles that of
mJAM1 D1D2 (3), although there are conformational differ-
ences between the two proteins in surface loops and at the
interdomain interface. Our structure also allows us to trace a
long loop between -strands C and D (CD loop) in D2 that was
disordered in the model for mJAM1 D1D2.
The asymmetric unit of the hJAM1 crystals contains two
independent but virtually identical chains (termed A and B).
Each chain assembles into a U-shaped homodimer with crystal-
lographic 2-fold symmetry. The dimer interface features an
extensive contact between the D1 domains and is reminiscent of
an arm-wrestling grip, with the GFCC faces of the two N-
terminal domains interlocking at an angle of 90° (Fig. 1 A and
B). Two crystallographically independent dimers are observed.
One is formed by chain A and its symmetry mate A, and the other
Table 1. Data collection and refinement statistics
Data set Native
Diffraction data*
Resolution range, Å 30–2.9
Completeness, % 85.1 (51.0)
Total reflections 27,850
Unique reflections 9,736
Rmerge,† % 11.4 (13.5)
I 8.8 (3.7)
Refinement statistics
Rcryst, %; work set‡ 22.0 (no II cutoff)
Rcryst, %; free set‡ 30.5 (no II cutoff)
rms deviation bond lengths, Å 0.02
rms deviation bond angles, ° 2.7
Number of waters 124
*Data sets were collected at 100 K and a wavelength of 1.1 Å. Values in
parentheses refer to the outermost resolution shell.
†Rmerge  hklI  IhklI, where I is the intensity of a reflection hkl, and I is
the average over symmetry-related observations of hkl.
‡Rcryst  hklFobs  FcalchklFobs, where Fobs and Fcalc are observed and calcu-
lated structure factors, respectively. Free set (28) contains 10% of the data.
Fig. 1. Structure of hJAM1 D1D2. (A and B) Ribbon drawings of the hJAM1
dimer, with one monomer shown in orange and the other in blue. Two
orthogonal views are displayed. Disulfide bonds are shown in green. (C) View
of the interface between two hJAM1 monomers. The interface is formed by
residues on the GFCC faces of two D1 domains. The view is along a crystal-
lographic dyad. Hydrogen bonds and salt bridges are represented by broken
cylinders. Amino acids are labeled in single-letter code.
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is formed by chains B and B. Two observations suggest that the
hJAM1 dimer is physiologically relevant: (i) the purified protein
elutes at the expected molecular mass for a dimer (48 kDa) by
size-exclusion chromatography and (ii) a similar dimeric struc-
ture was seen in the crystals of mJAM1 (3). With the exception
of the dimeric interaction, the arrangements of the molecules in
the hJAM1 and mJAM1 crystals are not related.
Structure of the Dimer. Residues involved in hJAM1 homodimer
formation are exclusively located on the concave GFCC face of
D1. The dimer interface includes four buried salt bridges (Arg-
59–Glu-61, Glu-61–Arg-59, Lys-63–Glu-121, and Glu-121–Lys-
63) as well as several hydrophobic contacts (Leu-72–Tyr-119,
Met-110–Met-110, and Tyr-119–Leu-72) (Fig. 1C). Hydrogen
bonds exist between the Tyr-75 and Glu-114 side chains.
Although the GFCC face of D1 also mediates homodimer
formation in the mJAM1 D1D2 structure (3), the relative
arrangements of the D1 domains in the two dimers are noticeably
different (Fig. 2A). The mJAM1 interdomain interface contains
only two salt bridges and fewer additional contacts (3). The
Lys-63–Glu-121 and Met-110–Met-110 interactions at the center
of the hJAM1 interface are absent in mJAM1, as are the
hydrogen bonds involving Tyr-75, Glu-114, and their symmetry-
related counterparts. These differences result in a smaller
interface in mJAM1 (Fig. 2 A). Using the program SURFACE (27)
and a standard probe radius of 1.4 Å, we calculate buried surface
areas of 1,380 and 1,200 Å2 for the hJAM1 and mJAM1 dimers,
respectively.
The observed differences in the hJAM1 and mJAM1 dimers
are noteworthy given the near absolute conservation of residues
at the dimer interfaces (Fig. 2B). The GFCC faces of hJAM1
and mJAM1 (residues 58–75 and 105–122 of hJAM1) can be
superimposed onto each other with an rms deviation of 0.4 Å for
the 36 C atoms. There are only six substitutions among these 36
aa, and none of the substituted residues engage in dimer contacts
(distances 	4 Å). Thus, differences in the arrangement of the
hJAM1 and mJAM1 dimer interfaces cannot be explained by
altered contacts mediated by substituted residues. Instead, these
differences are likely caused by crystal packing forces involving
other regions of the molecules, and they indicate that small
movements of one monomer with respect to the other can occur.
The dynamic nature of the JAM1 dimer interface may result
in part from its dependence on ionic interactions, which is
unusual for protein–protein interfaces. Low pH and moderately
high ionic strength lead to dissociation of the mJAM1 dimer
(35), indicating that ionic interactions represent the principal
means of association. We note that both structures were ob-
tained by using conditions of low ionic strength and at pH values
at which acidic side chains are expected to be deprotonated.
Thus, salt bridges are expected to exist in both cases. However,
the free energy contribution of salt bridges in an aqueous
environment is small (36). The JAM1 dimer interface, which is
stabilized primarily by salt bridges and contains several solvent
molecules, is therefore especially likely to undergo rearrange-
ment or dissociation.
Implications for the Structures of hJAM2 and hJAM3. The conserva-
tion of key features of the dimer interface in hJAM1 and
mJAM1 strongly suggests that this interface is responsible for the
dimeric structure of the protein in solution, as suggested (3).
Thus, it offers a framework for predicting the oligomeric state of
other JAM family members. Sequence alignments show that
most of the residues mediating dimer formation are conserved
in the two additional hJAM family members, hJAM2 and
hJAM3, which has led to the suggestion that these two molecules
form similar dimeric structures (3). Analysis of conserved res-
idues at the dimer interface, however, shows that several key
residues are not conserved in hJAM2 or hJAM3. Met-110, which
is located at the center of the hJAM1 interface (Fig. 1C) and
conserved in mJAM1, is replaced with a glutamic acid in both
hJAM2 and hJAM3. The nearby residue Thr-108 (Fig. 1C),
which also is conserved in hJAM1 and mJAM1, is replaced with
an arginine in hJAM2 and hJAM3. The presence of two
additional charged residues is almost certain to impart different
characteristics to the structure and stability of hJAM2 and
hJAM3 dimers. hJAM2 and hJAM3 have been shown to engage
in heterophilic interactions, with hJAM2 serving as a counter-
receptor for hJAM3 (12, 13). The precise distribution of residues
at the respective GFCC faces and secondary interactions may
favor heterodimeric contacts rather than homodimeric interac-
tions between these proteins. It is also possible that formation of
an hJAM2–hJAM3 dimer uses molecular regions other than
those described, although the D1 domain of hJAM2 is clearly
involved in facilitating this arrangement (14).
The hJAM1 residues involved in salt bridge formation (Arg-
59, Glu-61, Lys-63, Glu-121) and hydrophobic contacts (Leu-72,
Tyr-119) are highly conserved not only in the JAM1 sequences
of other mammals but also in those of nonmammalian verte-
brates such as zebrafish and the African clawed frog (data not
shown). This observation suggests that the dimeric structure of
JAM1 is present throughout vertebrates. We note that some
nonmammalian sequences have features that render them more
similar to JAM2 or JAM3 (e.g., substitution of Met-110 with
Glu), suggesting that versions of all three JAM variants exist in
vertebrates.
Implications for Homophilic Interaction at Tight Junctions. Analysis
of the crystal-packing arrangement of the mJAM1 molecules has
led to a model of JAM1 interactions at tight junctions (3). In this
model, a JAM1 dimer located at the surface of one cell engages
a dimer on the opposing cell via contacts in D1, producing an
extensive network of contacts between dimers. Although our
crystals contain two crystallographically nonequivalent copies of
hJAM1, we do not observe a similar contact involving either of
these molecules in our crystals, and thus our structural analysis
does not provide supporting evidence for the model presented by
Kostrewa et al. (3). In the hJAM1 crystals, two alternative
contacts between hJAM1 dimers that could form the basis for
interactions in tight junctions exist. However, neither of these
contacts is observed in the mJAM1 crystal lattice. One inter-
pretation of the available crystallographic data is that contacts
between JAM1 dimers in tight junctions involve low-affinity
Fig. 2. Comparison of dimeric arrangements in hJAM1 and mJAM1 (3). (A)
Superposition of dimeric structures of hJAM1 D1D2 (colored as in Fig. 1) and
mJAM1 D1D2 (gray). The superposition is based on D1 residues of one mono-
mer only (the orange monomer of hJAM1), which yielded a rms deviation of
0.55 Å for 2 
 90 C atoms. The matrix derived from this superposition was
applied to the entire dimer. (B) Conservation of residues at the mJAM1
and hJAM1 D1 domain dimer interfaces. One hJAM1 monomer is shown in
surface representation, and the other is shown as a blue ribbon. Residues
that are strictly conserved in mJAM1 are shown in orange and cover the entire
dimer interface.
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interactions that depend on the presence of additional proteins,
and these interactions cannot be easily reproduced by using
conditions that promote crystallization. Another interpretation
is that the JAM1 dimer itself, which is observed in the crystals
of hJAM1 and mJAM1, represents a physiologic contact present
in tight junctions. In this interpretation, JAM1 monomers would
engage JAM1 monomers on apposing cells to help mediate
homophilic cell–cell interactions. The dimensions for such a
model suggest that it deserves consideration, because it would
lead to a separation of cells of 85 Å, similar to the observed
distances at tight junctions of 100 Å. CAR is also thought to
mediate homophilic interactions between cells (37–39), and the
homodimeric structure of CAR has been interpreted to depict an
interaction between CAR monomers from apposing cells (40).
Similarities to CAR. The attachment proteins of adenovirus and
reovirus share structural and functional properties, which has led
to speculation that they have a common ancestor (17). Remark-
ably, the receptors for both viruses, CAR and JAM1, respec-
tively, also share key structural properties. CAR forms a ho-
modimer (40) that is structurally similar to the hJAM1
homodimer and also is formed by interactions between the
GFCC -sheets of the N-terminal D1 domains (Fig. 3). Al-
though the contacts between CAR monomers are somewhat
more hydrophobic and do not directly involve salt bridges (40),
several charged residues are present at the CAR–CAR interface
(Glu-56, Asp-68, Lys-121). It is possible that these side chains
interact via water molecules. Moreover, the relative arrangement
of the two CAR monomers is highly similar to that observed for
the two hJAM1 monomers (Fig. 3). Both contacts involve
concave GFCC -sheets that face each other at an angle of90°
and bury an almost identical amount of solvent [1,300 Å2 for the
CAR–CAR dimer (40) and 1,380 Å2 for hJAM1–hJAM1].
Homodimeric structures have been observed in a number of
other Ig superfamily proteins (41–45), but only one of these
proteins, CD2, forms dimers via the GFCC -sheet of D1 (45,
46). However, it is noteworthy that several Ig superfamily
receptors engage viral ligands via the GFCC -sheet. The HIV
glycoprotein gp120 binds to residues on the GFCC face of its
receptor CD4 (47), and the same region of CD4 also interacts
with its natural ligand MHC class II (48). Complexes of rhino-
viruses and coxsackievirus A21 with their receptor intercellular
adhesion molecule-1 (ICAM-1) also show that the interactions
involve residues at the top of ICAM-1 D1, a region that includes
part of the GFCC face (49, 50). Moreover, the adenovirus fiber
knob engages the same area of the GFCC face that mediates
formation of the CAR–CAR dimer (25, 40). The structure of the
complex between fiber knob and CAR shows a trimeric knob
decorated with three copies of monomeric CAR (25, 40).
Interaction of hJAM1 with the Reovirus Attachment Protein 1. The
crystal structure of the reovirus attachment protein 1 revealed
a putative binding site for JAM1 at the lower edge of the 1 head
domain (17). To investigate whether other JAM family members
serve as reovirus receptors, we transiently transfected CHO cells
with hJAM1, hJAM2, or hJAM3 and assayed transfected cells
for the capacity to support reovirus infection. Expression of
JAM proteins at the cell surface was confirmed by flow cytom-
etry (Fig. 4A). In contrast to cells transfected with hJAM1, cells
transfected with hJAM2 or hJAM3 were not infected by reovirus
(Fig. 4B). Our findings clearly demonstrate that reovirus recog-
nizes structural features that are present in hJAM1 but not in
hJAM2 or hJAM3.
To define structural features unique to JAM1 and potentially
involved in contacting 1, we identified conserved sequences in
hJAM1 and mJAM1 that are not conserved in the other two
JAM family members (Fig. 4C). Both hJAM1 and mJAM1 serve
as reovirus receptors (1), whereas hJAM2 and hJAM3 do not.
Because the D1 domain of hJAM1 is necessary and sufficient for
interaction with 1 (J.C.F. and T.S.D., unpublished observa-
tions), our analysis was restricted to that domain. Residues
unique to hJAM1 D1 and mJAM1 D1, and therefore likely to
participate in 1 binding, cluster in three main areas (Fig. 4D):
a region at the dimer interface (shown in orange) and two
surface-exposed regions at the ‘‘back’’ of the molecule, opposite
the dimer interface (shown in green and magenta, respectively).
All three areas are candidates for interaction with 1.
Interestingly, the ‘‘top’’ of the hJAM1 dimer does not contain
conserved residues, and therefore we hypothesize that 1 either
engages the side of the hJAM1 dimer (via the magenta or green
surfaces) or the JAM1 dimer interface (via the orange surface).
The green surface near the top of D1 comprises the BC loop and
the beginning of strand C. This surface is most complementary
in shape and size to the proposed JAM1-binding region of 1
(17) and, thus, it is a good candidate for 1–JAM1 interactions.
The equivalent regions in JAM2 and JAM3 likely have a
different structure because of two-residue insertions (Fig. 4C),
perhaps explaining the inability of these proteins to serve as
reovirus receptors. The magenta-colored regions at the ‘‘back’’
of the protein contain three solvent-exposed side chains, Lys-47,
Thr-88, and Thr-95, which also could participate in the interac-
tion with 1.
The interdimer interface of JAM1 (the orange surface in Fig.
4D) is not accessible to 1 in the context of a JAM1–JAM1
dimer. However, 1 might engage this surface in monomeric
forms of JAM1. Such a mechanism of binding is identical to the
strategy used by the adenovirus fiber knob to bind the mono-
meric form of CAR (25). Indeed, comparison of the sequences
of JAM1 and CAR shows that JAM1 residues highlighted in
orange cluster in the same region as the CAR residues known to
bind fiber (Fig. 4C). Although we have no evidence to suggest
that 1 binds to JAM1 in a similar manner, the similarities
exhibited by 1 and fiber, and between JAM1 and CAR, indicate
that such an interaction might occur. The affinity of the 1 head
domain for hJAM1 is in the nanomolar range (6 
 108 M) (1).
Although the affinity of JAM1 for itself is not known, studies
using recombinant mJAM1 demonstrated that a significant
portion of this protein is monomeric under physiologic condi-
tions (35). This finding suggests that JAM1–JAM1 interactions
Fig. 3. Dimeric structures of virus receptors hJAM1 and CAR. The D1 domains
of hJAM1 (Upper) and CAR (Lower) engage in a conserved mode of dimer-
ization based on interactions between the concave GFCC -sheets. Disulfide
bonds are in green.
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are weak. Therefore, it seems plausible that 1 binds to mono-
meric JAM1, perhaps by engaging residues that form the JAM1–
JAM1 interface.
Conclusions
The crystal structure of the hJAM1 ectodomain provides in-
sights into how JAM1 functions in tight junction formation and
viral attachment. A key feature of JAM1 is its capacity to form
dimers via an extensive interface in its N-terminal domain. This
interface is distinguished from traditional protein–protein in-
terfaces by its highly polar character and its capacity to accom-
modate substantial rearrangements. The latter is evidenced by
the different dimeric structures of hJAM1 and mJAM1 despite
absolute conservation of residues at the interface. We think it
possible that the dynamic nature of the interface plays a role in
mediating and perhaps facilitating transitions between mono-
meric and dimeric forms of JAM1. Moreover, the dynamic
nature of the interface likely distinguishes JAM1 from the other
JAM family members, JAM2 and JAM3, both of which contain
substitutions that are predicted to alter the stability of the
interface.
Previous work from our laboratories has shown that the adeno-
virus and reovirus attachment proteins share many structural and
functional features (17). Here we show that the similarities also
extend to their receptors. The crystal structure of hJAM1 features
a dimeric arrangement that closely resembles that seen in the
adenovirus receptor, CAR. Parallels in the structures of these
molecules are especially intriguing in light of the recent observation
that CAR, like JAM1, is a component of cell–cell junctions (37–39).
Thus, both viral and cellular determinants of adenovirus and
reovirus binding exhibit striking structural similarities, which sug-
gest conserved strategies of attachment among these viruses.
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Fig. 4. Interaction of reovirus with hJAM1. (A) Transiently transfected CHO cells display surface expression of JAM family members. CHO cells were transiently
transfected with hJAM1, hJAM2, or hJAM3 and screened for surface expression of JAM proteins by flow cytometry. (B) Transfection of CHO cells with hJAM1,
but not hJAM2 or hJAM3, rescues infection by reovirus strain T1L. Shown are infected cells as detected by indirect immunofluorescence using rabbit antireovirus
sera. (C) Sequence alignment, with residues conserved in hJAM1 and mJAM1, but not in hJAM2 or hJAM3, highlighted in orange, magenta, and green. Arrows
indicate -strands. The sequence of CAR was aligned with the JAM sequences using CLUSTALW (www.ebi.ac.ukclustalw). CAR residues contacting the adenovirus
fiber knob (distance4 Å) in the complex (25) are highlighted in yellow. Residues conserved in all sequences are shown in bold. (D) The hJAM1 D1D2 dimer viewed
from opposite angles, with one monomer shown in surface representation and the other shown as a blue ribbon. The side chains of conserved residues from
C were mapped onto the hJAM1 D1D2 surface by using the same color code. Residues colored in orange, green, or magenta cluster in three different surface
areas. Residues shaded gray in C are buried and not visible in this representation.
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The utility of adenovirus (Ad) vectors for gene transduction can be
limited by receptor specificity. We developed a gene-delivery
vehicle in which the potent Ad5 vector was genetically reengi-
neered to display the mucosal-targeting 1 protein of reovirus
type 3 Dearing (T3D). A 1 construct containing all but a small
virion-anchoring domain was fused to the N-terminal 44 aa of Ad5
fiber. This chimeric attachment protein Fibtail-T3D1 forms trimers
and assembles onto Ad virions. Fibtail-T3D1 was recombined into
the Ad5 genome, replacing sequences encoding wild-type fiber.
The resulting vector, Ad5-T3D1, expresses Fibtail-T3D1 and
infects Chinese hamster ovary cells transfected with human or
mouse homologs of the reovirus receptor, junctional adhesion
molecule 1 (JAM1), but not the coxsackievirus and Ad receptor.
Treatment of Caco-2 intestinal epithelial cells with either JAM1-
specific antibody or neuraminidase reduced transduction by Ad5-
T3D1, and their combined effect decreased transduction by 95%.
Ad5-T3D1 transduces primary cultures of human dendritic cells
substantially more efficiently than does Ad5, and this transduction
depends on expression of JAM1. These data provide strong evi-
dence that Ad5-T3D1 can be redirected to cells expressing JAM1
and sialic acid for application as a vaccine vector.
Adenovirus (Ad) vectors are potent gene-delivery vehiclescapable of eliciting both mucosal and systemic immune
responses (1). Human Ad serotypes 2 and 5 (Ad2 and Ad5) bind
and enter cells by using the combined interactions of the fiber
and penton base proteins with cellular receptors. The fiber
protein is an elongated trimer with an N-terminal fibrous tail
domain (shaft) and a C-terminal globular head domain (knob).
Ad2 and Ad5 engage the coxsackievirus and Ad receptor (CAR)
(2, 3) via a binding site located in the knob (4). CAR is a member
of the Ig superfamily (2, 3) expressed at regions of cell–cell
contact (5). After fiber-mediated attachment, the penton base
binds to cell surface v integrins, which mediate internalization (6).
Although Ad5 vectors transduce many types of cells, the
efficiency of these vectors is limited if cells lack one or more of
its receptors (7). For example, dendritic cells (DCs) do not
express CAR and are poorly transduced by Ad5 (8). This
relatively poor transduction of DCs can be enhanced by reengi-
neering the vector to target alternative receptors (9, 10). Ad
serotypes that bind to other receptors [e.g., CD46 (11)]
mediate increased transduction of immunologically relevant
cells (12), but these vectors are more promiscuous than Ad5
and deliver genes into cells that may not contribute to vacci-
nation and thus may increase toxicity. Therefore, although
potent, current Ad vectors lack sufficient specificity to func-
tion in some applications.
Mammalian reoviruses are nonenveloped, double-stranded
RNA viruses with a broad host range (13). Reovirus infections
are common, but most are asymptomatic. Reovirus enters the
host by either the respiratory or enteric routes and infects
epithelium and associated lymphoid tissue (14). The reovirus
attachment protein, 1, plays a key role in targeting the virus to
distinct cell types, including those at mucosal surfaces (15–18).
Similar to the Ad fiber, reovirus 1 is an elongated trimer with
head-and-tail morphology (19–21). A domain in the fibrous tail
of serotype 3 Dearing (T3D) 1 binds to -linked sialic acid
(22–25), whereas the head binds to junctional adhesion molecule
1 (JAM1) (26). JAM1 is an Ig-superfamily member expressed by
a variety of cells including DCs (27) and epithelial and endo-
thelial barriers (28–30).
The structures of the Ad fiber (31) and reovirus 1 (32)
proteins are strikingly similar (Fig. 1). The two proteins are the
only structures known to date to form trimers by using triple
-spiral motifs. The fiber shaft most likely is composed entirely
of -spiral repeats (31), whereas the 1 tail is predicted to also
contain an -helical coiled-coil N-terminal to the -spiral region
(32). The head domains of both proteins are formed by eight
antiparallel -strands with identical interstrand connectivity.
Therefore, although Ad and reovirus belong to different virus
families and have few overall properties in common, the ob-
served similarities between the attachment proteins and recep-
tors of these viruses suggest a conserved mechanism of binding.
Based on the structural similarities between Ad fiber and
reovirus 1, we engineered chimeric fiber-1 attachment pro-
teins to exploit the JAM1- and sialic acid-binding properties of
1. Of those tested, only a near-full-length version of 1 grafted
onto the virion-insertion domain of Ad fiber (Fibtail-T3D1)
formed trimers and assembled onto Ad particles. We show here
that when the fiber gene in the Ad5 genome is replaced with
Fibtail-T3D1, the resulting virus, Ad5-T3D1, is capable of
infecting intestinal epithelial cells expressing JAM1 and sialic
acid and primary human DCs expressing JAM1. These data
provide proof of principle for the development of chimeric Ad
vectors encoding reovirus 1 for gene delivery to mucosal
surfaces. This work also establishes a foundation for the use of
Ad-1 chimeric viruses as a template to enable facile reverse
genetic manipulation of the reovirus attachment protein for
studies of virus–cell and virus–host interactions.
Methods
Cells, Antibodies, and Viruses. 293A (Q-BIOgene, Carlsbad, CA)
and Chinese hamster ovary (CHO) cells (American Type Cul-
ture Collection) were maintained as described (10). 633 cells, a
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derivative of A549 cells expressing E1, E2A, and Ad5 fiber, were
provided by D. Von Seggern (The Scripps Research Institute, La
Jolla, CA) and maintained as described (33). Caco-2 cells
(American Type Culture Collection) were maintained in Alpha
minimum essential medium (GIBCO) with 20% FBS. Primary
human DCs (NHDC, Cambrex, Baltimore) were maintained
according to vendor protocol.
The human (h)CAR-specific mAb RmcB was purified from
CRL-2379 hybridoma cells (American Type Culture Collection).
The hJAM1-specific mAb J10.4 was provided by Chuck Parkos
(Emory University School of Medicine, Atlanta). Rabbit poly-
clonal serum 1561 was raised against the N-terminal region of
Ad5 fiber (peptide ARPSEDTFNPVY). The c-Myc-specific
mAb was purchased from PharMingen.
Ad vectors used in this study are based on the AdEasy system
(Q-BIOgene) and carry the full E1- and E3-deleted Ad5 genome
with the firefly luciferase gene, an internal ribosome entry site,
and the humanized Renilla GFP expressed from a cytomegalo-
virus (CMV) immediate-early promoter in the E1 region.
Generation of Chimeric Fiber-1 Attachment Proteins. Fiber-1 fu-
sion constructs were generated by using  phage red recombi-
nase (34) expressed in Escherichia coli strain BW25113pKD46
(35) obtained from the E. coli Genetic Stock Center (http:
cgsc.biology.yale.edu) as follows: Fibshaft-T3D1, consisting of
the N-terminal 396 aa of Ad5 fiber fused to amino acid 292 of
T3D 1; Fib8-T3D1, consisting of the N-terminal 170 aa of Ad5
fiber fused to amino acid 167 of T3D 1; and Fibtail-T3D1,
consisting of the N-terminal 44 aa of Ad5 fiber fused to amino
acid 18 of T3D 1. Sequences encoding the reovirus T3D 1
protein flanked by a bovine growth hormone polyadenylation
signal and a zeocin-resistance gene were amplified by using Pfu
polymerase (Stratagene) and primers containing 39-nt over-
hangs homologous to the pCMVfiber plasmid. The pCMVfiber
plasmid, containing the Ad5 fiber gene expressed from a CMV
immediate-early promoter, was cotransformed with the PCR
product into the  phage red strain BW25113pKD46. Recom-
binants were selected by using zeocin-containing agar plates.
Fibtail-T3D1 was subcloned into a plasmid containing se-
quences homologous to E4 and then recombined into the Ad5
genome to replace the fiber gene using red recombinase. To aid
in detection of the chimeric protein, two c-Myc tags (C2), and
one hexahistidine tag (H6) were added to the C terminus of the
chimera (Fibtail-T3D1C2H6) before recombination. The re-
combinants were screened for loss of the fiber gene by restriction
endonuclease mapping and sequencing.
Protein Expression and Characterization. CHO cells were trans-
fected with plasmids encoding fiber-1 chimeras by using Lipo-
fectamine-PLUS (Invitrogen), and cell extracts were harvested
for SDSPAGE. Immunoblots were performed as described (10).
Generation of a Chimeric Ad Vector. Linearized Ad genome en-
coding the Fibtail-T3D1C2H6 chimera was transfected into 633
cells and maintained in the presence of 0.3 M dexamethasone
and 4 gml polybrene. Virus was propagated, purified by CsCl
gradient centrifugation, and quantitated as described (36). The
resultant recombinant virus, Ad5-T3D1, was amplified for a
final round by using 293A cells to remove any residual fiber from
newly assembled virions.
CsCl-banded Ad5, CAR-ablated biotinylated Ad [Ad5-BAP-
TR (10)], and Ad5-T3D1 were precipitated with trichloroacetic
acid. Pellets were resuspended in loading buffer, and 4  1010
particles per lane were resolved by SDSPAGE and immuno-
blotting. For total protein analysis, precipitated virus (1.5 1011
particles per lane) was resolved by SDSPAGE, and gels were
stained with Coomassie blue.
Transduction of CHO Cells Transfected with Receptor Constructs.
CHO cells were transfected with plasmids expressing hCAR,
hJAM1, or murine (m)JAM1 (37, 38). After 48 h, the cells were
washed once with Hanks’ balanced salt solution (GIBCO) with
1% BSA (HBSS-BSA) and adsorbed with 5,000 particles per cell
of Ad5-T3D1 at 4°C for 30 min. Cells were washed twice with
HBSS-BSA, and fresh medium was added. After incubation at
37°C for 24 h, cells were lysed, and luciferase activity (in lumens)
was measured as described (10).
Transduction of Caco-2 Cells and Primary DCs After Receptor Blockade.
Cells were harvested, washed with HBSS-BSA, and incubated in
suspension with 10 gml of either hCAR-specific mAb RmcB
or hJAM1-specific mAb J10.4 at 4°C for 30 min. Alternatively,
cells were treated with 333 milliunitsml of Clostridium perfrin-
gens neuraminidase type X (Sigma) at 37°C for 30 min to remove
cell-surface sialic acid, followed by two washes with HBSS-BSA.
Cells then were adsorbed with 5,000 particles per cell of Ad5-
Fig. 1. Full-length models of Ad5 fiber (Upper) and reovirus 1 (Lower). The three monomers within each trimer are shown in red, orange, and blue. Both
proteins have head-and-tail morphology, with an eight-stranded -barrel domain forming the head. The Ad5 fiber shaft is predicted to consist of 21 -spiral
repeats (31). The Ad5 fiber model was generated by adding 17 -spiral repeats to the four present in the crystal structure of an Ad2 fragment, which also has
21 -spiral repeats (31). Sequence predictions suggest that 1 contains an N-terminal 135-residue -helical coiled coil followed by eight -spiral repeats and
the globular head domain (32, 49). The1 model was generated by first adding five-spiral repeats to the N terminus of the crystallized fragment (32). This model
then was joined with a 135-residue trimeric coiled coil formed by elongating an existing coiled-coil structure (50). The N-terminal 45 and 39 residues of fiber and
1, respectively, are not included in the model, because they form a virion-anchoring structure (indicated by gray lines). The overall lengths of the fiber and 1
models are 325 and 385 Å, respectively, which is consistent with data from electron microscopy studies. This figure was prepared by using RIBBONS (51).
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T3D1 at 4°C for an additional 30 min, washed twice, and seeded
onto 24-well plates in fresh medium. After incubation at 37°C for
24 h, cells were harvested for determination of luciferase activity.
Results
Design and Characterization of a Functional Fiber-1 Chimera. Based
on the structural similarities between Ad5 fiber and reovirus 1
(Fig. 1), we engineered three Ad fiber-reovirus 1 chimeras with
increasingly larger portions of 1 protein replacing structurally
homologous regions of fiber (Fig. 2A). Fibshaft-T3D1 contains
the N-terminal 21 -spiral repeats of fiber fused to the head
domain of T3D 1. Fib8-T3D1 contains the N-terminal eight
-spiral repeats of fiber fused to the T3D 1 -spiral and head
domains. Fibtail-T3D1 contains the N-terminal 44 aa virion-
anchoring domain (39) fused to T3D 1 lacking only the
N-terminal 17 amino acids. After transfection of CHO cells, each
of the chimeric attachment proteins was expressed, but only
Fibtail-T3D1 formed trimers (Fig. 2B and data not shown),
suggesting that only this chimera maintains native folding.
Production and Characterization of an Ad Vector Expressing a Chi-
meric Fiber-1 Attachment Protein. The Fibtail-T3D1 gene was
recombined into an Ad5 genome lacking E1 and E3 to replace
the fiber gene by using  phage red recombinase (34). During the
cloning process, two c-Myc tags (C2) and one hexahistidine tag
(H6) were added to the C terminus of Fibtail-T3D1 (Fibtail-
T3D1C2H6) to facilitate protein detection. The resulting virus,
Ad5-T3D1, was rescued by transfection and production in 633
fiber-expressing cells (33). After amplification in 633 cells, the
virus was passaged in 293A cells to eliminate fiber from the
virions and allow only Fibtail-T3D1C2H6 to be encapsidated.
To determine whether Fibtail-T3D1C2H6 was encapsidated
onto Ad5 virions, CsCl-purified Ad5, Ad5-BAP-TR, which
displays biotinylated fibers (10), and Ad5-T3D1 were analyzed
by immunoblotting with antibodies specific for either the fiber N
terminus or the c-Myc epitope tag (Fig. 3A). Comparison of the
immunoblots demonstrated that Fibtail-T3D1C2H6 was en-
capsidated onto Ad5 virions at levels similar to those of fiber on
Ad5 and Ad5-BAP-TR. As anticipated, the anti-c-Myc antibody
recognized both Ad5-BAP-TR and Ad5-T3D1, which contain
c-Myc tags but not wild-type fiber. Coomassie blue staining
demonstrated that relative amounts of the capsid proteins of
wild-type Ad5 and Ad5-T3D1 were indistinguishable (Fig. 3B).
Thus, Fibtail-T3D1C2H6 is encapsidated onto Ad virions and
enables normal virion maturation.
Transient Transfection of CHO Cells with JAM1 Rescues Infection by
Ad5-T3D1. To determine whether the chimeric Fibtail-T3D1
attachment protein could bind to JAM1, CHO cells were
transfected with plasmids expressing hCAR, hJAM1, and
mJAM1 and tested for infection by luciferase-expressing Ad5-
T3D1. CHO cells were chosen for these studies, because they
lack both CAR and JAM1 and are poorly infected by both Ad
and reovirus (38). Transduction of CHO cells by Ad5-T3D1
was increased substantially by expression of either hJAM1 or
mJAM1 but not by expression of hCAR (Fig. 4A), the receptor
for Ad5 (2, 3). These data indicate that the JAM1-binding
domain of Ad5-T3D1 is functional and can target JAM1-
expressing cells in a species-independent fashion.
Inhibition of Binding to JAM1 and Sialic Acid Blocks Ad5-T3D1
Infection of Caco-2 Cells. We next tested the capacity of hJAM1-
specific mAb J10.4 and C. perfringens neuraminidase to inhibit
transduction by Ad5-T3D1. Caco-2 intestinal epithelial cells, a
model for enteric mucosal surfaces (40, 41), were used for these
experiments, because these cells express CAR, JAM1, and sialic
acid (26, 42). Transduction by Ad5-T3D1 was inhibited 50% by
JAM1-specific mAb J10.4 and 80% by neuraminidase (Fig. 4B).
Combined treatment with both mAb J10.4 and neuraminidase
reduced transduction nearly 95%. In contrast, isotype-matched
hCAR-specific mAb RmcB, used as a negative control, did not
diminish luciferase transduction (Fig. 4B).
To ensure that JAM1-dependent transduction by Ad5-T3D1
depends on 1 and not another Ad protein, we tested the
capacity of the T3D 1-specific mAb 9BG5 (24) to block
infection of Caco-2 cells. In contrast to T1L 1-specific mAb 5C6
(24), mAb 9BG5 inhibited transduction in a dose-dependent
fashion (data not shown). We noted a similar decrease in
transduction efficiency after incubation of Ad5-T3D1 with
sialoglycophorin, which is known to interact with reovirus T3D
1 (22), before infection (data not shown). These results dem-
onstrate that transduction by Ad5-T3D1 requires 1 and its
receptors, JAM1 and sialic acid.
Ad5-T3D1 Transduces Primary Human DCs. DCs play important
roles in induction of adaptive immune responses (43). To
determine whether Ad5-T3D1 is capable of transducing DCs,
we infected primary cultures of human DCs with Ad5 and
Ad5-T3D1. DCs express JAM1 but not CAR (Fig. 5A), which
is consistent with previous observations (27). Transduction of
DCs by Ad5-T3D1 was substantially more efficient than by Ad5
(Fig. 5B). Moreover, transduction was eliminated almost com-
pletely by treatment with hJAM1-specific mAb J10.4 (Fig. 5B).
These findings suggest that Ad5-T3D1 may have utility for
transducing CAR-negative DCs at mucosal and other sites.
Fig. 2. Design and expression of chimeric fiber-1 attachment proteins. (A)
Schematic diagram of the chimeric fiber-1 attachment proteins described in
the text. Regions corresponding to fiber and 1 in the diagrams are shaded
black and gray, respectively (not drawn to scale). Fiber tail, which mediates
virion anchoring, is represented as a small cylinder, the -helical coiled coils as
small ovals, the -spiral repeats as large cylinders, and the head domain as
three large ovals. (B) Immunoblots of denatured (boiled) and native (un-
boiled) lysates of CHO cells transfected with plasmid expressing Fibtail-T3D1
probed with a serum (1561) that recognizes the N-terminal region of Ad5
fiber.
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Discussion
In this study, we fused two structurally homologous viral attach-
ment proteins, Ad fiber and reovirus 1, to produce a functional
chimeric virus, Ad5-T3D1. Of the three fiber-1 chimeras tested,
only Fibtail-T3D1 bearing the Ad5 fiber virion-insertion domain
fused to an almost-full-length version of T3D 1 protein formed
trimers and assembled onto Ad virions. The lack of trimerization of
Fib8-T3D1 and Fibshaft-T3D1 was surprising, because both the
head and tail regions of 1 contain trimerization domains (44),
whereas the fiber knob domain initiates and maintains trimeriza-
tion (45). Because only Fibtail-T3D1 formed trimers, it is likely
that the C-terminal trimerization domain of 1 is insufficient for
trimerization of the fiber shaft. Alternatively, it is possible that the
chimeric Fib8-T3D1 and Fibshaft-T3D1 proteins do not form
trimers, because the fused -spiral junctions are imperfectly
matched.
In Ad5-T3D1 virions, Fibtail-T3D1 was encapsidated at levels
comparable with wild-type fiber. Furthermore, the capsid protein
profile of Ad5-T3D1 is identical to that of wild-type Ad5. Most
importantly, experiments using receptor-transfected cells, anti-
bodies, and reagents that block 1–sialic acid interactions provide
Fig. 3. Characterization of Ad5-T3D1. Ad5 virions expressing wild-type fiber (Fiberwt), CAR-ablated biotinylated fiber (Fiber-BAP-TR) (10), and Fibtail-
T3D1C2H6 were precipitated with trichloroacetic acid. (A) Precipitated particles (4  1010 per lane) were resolved by SDSPAGE and immunoblotted with
anti-c-Myc mAb 9E10 or antiserum 1561, which recognizes the N-terminal region of Ad5 fiber. (B) Precipitated particles (1.5  1011 per lane) were resolved by
SDSPAGE and stained with Coomassie blue.
Fig. 4. Ad5-T3D1 transduction is mediated by JAM1 and sialic acid. (A) CHO cells were transiently transfected with plasmids encoding hCAR, hJAM1, or mJAM1.
After 48 h of incubation to permit receptor expression, cells were adsorbed with 5,000 particles per cell of Ad5-T3D1 and harvested 24 h later for luciferase assay.
Transduction was measured in lumens. (B) Caco-2 cells were either untreated or treated with 10 gml hCAR-specific mAb RmcB (CAR mAb), 10 gml
hJAM1-specific mAb J10.4 (JAM1 mAb), 333 milliunitsml C. perfringens neuraminidase (NM), or both JAM1 mAb and neuraminidase. Cells were adsorbed with
5,000 particles per cell of Ad5-T3D1 and harvested 24 h later for luciferase assay. Transduction was measured in lumens. The results are presented as the means
for three independent experiments. Error bars indicate SD. A paired Student’s t test was performed to compare transduction of transfected or treated cells versus
mock or untreated cells (*, P  0.01; **, P  0.05; ns, not significant).
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compelling evidence that Ad5-T3D1 displaying Fibtail-T3D1
retains both the JAM1- and sialic acid-binding functions of the T3D
1 protein.
We envision at least four applications for chimeric Ad vectors in
which the CAR-binding functions of fiber have been replaced with
the JAM1- and sialic acid-binding functions of 1. First, Ad vectors
based on fiber-1 chimeras may serve to efficiently target mucosal
sites for enhanced induction of immune responses at mucosal
surfaces. Second, because JAM1 and sialic acid are expressed on a
variety of cells, Ad5-T3D1 and its derivatives may have utility for
transducing cells deficient in CAR (e.g., DCs and certain types of
cancer cells). Third, because 1 incorporates its own trimerization
motifs, fiber-1 fusions may provide a trimeric scaffold for the
display of other cell-targeting ligands in a manner analogous to
fiber-fibritin chimeras (46). In support of this approach, we recently
appended single-chain antibodies onto truncated forms of Fibtail-
T3D1 (unpublished data). Fourth, Ad vectors based on Ad5-
T3D1 can be used as a simple genetic platform for directed
mutagenesis of 1 for studies of reovirus tropism and receptor-
linked signaling.
The opportunity to use Ad vectors encoding fiber-1 chimeras
for mucosal targeting is especially appealing. Increased delivery of
antigens to intestinal epithelial cells and Peyer’s patch lymphocytes
by such vectors might result in more potent and less toxic gene-
based vaccines. Reovirus binds to murine microfold cells (15, 16,
18), and the 1 protein plays an important role in conferring this
tropism (18, 47). Interactions of Ad5-1 vectors with microfold cells
may facilitate efficient delivery to underlying Peyer’s patches for
induction of immune responses in the gut. Alternatively,1-bearing
Ad vectors may directly infect DCs at the luminal surface, which are
known to shuttle bacteria across epithelial monolayers by opening
tight junctions and sampling the intestinal lumen (48). DCs express
tight junction proteins, including JAM1 (27), which are hypothe-
sized to facilitate epithelial barrier penetration. Our finding that
Ad5-T3D1 transduces primary DCs more efficiently than wild-
type Ad5 suggests that Ad5-1 vectors may be useful for antigen
gene delivery to DCs in the intestine and other sites.
Findings described in this report indicate that Ad vectors can be
efficiently retargeted to cells expressing JAM1 and sialic acid by the
reovirus attachment protein 1. By virtue of the capacity to infect
both intestinal epithelial cells and DCs, Ad5-1 vectors may have
utility in the induction of immune responses at mucosal surfaces
and thus prevention of infection at the site of pathogen entry. These
vectors also will allow a precise determination of the contribution
of the JAM1- and sialic acid-binding properties of1 to interactions
of 1 with cells in vivo. This approach should lead to improved Ad
vectors for gene delivery and enhance an understanding of 1
biology.
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